

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, C07K 14/47, 16/18, C12Q 1/68, G01N 33/53, 33/574, A61K 38/17, 39/395, 48/00, A61P 35/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/50595</b> <b>(43) International Publication Date:</b> 31 August 2000 (31.08.00)
<b>(21) International Application Number:</b> PCT/US00/04929 <b>(22) International Filing Date:</b> 25 February 2000 (25.02.00)  <b>(30) Priority Data:</b> 09/257,417 25 February 1999 (25.02.99) US  <b>(71)(72) Applicants and Inventors:</b> GOUT, Ivan [UA/GB]; Ludwig Institute for Cancer Research, Coutauld Building, 91 Riding House St., London W2 1PG (GB). RÖDNIN, Nikolay [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). FILONENKO, Valery [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). MATSUKA, Genadiy [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). SCANLAN, Matthew [US/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US). OLD, Lloyd [US/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US). BILYNSKY, Boris [UA/UA]; Lviv State Medical University, Dept. of Oncology, 69 Pekarska St., Lviv, 290010 (UA).	<b>(74) Agents:</b> DIGIGLIO, Frank, S. et al.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Garden City, NY 11530 (US).  <b>(81) Designated States:</b> AU, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> NUCLEIC ACID MOLECULES ASSOCIATED WITH MELANOMA AND THYROID TUMORS  <b>(57) Abstract</b>  The present invention relates to isolated nucleic acid molecules associated with melanoma or thyroid tumors and compositions derived therefrom. The present invention further relates to methods for diagnosing and treating melanoma, thyroid tumors and other related pathological conditions such as rectal cancer, lung cancer, breast cancer and colon cancer, by employing such nucleic acid molecules and compositions.		

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACID MOLECULES ASSOCIATED  
WITH MELANOMA AND THYROID TUMORS

**FIELD OF THE INVENTION**

5                   This invention relates to isolated nucleic acid molecules associated with melanoma and thyroid tumors as well as uses thereof for diagnosing and treating melanoma and thyroid tumors.

10                   **BACKGROUND OF THE INVENTION**

                  Recent advances in the understanding of the molecular mechanisms of antigen recognition have led to many novel immunotherapy approaches for the treatment of human cancer. One approach is by stimulating a patient's immune system with antigens that are specifically expressed by cancerous cells, i.e., tumor vaccines. Specific tumor vaccines require pre-identification of tumor associated antigens, i.e., molecules that are either specifically expressed or overexpressed in tumor cells.

20                   Extensive efforts have been made to identify tumor associated antigens in humans by using two approaches which are referred to as the genetic approach and the biochemical approach. The genetic approach is exemplified by dePlaen et al., *Proc. Natl. Sci. USA* 85: 2275 (1988), incorporated herein by reference. In this approach, cDNA libraries prepared from antigen-positive tumor-cell lines are transfected into antigen-negative recipient cells, such as COS cells or variants of tumor cell lines. The transfectants are subsequently screened for the expression of tumor antigens which are recognized by tumor-specific cytolytic T-Lymphocyte clones ("CTLs"). The biochemical approach, exemplified by Mandelblom et

al. *Nature* 369: 69 (1994) which is incorporated herein by reference, is based on acidic elution of peptides which are bound to MHC-class I molecules at the surface of tumor cells. Such elution produces  
5 pools of peptides which are subsequently fractionated by reverse-phase high performance liquid chromatography (HPLC). Tumor specific antigenic peptides are subsequently identified based on their ability to activate tumor-specific CTL clones.

10 Application of these two approaches has led to the molecular identification of new human antigens in human tumors, most notably in malignant melanoma, such as MAGE-1, Tyrosinase and MART-1. See, e.g., van der Bruggen et al., *Science* 254: 1643-1647 (1991);  
15 Brichard et al., *J. Exp. Med.* 178: 489-495 (1993); Kawakami et al., *Proc. Natl. Acad. Sci. USA* 91: 3515-3519; Cox et al., *Science* 264: 716-719 (1994).

However, these two approaches have the following disadvantages. First, such methods are  
20 enormously cumbersome, time-consuming and expensive. Second, these methods depend on the establishment of autologous tumor cells in culture and isolation of stable autologous CTL clones that recognize antigens on the cultured tumor cells. It is difficult to establish  
25 cell lines from certain types of tumors, as shown by, e.g., Oettgen, et al., *Immunol. Allerg. Clin. North. Am.* 10:607-637 (1990). In addition, malignant cell lines established from a patient which are capable of growing *in vitro* may not express the complete spectrum  
30 of tumor associated antigens of the patient's original tumor. It is also known that some epithelial cell type cancers are poorly susceptible to CTLs *in vitro*, precluding routine analysis. Third, the relevance of

an identified tumor associated antigen to the  
respective tumor *in vivo* remains to be proven, as the  
respective CTLs can be obtained not only from patients  
with the respective tumor, but also from healthy  
5 individuals.

These problems have stimulated the art to  
develop alternative methodologies. One such  
methodology is described by Sahin et al., *Proc. Natl.*  
*Acad. Sci. USA* 92: 11810-11913 (1995), incorporated  
10 herein by reference. Also, see U.S. Patent No.  
5,698,396 and International Application WO 96/40209,  
both of which are incorporated herein by reference.  
According to this method, a cDNA library is prepared  
from a pathological sample of a patient, e.g., tumor  
15 cells. The library is expressed in host cells, and  
screened with diluted serum from a patient which has  
been pre-treated to remove interfering binding  
partners. Host cells expressing the antigens are  
identified by their strong reactivity toward the  
20 antibodies in the serum in a binding assay. This  
method is also known as the SEREX method ("Serological  
Identification of Antigens by Recombinant Expression  
Cloning").

Application of the SEREX methodology has  
25 confirmed the expression of previously identified tumor  
associated antigens that are associated with melanoma,  
renal cell carcinoma and Hodgkins' disease.  
Application of the SEREX methodology has also led to  
the identification of novel genes encoding tumor-  
30 associated antigens, such as HOM-RCC-3.11, HOM-HD-21  
and NY-ESO-1. See Sahin et al. (1995); Türeci et al.  
(1997a), *J. Biol. Chem.* 272: 6416- 6422; Crew et al.  
(1995), *EMBO J.* 144: 2333-2340; Chen et al. (1997),

*Proc Natl. Acad. Sci. USA* 94: 1914-1918, review by  
Türeci et al. (1997b) *Molecular Medicine Today* 3(8):  
342-349 and review by Sahin et al. (1997) *Current*  
*Opinion in Immunology* 9: 709-716 . Since the  
5 molecular identification of immunogenic proteins by the  
SEREX methodology is based on the reactivity of such  
proteins with patients' sera, immunogenic proteins  
which can be identified by SEREX are not restricted to  
cell-surface antigens and include a more complete  
10 repertoire of proteins expressed by a tumor. In fact,  
the SEREX methodology permits the identification of  
proteins which are abnormally expressed by cells of any  
pathological condition that are capable of eliciting a  
strong antibody immune response in the patient.

15           The antigens identified by SEREX can be  
classified into different categories based on the  
expression patterns of these antigens, as described by  
Türeci et al. (1997b), *Molecular Medicine Today* 3(8):  
342- 349. One category of the SEREX-detected antigens  
20 are tumor-specific antigens derived from  
transcriptionally activated genes which are not  
expressed in normal tissues, such as HOM-MEL-40.  
Another category of the SEREX-detected antigens are  
differentiation antigens which are expressed in tumor  
25 cells as well as in normal cells developed from the  
same precursor origin, e.g., Tyrosinase. Yet another  
category of the SEREX-detected antigens are derived  
from mutated genes, such as a mutated tumor suppressor  
gene p53. Still another category of the SEREX-detected  
30 antigens are products of alternative splicing, e.g.,  
the splice variant of restin (associated with Hodgkin's  
disease). The majority of the SEREX-detected antigens

are encoded by genes which are expressed in normal tissues and are overexpressed in tumors, e.g., HOM-HD-21 (associated with Hodgkin's disease) and carbonic anhydrase (associated with renal cancer). SEREX has also identified antigens encoded by genes which are expressed at similar levels in normal tissues and in tumors, such as CCAAT enhancer-binding protein HOM-MEL-2.4. It is proposed that this category of tumor associated antigens are detected by SEREX perhaps due to unusual protein processing, and therefore, unusual presentation of antigens in tumors. SEREX has also identified non-cancer-related autoantigens involved in, e.g., autoimmune diseases, such as NY-ESO-2' (encoding U1 snRNP).

In accordance with the present invention, the SEREX methodology has been applied to melanoma samples and thyroid tumor samples. A number of nucleic acid molecules have been isolated and sequenced. These results are the subject of this invention, which are elaborated upon the disclosure which follows.

#### SUMMARY OF THE INVENTION

The present invention is directed to isolation and identification of nucleic acid molecules which are associated with melanoma and thyroid tumors. In particular, ten nucleic acid molecules have been isolated by applying the SEREX methodology to melanoma samples, and ten nucleic acid molecules have been isolated by applying the SEREX methodology to thyroid tumor samples.

Accordingly, one embodiment of the present invention is directed to newly isolated nucleic acid

molecules, MEL 3, MEL7, Thy5, Thy6, Thy 11, Thy14 and Thy 15 (SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20). The present invention also contemplates nucleic acid molecules, the complement sequences of which hybridize under stringent conditions to at least one of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20.

The present invention further contemplates vectors containing any one of the above nucleic acid molecules, as well as host cells transformed with such vectors. In a preferred embodiment, the present invention provides an antigen presenting cell transformed with one of such expression vectors, having an HLA/peptide complex at the cell surface.

In another embodiment, the present invention provides proteins encoded by the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20 or parts thereof.

Still another embodiment of the present invention provides antibodies directed towards a protein encoded by any one of the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20 or parts thereof.

The present invention is also directed to isolated HLA/peptide complexes, wherein the peptide is encoded by a fragment of any one of the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20.

A further aspect of the present invention is directed to methods for diagnosing pathological conditions characterized by an abnormal expression of at least one of the nucleic acid molecules encompassing SEQ ID NOS: 1-20. The pathological condition includes melanoma, the presence of a thyroid tumor, rectal



cancer, lung cancer, breast cancer or colon cancer. According to the present invention, the determination of the abnormal expression of a nucleic acid molecule can be made by assaying a component manifesting the expression of such molecule, such as mRNA, protein(s), antibodies in the serum, presence of specific CTLs, or cells presenting an antigenic peptide.

Another aspect of the present invention is directed to pharmaceutical compositions. The pharmaceutical compositions of the present invention can include an antisense molecule of one or more of the nucleic acid molecules encompassing any one of SEQ ID NOS: 1-20, a protein encoded by a nucleic acid molecule encompassing any one of SEQ ID NOS: 1-20 or parts of such protein, an antibody directed to such a protein, a cell presenting an antigenic peptide at the surface, a CTL generated ex vivo against such cell, or combinations thereof.

The subject therapeutic compositions of the present invention may be administered to a subject for treating a pathological condition in the subject, which is characterized by an abnormal expression of at least one of the nucleic acid molecules encompassing SEQ ID NOS: 1-20. Accordingly, methods of treatment are also provided by the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to isolated nucleic acid molecules that are associated with melanoma or thyroid tumors. The present invention further relates to proteins encoded by such nucleic acid molecules, antibodies directed against such proteins and cells expressing such nucleic acid

molecules. The present invention also provides pharmaceutical compositions as well as methods for diagnosing and treating melanoma, thyroid tumors and other related pathological conditions.

5           Nucleic acid molecules encoding tumor associated antigens have been identified by employing the SEREX methodology as described by Sahin et al. (1995). According to SEREX, samples of suspected abnormality, e.g., tumor cells, can be obtained from  
10 patients via routine clinical procedures. RNAs are purified from the freshly isolated samples for preparing a cDNA library, which is subsequently cloned into an appropriate expression vector. The choice of vectors may vary, depending on the host cells. When  
15 the host cell is a eukaryotic cell, yeast, viral or baculoviral vectors are preferred. When the host cell is a prokaryotic cell, then phage vectors are preferred, such as a  $\lambda$  phage vector. The resulting vector-carried library is then transformed into a host  
20 cell. The skilled artisan is familiar with the choice of host cells, including bacteria cells such as strains of *E. coli*, strains of *Pseudomonas* such as *Pseudomonas aeruginosa* or strains of *Bacillus*, yeast cells such as strains of *Saccharomyces* or *Pichia pastoris*, CHO cells  
25 such as CHO-1, COS cells such as COS-7 and insect host cells such as *Spodoptera frugiperda*. Once the host cells receive the vectors, the cells are cultivated and induced so as to express the proteins encoded by the nucleic acid molecules of the cDNA library.

30           The expressed proteins as well as derivatives thereof, such as posttranslationally-modified products (e.g., glycoproteins or lipoproteins) and polypeptide or peptide fragments processed therefrom, are then

5 contacted with a sample secured from a patient for  
identifying the clones of interest. A preferred sample  
is the patient's body fluid, such as serum. The serum  
may be obtained via routine clinical procedures from  
both autologous and non-autologous patients afflicted  
with the relevant pathological condition such as a  
tumor. Such serum is treated prior to use in order to  
remove components in the serum which recognize either  
the host cell or molecules derived from the vector  
10 other than the specific target molecule. Such  
pretreatment procedure is described by, e.g., Sahin et  
al. (1995).

15 When the expressed proteins and derivatives  
thereof are contacted with the pretreated patient's  
sample, the immune components present in the patient's  
sample, e.g., IgG, which are specific for a protein or  
derivative thereof will bind thereto. Preferably, the  
proteins and derivatives can be immobilized to a solid  
material, e.g., nitrocellulose, to facilitate the  
20 binding. The binding can be detected by a variety of  
assays, for example, assays using anti-human IgG  
conjugated with an identifiable label, such as an  
enzyme, a dye, or a radiolabel. Once positive clones  
are identified, i.e., clones expressing proteins or  
25 derivatives which are bound by the immune components  
from the patient's sample, the corresponding cDNA can  
be isolated and sequenced via routine procedures.

30 The SEREX methodology permits the  
identification of not only cell surface antigens, but  
any molecules which are abnormally expressed by cells  
that are capable of eliciting a strong antibody immune  
response in the patient. See, e.g., Türeci et al.  
(1997b).

By applying the SEREX methodology to human melanoma samples and thyroid tumor samples, the present invention provides the isolation and identification of nucleic acid molecules associated with melanoma (MEL 1-10) and nucleic acid molecules associated with thyroid tumors (Thy 1-3, 5-6, 9, 11-12 and 14-15), respectively (SEQ ID NOS: 1-20). These nucleic acid molecules have been compared with sequences in the databases and are resolved into both known and unknown sequences. Table II summarizes the results. Whether previously known or unknown, these isolated nucleic acid molecules have been identified by the instant invention to be associated with either melanoma or thyroid tumors.

Accordingly, one embodiment of the present invention is directed to newly isolated nucleic acid molecules that are associated with melanoma (MEL3 and MEL7) or thyroid tumors (Thy 5-6, 11 and 14-15). In particular, the present invention contemplates isolated nucleic acid molecules having a sequence as set forth in any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

The term "associated" or "association" is used herein to indicate that a relevant nucleic acid molecule is abnormally expressed in melanoma or thyroid tumors. These nucleic acid molecules may also be expressed by cells other than melanoma cells or thyroid tumor cells, e.g., cells of other types of tumors, or cells of other disorders such as an autoimmune disorder. For example, the present invention has also shown that the isolated nucleic acid molecules scored positive in the SEREX screening assay using sera from patients having rectal, lung, breast or colon cancer, indicating that an abnormal expression of these nucleic

acid molecules is also present in rectal, lung, breast or colon cancer.

The term "abnormal expression" as used herein refers to an expression that is not present in normal cells or an expression that is present in normal cells at a lower level. In the present invention, "an abnormal expression" can also be used to refer to an unusual processing of the protein expressed from a nucleic acid, which is not present in normal cells and which results in unusual presentation of antigenic peptides at the cell surface.

Another embodiment of the present invention is directed to nucleic acid molecules, the complement sequences of which hybridize under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

"Stringent conditions" as used herein refer to conditions such as those specified in US Patent No. 5,342,774, i.e., 18 hours of hybridization at 65°C, followed by four one-hour washes with 2x SSC, 0.1% SDS, and a final wash with 0.2x SSC, more preferably 0.1x SSC, and 0.1% SDS for 30 minutes, as well as alternate conditions which afford the same level of stringency, and more stringent conditions.

In accordance with the present invention, molecules having a sequence, the complementary sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20, can include nucleic acid molecules having substantial homology to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20; parts of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20; degenerate sequences; and modified forms of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20, such as mutant forms with base pair substitutions, deletions or insertions. In

the event that SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 are fragments of full-length genes, such genes are also contemplated by the present invention as nucleic acid molecules having a sequence, the complementary sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

As used herein, "a part" of a nucleic acid molecule refers to a fragment of the nucleic acid molecule having sufficient length to encode an antigenic peptide of at least 8 or 9 amino acids. In particular, the present invention contemplates "unique" fragments of nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20. A unique fragment is one that is a "signature" for the larger nucleic acid molecule. It is, for example, long enough to selectively distinguish the sequence of interest from others. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 will require longer segments to be unique while others will require only shorter segments, typically between 12 and 32 nucleotides. Those skilled in the art are well versed in methods for selecting such sequences, e.g., by comparing the sequence of the fragment to those in known databases. *In vitro* confirmatory hybridization and sequencing analysis may also be used. According to the present invention, the unique fragments do not include sequences present in the prior art, such as ESTs and the like. Further according to the present invention, a unique fragment can be a functional fragment. A functional fragment of a nucleic acid molecule of the present invention is a fragment which

retains some functional property of the larger nucleic acid molecule, such as a fragment that encodes an antigenic epitope associated with melanoma or thyroid tumors.

5           The skilled artisan is fully capable of making, by following routine procedures, a nucleic acid molecule, the complement sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20. The skilled artisan can  
10 determine, for example, whether SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 encompasses a complete open reading frame, and if not, can isolate the full length molecules that encompass a complete open reading frame by following standard procedures, e.g., DNA  
15 hybridization-based cloning. See, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York.

20           The skilled artisan is also able to make fragments of these isolated nucleic acid molecules by using standard recombinant cloning techniques. The skilled artisan can further determine whether a fragment of an isolated nucleic acid molecule encodes the antigen(s) responsible for the immune response  
25 elicited in the patient and the resulting hyper-immunoreactive serum. This can be accomplished by following a number of well-known methods. For example, various portions of a nucleic acid molecule can be cloned into an appropriate expression vector which can  
30 be subsequently introduced into a desired host cell. Afterwards, polypeptides or peptides expressed from the respective DNA fragments can be tested for antigenicity by, e.g., using the patient's serum in a binding assay

5 routinely used in the SEREX methodology as described hereinabove; or using CTL clones with pre-defined specificity. Alternatively, one skilled in the art can chemically synthesize polypeptide or peptide fragments directly based on the nucleotide sequence of a fragment, and the antigenicity of the peptide can be determined by the reactivity toward the patient's serum in a binding assay, for example.

10 The skilled artisan is also able to isolate nucleic acid molecules having substantial homology to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 by following standard procedures, e.g., DNA hybridization-based cloning procedure. See, e.g., Sambrook et al. (1989).

15 In another embodiment, the nucleic acid molecules of the present invention or parts thereof have been inserted into expression vectors. The choice of vectors can be determined by those skilled in the art. When the host cell is a eukaryotic cell, viral (e.g., retroviral, adenoviral or pox), yeast or baculoviral vectors are preferred. When the host cell is a prokaryotic, then phage vectors are preferred, such as a  $\lambda$  phage vector. It is routine for those skilled in the art to construct expression vectors in which a nucleic acid molecule of interest is placed in operable linkage to a desired promoter so as to effect the expression of the polypeptide or peptide encoded by such nucleic acid molecule in host cells. See, e.g., Sambrook et al. (1989).

25 30 The present invention also provides expression vectors which include nucleic acid molecules encoding a series of epitopes, known as "polytopes" (Thompson et al. (1995) in *Proc. Natl. Acad. Sci. USA*



92: 5845-5849; Gilbert et al., *Nature Biotechnol.* 15:  
1280- 1284, 1997). The epitopes can be arranged in  
sequential or overlapping fashion, with or without the  
natural flanking sequences, and can be separated by  
unrelated linker sequences if desired. The polytope is  
processed in host cells to generate individual epitopes  
which can be recognized by the immune system. Thus,  
for example, peptides derived from the polypeptide  
having an amino acid sequence encoded by any one of the  
nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17  
and 19-20 of the instant invention, which are presented  
by MHC molecules and recognized by CTL or T helper  
lymphocytes can be combined with peptides from other  
tumor rejection antigens (e.g., by preparation of  
hybrid nucleic acids or polypeptides) to form  
"polytopes". Exemplary tumor associated peptide  
antigens that can be administered to induce or enhance  
an immune response are derived from tumor associated  
genes and encoded proteins including MAGE-1, MAGE-2,  
MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9,  
MAGE-10, MAGE-11, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-  
5, GAGE-6, BAGE-1, RAGE-1, LB33/MUM-1, DAGE, NAG, MAGE-  
Xp2, MAGE-Xp3, MAGE-Xp4, tyrosinase, brain glycogen  
phosphorylase, Melan-A, and MAGE-C1. For example,  
antigenic peptides characteristic of tumors include  
those listed in Table I below.

Table I: Exemplary Antigens

Gene	MHC	Peptide	Position	SEQ ID NO:
MAGE-1	HLA-A1	EADPTGHSY	161-169	21
	HLA-Cw16	SAYGEPRKL	230-238	22
MAGE-3	HLA-A1	EVDPIGHLY	168-176	23
	HLA-A2	FLWGPRALV	271-279	24
	HLA-B44	MEVDPIGHLY	167-176	25
BAGE	HLA-Cw16	AARAVFLAL	2-10	26
GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	27
RAGE	HLA-B7	SPSSNRIRNT	11-20	28
GnT-V	HLA-A2	VLPDVFIRC (V)	2-10/11	29
MUM-1	HLA-B44	EEKLIVVLF	exon 2/ intron	30
		EEKLSVVLF (wild type)		31
CDK4	HLA-A2	ACDPHSGHFV	23-32	32
		ARDPHSGHFV (wild type)		33
$\beta$ -catenin	HLA-A24	SYLDSGIHF	29-37	34
		SYLDSGIHS (wild type)		35
Tyrosinase	HLA-A2	MLLAVLYCL	1-9	36
	HLA-A2	YMNGTMSQV	369-377	37
	HLA-A2	YMDGTMSQV	369-377	38
	HLA-A24	AFLPWHRLF	206-214	39
	HLA-B44	SEIWRDIDF	192-200	40
	HLA-B44	YEIWRDIDF	192-200	41
	HLA-DR4	QNILLSNAPLGP QFP	56-70	42
	HLA-DR4	DYSYLQSDPDS FQD	448-462	43
Melan-A <sup>MOART-1</sup>	HLA-A2	(E)AAGIGILTV	26/27-35	44
	HLA-A2	ILTVILGVL	32-40	45
gp100 <sup>Pmel117</sup>	HLA-A2	KTWGQYWQV	154-162	46
	HLA-A2	ITDQVPFSV	209-217	47
	HLA-A2	YLEPGPVTA	280-288	48
	HLA-A2	LLDGTATLRL	457-466	49
	HLA-A2	VLYRYGSFSV	476-485	50
DAGE	HLA-A24	LYVDSLFFL	301-309	51
MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	52

The peptides of SEQ ID NOS: 41, 51 and 52 are presented in U.S. Application Serial No. 08/724,774, PCT Application Publication No. WO96/10577 and U.S. Application Serial No. 08/713,354, respectively. Other exemplary peptides include those listed in U.S. Patent

Applications 08/672,351, 08/669,590, 08/487,135,  
08/530,569 and 08/880,693. Other examples are known to  
one of ordinary skill in the art (for example, see  
Coulie, *Stem Cells* 13: 393-403, 1995), and can be used  
5 in the invention in a like manner as those disclosed  
herein.

It is known that tumors express a set of  
tumor antigens, of which only certain subsets may be  
expressed in the tumor of any given patient. Polytopes  
10 can be prepared which correspond to the different  
combination of epitopes representing the subset of  
tumor rejection antigens expressed in a particular  
patient. Polytopes also can be prepared to reflect a  
broader spectrum of tumor rejection antigens known to  
15 be expressed by a tumor type.

The present invention further contemplates  
host cells for propagating and/or expressing the  
nucleic acid molecules of the present invention. Those  
skilled in the art are equally familiar with the choice  
20 of cell lines and the procedures to transform or  
transfect such cell lines. Examples of the cell lines  
include, but are not limited to, eukaryotic cells such  
as COS cells (e.g., COS-7), CHO cells (e.g., CHO-1),  
NIH 3T3 cells, yeast cells (e.g., strains of  
25 *Saccharomyces* or *Pichia pastoris*), insect cells (e.g.,  
*Spodoptera frugiperda*); and prokaryotic cells such as  
strains of *E. coli*, strains of *Pseudomonas* (e.g.,  
*Pseudomonas aeruginosa*) or strains of *Bacillus*.

In a preferred embodiment, the present  
30 invention provides an antigen presenting cell  
transformed with an expression vector as described  
hereinabove.

"Antigen presenting cells" as used herein refer to cells expressing at least one MHC class I or class II molecule, which include, but are not limited to, professional antigen presenting cells such as B cells, monocytes, macrophages, dendritic cells and T cells; and facultative antigen presenting cells such as fibroblasts and endothelium cells. Antigen presenting cells can be isolated from tissue or blood samples. Both normal and malignant cells can be employed. Cell lines established in tissue culture from such samples can also be used. Many such cell lines are available from American Type Culture Collection (ATCC), Rockville, Maryland. Those skilled in the art can determine whether a chosen antigen presenting cell expresses at least one MHC molecule that is capable of presenting a peptide derived from a particular nucleic acid molecule. See, e.g., Coligan et al. (1994). Such cell can then be transfected with an expression vector which, under appropriate conditions, leads to the expression on the cell surface of one or more antigenic peptides encoded by fragments of the nucleic acid molecule of interest, complexed with appropriate MHC molecules,.

Another embodiment of the present invention is directed to proteins encoded by the isolated nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 or parts thereof.

The term "protein" used herein refers to both the unmodified forms (precursors) and post-translationally modified forms of a protein. Eukaryotic cells are well known for their ability to post-translationally modify proteins, so as to produce glycoproteins and lipoproteins, for example. According

to the present invention, the term "protein" also encompasses polypeptides and peptides.

The term "polypeptide" as used herein refers to a chain of at least 10 contiguous amino acids. The term "peptide" used herein refers to a chain of at least 8 or 9 amino acids.

The protein encoded by a nucleic acid molecule can be produced by routine recombinant expression in a desired host cell and subsequently purified by various known procedures, such as chromatography. A polypeptide or peptide can also be chemically synthesized according to its coding sequence in a standard peptide synthesizer. Those skilled in the art can also isolate antigenic peptides directly from the MHC/peptide complexes of antigen-expressing cells by, e.g., a method disclosed by Mandelblom et al. (1994). According to such method, peptides are eluted from the MHC-peptide complexes at the surface of antigen-expressing cells. The resulting pools of peptides are fractionated by HPLC and screened with antigen-specific CTL clones. Specific antigenic peptides can be identified and isolated based upon their ability to provoke specific CTL clones.

Purified proteins can be used as immunogens, either alone or in combination with an adjuvant such as saponins, GM-CSF, or interleukins. Immunogens such as these may be used, for example, to generate antibodies.

Accordingly, the present invention also contemplates antibodies directed against the proteins encoded by the nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 or parts thereof.

There are a variety of ways to obtain specific antibodies. Antibodies can be generated by

administering a protein of interest, either alone or in combination with an adjuvant, to various hosts, such as a rabbit, a mouse, or a sheep. Both monoclonal or polyclonal antibodies can be obtained using such immunized host. The methods for generating polyclonal and monoclonal antibodies are well known in the art. See, e.g., Coligan et al. *Current Protocols in Immunology*, John Wiley & Sons Inc., New York, New York (1994). Fragments of antibodies, such as Fab, F(ab)<sub>2</sub>, and the like, as well as recombinantly produced antibodies, are also contemplated by the present invention.

Another embodiment of the present invention is directed to isolated peptide/HLA complexes. Preferably, the peptide in such isolated peptide/HLA complexes is encoded by a fragment of any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

According to this embodiment, once the type of the HLA molecule capable of presenting a peptide is ascertained, such HLA molecule can be produced by any appropriate recombinant expression system, e.g., an *E. coli*-based expression system. As described above, peptides can be obtained by a number of ways, such as chemical synthesis or recombinant expression. The peptides and the presenting HLA molecules can then be mixed *in vitro* under conditions that favor the formation of HLA/peptide complexes. Such conditions are well known in the art. See, e.g., Garboczi et al. (*Proc. Natl. Acad. Sci. USA* 89: 3429-3433, 1992 and Altman et al. (*Science* 274: 94-96, 1996).

In another embodiment, the present invention provides methods of diagnosing a pathological condition

characterized by an abnormal expression of one or more of the nucleic acid molecules of the present invention.

The term "diagnosing" as used herein encompasses determining or monitoring the onset of, the progression of, the regression of, or the efficacy of a therapeutic regime for, a pathological condition.

Pathological conditions characterized by an abnormal expression of one or more of the nucleic acid molecules SEQ ID NOS: 1-30 of the present invention include, but are not limited to melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

Diagnosis of a pathological condition can be accomplished by determining an abnormal expression of at least one, i.e., one or more, nucleic acid molecule that is associated with such pathological condition. By comparing the expression in a sample from a patient suffering a pathological condition, with the expression in a normal sample, the skilled artisan can readily determine whether a relevant nucleic acid molecule is abnormally expressed in such pathological condition.

The abnormal expression of a nucleic acid molecule can manifest as an abnormal level of the mRNA of such nucleic acid molecule, the protein or peptide fragments encoded by such nucleic acid molecule, serum antibodies against such protein or peptide fragments, peptide/MHC complexes at the cell surface, or CTLs specific for certain peptide/MHC complexes. Accordingly, there are various assays which can be employed to detect the abnormal expression of a subject nucleic acid molecule.

A sample of suspected abnormality can be taken from a patient, such as a tissue biopsy sample,

or body fluid sample such as serum. The expression of a protein of interest in such sample can be determined by a variety of diagnostic assays.

One type of diagnostic assay is based on determination of the level of mRNA of a nucleic acid molecule associated with the pathological condition in question. Thus, for example, diagnosis of melanoma can be based on assaying the level of mRNA of, preferably, the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67-encoding gene (SEQ ID NOS: 23 and 24), the CENP-B-encoding gene (SEQ ID NO: 25), or nucleic acid sequences encompassing SEQ ID NO: 3 or 7. Diagnosis of thyroid tumors can be based on assaying the level of mRNA of, preferably, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), or nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20. Similarly, diagnosis of rectal, lung, breast, colon cancer or any other pathological condition can be based on assaying the level of the mRNA of one or more of SEQ ID NOS: 3, 7, 14-15, 17, 19-30 that are associated with the relevant pathological condition. For example, diagnosis of rectal cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21-24, 26, or 30, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID NOS: 14-15 or 20. Diagnosis of lung cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21 and 23-25, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID



NOS: 14-15 or 20. Diagnosis of breast cancer can be based on determining the level of, preferably, the mRNA of any one of SEQ ID NOS: 23 or 24, or the mRNA of a nucleic acid molecule encompassing SEQ ID NOS: 15.

5 Diagnosis of colon cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21-24, 26 or 29-30, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID NOS: 14-15 or 19-20. The methods for determining the level of  
10 mRNA are well within the ken of those skilled in the art, such as Northern Blot analysis or PCR analysis.

Another type of diagnostic assay is based on determination of the amount of protein expressed from the nucleic acid molecules associated with the  
15 pathological condition in question, or parts of such proteins. For example, for diagnosing melanoma, the protein to be examined can be the repressor protein encoded by SEQ ID NO: 21, the protein encoded by KIAA0201 (SEQ ID NO: 22), Ki-67 antigen (encoded by SEQ  
20 ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25) or the protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7. Preferably, diagnosis of melanoma is based on detecting proteins encoded by any one of SEQ ID NOS: 1-10. For diagnosing  
25 thyroid tumors, the protein to be examined can be TAFII68 (encoded by SEQ ID NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceramidase (encoded by SEQ ID NO: 30), or a  
30 protein encoded by any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20. Preferably, diagnosis of the presence of a thyroid tumor is based on detecting proteins encoded by

any one of SEQ ID NOS: 11-20. Similarly, diagnosis of rectal, lung, breast or colon cancer, or any other pathological condition can be based on assaying one or more proteins encoded by any one, i.e., one or more, of  
5 SEQ ID NOS: 1-30, that is associated with the relevant cancer. One skilled in the art can use various assays including, e.g., SDS-gels or 2D gels, Western Blot Analysis, ELISA and immunofluorescence flow-cytometry.

Still another type of diagnostic assay is  
10 based on detection of antibodies in the serum that are specific for a protein associated with a pathological condition in question or parts of such protein. Thus, in this type of assay, antibodies are detected by using the specific antigens in assays such as Western Blot or  
15 affinity chromatography, or a SEREX screening assay described herein. Antibodies specific for an antigenic peptide can also be detected by using cells which express and present the antigenic peptide at the surface in the context of an MHC molecule via assays  
20 such as FACS.

Another type of diagnostic assay is based on detection of cells in the patient's sample, which cells have at their surface, a peptide encoded by a fragment of a nucleic acid molecule associated with the  
25 pathological condition in question. For example, for diagnosing melanoma, such nucleic acid molecule includes the gene encoding the repressor protein (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B-  
30 encoding gene (SEQ ID NO: 25), or the nucleic acid sequences encompassing SEQ ID NO: 3, or 7; and preferably, such nucleic acid molecule is any one of SEQ ID NOS: 1-10. For diagnosing thyroid tumors, such

nucleic acid molecule includes genes encoding TAFII68 (SEQ ID NO: 26), lipocortin II (SEQ ID NO: 27), thyroglobulin (SEQ ID NO: 28), thymosin (SEQ ID NO: 29), or the acid ceramidase-encoding gene (SEQ ID NO: 30), or any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20; and preferably, such nucleic acid molecule is any one of SEQ ID NOS: 11-20. Likewise, for diagnosing rectal, lung, breast or colon cancer, the nucleic acid molecule can include any one of SEQ ID Nos: 1-30 that is associated with the relevant cancer. To determine the presence of such cell in a patient's sample, cellular-immuno assays can be employed, e.g., FACS analysis using antibodies raised against such peptide, or cytotoxic assays using pre-established CTLs specific for such peptide.

Another type of diagnostic assay is based on detection of CTLs in the patient's sample that are specific for a peptide of a protein associated with the pathological condition in question. Methods for detecting CTLs specific for an antigen are known in the art and are described hereinabove, such as assays for <sup>51</sup>Cr release, TNF production or IFN-gamma production.

According to the present invention, the present methods of diagnosis are applicable not only to the pathological conditions exemplified, such as melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer or colon cancer, but also to pathological conditions in general that are characterized by an abnormal expression of one or more of the subject nucleic acid molecules of the present invention. The isolated nucleic acid molecules of the present invention are clearly expressed in an abnormal

manner in patients having melanoma, thyroid tumor, rectal, lung, breast or colon cancer. These molecules may also be expressed abnormally in other tumors or in cells associated with other pathological disorders.

5 Thus, the techniques described hereinabove can be employed for diagnosing a pathological condition characterized by an abnormal expression of one of the nucleic acid molecules having a sequence encompassing one or more of SEQ ID NOS: 1-20.

10 In another embodiment, the present invention provides pharmaceutical compositions. The pharmaceutical compositions of the present invention are useful for treating pathological conditions characterized by an abnormal expression of one or more  
15 of the instant nucleic acid molecules of the present invention.

One pharmaceutical composition of the present invention includes an antisense molecule of one of the repressor protein-encoding gene (SEQ ID NO: 21), the  
20 KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the  
25 thyroglobulin -encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of such nucleic acid molecules.  
30 Preferably the antisense molecule is about 10-100 nucleotides in length and is carried by a suitable vector, such as a retroviral vector or a viral vector. The choice of vectors for such purpose is well-known in

the art, e.g., Vaccinia. The use of antisense molecules for inhibiting gene expression is known in the art.

Another pharmaceutical composition of the present invention includes a protein encoded by one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of such nucleic acid molecules. Preferably, the protein is encoded by one of SEQ ID NOS: 1-20 or parts thereof. Such proteins can be administered to a subject to provoke or augment an immune response in the subject against the abnormally expressed proteins.

Still another pharmaceutical composition of the present invention includes an antibody specific for a protein encoded by one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25) and nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAF 1168-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences

encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of these nucleic acid molecules. Preferably, the antibody is specific for a protein encoded by any one of SEQ ID NOS: 1-20 or parts of such proteins. Both polyclonal antibodies and monoclonal antibodies can be used. Monoclonal antibodies are preferred.

Another pharmaceutical composition of the present invention includes an antigen-presenting cell having at the cell surface, in the context of MHC molecules, one or more antigenic peptides encoded by a fragment(s) of one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25) and nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II - encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20. The antigen presenting cells to be used in the pharmaceutical composition of the present invention express MHC molecules that are compatible with the MHC molecules of the patient being treated. At least one of the MHC molecules expressed by such cells is capable of presenting a peptide encoded by a fragment of a subject nucleic acid molecule. The choice of antigen presenting cells is described hereinabove.

In accordance with the present invention, antigen presenting cells can be further modified to express other molecules for augmenting immunogenicity. A number of immune response potentiating molecules can

be used, including lymphokines, costimulatory molecules such as B7-1 (CD80), B7-2 (CD86), LFA-3, LFA-1 and CD40. B7 molecules, by interacting with CD28 or CTLA-4 molecules on T cells, potentiate T cell proliferation and effector function such as antitumor activity. See, e.g., Zheng et al., *Proc. Natl. Acad. Sci. USA* 95: 6284-6289 (1998); Wang et al., *J. Immunol.* 19: 1-8 (1996). The interaction of LFA-3 on antigen presenting cells with CD2 on T cells induces T cell to produce IL-2 and IFN-gamma (Fenton et al., *J. Immunol.* 21(2): 95-108, 1998). Complete CTL activation and effector function requires Th cell help through the interaction between the CD40 ligand expressed on Th cells and the CD40 molecules expressed on antigen presenting cells (Ridge et al., *Nature* 393:474, 1998; Bennett et al., *Nature* 393: 478, 1998; and Achenberger et al., *Nature* 393: 480, 1998). These additional immune-potentiating molecules can be included in any of the expression vectors (such as retroviral, adenoviral, or pox vectors) and introduced into antigen presenting cells by, e.g., transfection.

The pharmaceutical compositions of the present invention can also include a pharmaceutical acceptable carrier. As used herein, a pharmaceutically acceptable carrier includes any and all solvents, including water, dispersion media, culture from cell media, isotonic agents and the like that are non-toxic to the patient. Preferably, it is an aqueous isotonic buffered solution with a pH of around 7.0. The use of such media and agents in therapeutic compositions is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutical compositions of the present invention,

use of such conventional media or agents in the pharmaceutical compositions are contemplated. Supplementary active ingredients can also be incorporated into the compositions.

5           In a further embodiment, the pharmaceutical compositions of the present invention are used to treat pathological conditions characterized by an abnormal expression of one or more of the instant nucleic acid molecules of the present invention. Accordingly, the  
10           present invention provides methods of treating a subject suffering a pathological condition characterized by an abnormal expression of one or more of the instant nucleic acid molecules, by administering to such subject a therapeutically effective amount of a  
15           pharmaceutical composition of the present invention.

          The term "treating" means delaying the onset of a pathological condition or alleviating a pathological condition by controlling the expression of the nucleic acid molecule being abnormally expressed  
20           under such pathological condition. "Alleviating" is indicated by, in the case of tumor, inhibition of tumor growth, reduction in tumor size, inhibition of tumor metastasis and the like.

          "A pathological condition" as defined  
25           hereinabove, includes, but is not limited to, melanoma the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer or colon cancer. For treating melanoma, pharmaceutical compositions derived from melanoma-associated nucleic acid molecules (such as  
30           antisense molecules, proteins, antibodies or cells) are preferred. For treating thyroid tumors, pharmaceutical compositions derived from thyroid tumor-associated nucleic acid molecules are preferred. Likewise, for



treating any other pathological condition, such as rectal cancer, lung cancer, breast cancer or colon cancer, preferred pharmaceutical compositions to be used in the treatment are those derived from the nucleic acid molecules associated with that condition.

One method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, an antisense molecule of such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by administering to the subject, one or more of an antisense molecule of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), or nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts of these nucleic acid molecules; a subject having thyroid tumors can be treated by administering to the subject one or more of an antisense molecule of the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of these nucleic acid molecules.

Preferably, the antisense molecule is contained in a vector suitable for expression in the subject being treated. The choice of vectors for such purpose is well-known in the art and can be viral or retroviral vectors, e.g., a Vaccinia vector. A vector carrying the antisense DNA can be administered to a

subject in an amount sufficient to inhibit the expression of the protein. Such vector can be administered alone or with a carrier, such as a liposome, which facilitates the incorporation of the vector into a cell.

Another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, a protein encoded by such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by administering to the subject, the repressor protein (encoded by SEQ ID NO: 21), the protein encoded by KIAA0201 (SEQ ID NO: 22), Ki-67 (encoded by SEQ ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25), a protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts or combinations thereof. A subject having thyroid tumors can be treated by administering to the subject, TAF II68 (encoded by SEQ ID NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceramidase encoded by SEQ ID NO: 30), a protein encoded by any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts or combinations thereof.

The proteins are administered in an amount sufficient to provoke or augment an immune response in the subject which eliminate the abnormally expressed proteins. The proteins can be combined with one or more of the known immune adjuvants, such as saponins, GM-CSF, interleukins and so forth. Small peptides may

also be coupled to the well-known conjugates to achieve the desired immunogenicity.

Still another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, an antibody directed against the protein encoded by such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by administering to the subject, one or more of an antibody directed against the repressor protein (encoded by SEQ ID NO: 21), the protein encoded by the KIAA0201 (SEQ ID NO: 22), Ki-67 (encoded by SEQ ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25), or a protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts of these proteins. A subject having thyroid tumors can be treated by administering to the subject, one or more of an antibody directed against TAFII68 (encoded by SEQ ID NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceramidase (encoded by SEQ ID NO: 30), or a protein encoded by any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of these proteins. The antibodies can be administered alone or with pharmaceutically acceptable carriers in an amount sufficient to inhibit the function of the protein or proteins.

Still another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject,

an antigen presenting cell having one or more antigenic peptides complexed with MHC molecules, which peptides are encoded by fragments of such nucleic acid molecule.

5       The cells are preferably treated to be rendered non-proliferative before the administration to the subject suffering a relevant pathological condition. The cells are administered to a patient in an amount sufficient to stimulate an immune response against the protein that is abnormally expressed in the patient. Such cells may present epitopes to T cells and/or B cells, leading to a cellular immune response and/or a humoral immune response in the subject. According to the present invention, the induced immune response can alleviate the pathological condition by  
10       cytotoxic killing and/or antibody-mediated killing of the cells of abnormality.

15       In addition to direct administration to a subject for treatment, antigen presenting cells expressing an MHC/peptide complex of interest can be used in an ex vivo regime to generate cytolytic T cells specific for the peptide being presented. The procedure to develop such specific CTLs *in vitro* is known in the art, e.g., as disclosed by the United States Patent No. 5,342,774. Briefly, a blood sample  
20       containing T cell precursors is taken from a subject, preferably, the autologous patient. PBLs are purified from such blood sample and are incubated with stimulator cells, in this case, the antigen presenting cells expressing a MHC/peptide complex. Specific CTLs are thus produced which can be detected by standard  
25       assays, such as Cr<sup>51</sup> release or secretion of IFN-gamma. CTL cells generated as such can be reperfused to the patient and alleviate the pathological condition by  
30

lysing the cells abnormally expressing the peptide/MHC complex. See related teachings by Greenberg (1986) *J. Immunol.* 136 (5): 1917; Riddel et al. (1992) *Science* 257: 238; Lynch et al. (1991) *Eur. J. Immunol.* 21: 1403; and Kast et al. (1989) *Cell* 59: 603.

For practicing the treatment methods of the present invention, a pharmaceutical composition as described hereinabove can be administered to a patient in need thereof in any convenient manner, e.g., by subcutaneous (s.c.), intraperitoneal (i.p.), intra-arterial (i.a.), or intravenous (i.v.) injection..

The precise amount of a pharmaceutical composition to be administered so as to be therapeutically effective, can be determined those skilled in the art with consideration of individual differences in age, weight, tumor size, severity of the pathological condition and so forth.

All the publications mentioned in the present disclosure are incorporated herein by reference. The terms and expressions which have been employed in the present disclosure are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

The present invention is further illustrated but not limited by the following examples.

### Example 1

#### Isolation of cDNA clones using the SEREX methodology.

5 Two thyroid tumor cDNA libraries and one melanoma cDNA library were prepared, using standard techniques. See Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York. The libraries were screened using the SEREX methodology as described supra and set forth by Sahin et al. (1995) and by Chen et al., *Proc. Natl. Acad. Sci. USA* 94: 1914 (1997), incorporated herein by reference.

15 More specifically, total RNA was isolated from tumor cells secured from three individuals, Patient 1 with melanoma, Patients 2 and 3 with thyroid tumors. The RNA from each patient was used to prepare a cDNA library, resulting in three cDNA libraries, named as Mel-N1, Thy-N1, and Thy-N2, respectively. Each of these cDNA libraries was cloned into  $\lambda$ ZAP phage vectors (Short et al., *Nucleic Acids Res.* 16: 7583, 1988). Bacteria of the strain *E. Coli* XL1-Blue was then transfected with the recombinant phages derived from one of the described phage cDNA libraries, plated at a density of  $4-5 \times 10^3$  pfus (plaque forming units) per plate, and incubated for eight hours at 37°C. A nitrocellulose membrane was then placed on each plate, followed by overnight incubation.

30 The membrane was subsequently washed four times with TBS containing 0.05% Tween-20, and was immersed afterwards in TBS containing 5% non-fat dried milk. After one hour, the nitrocellulose membranes were washed three times with TBS, followed by the incubation with diluted human serum secured from the

autologous patient. The serum was pretreated, as described in detail by Sahin et al. (1995), U.S. Patent No. 5,698,396 and International Application WO 96/40209, to deplete interfering antibodies directed against antigens derived from *E. Coli* and phages. The stripped human serum was diluted 1:100 in TBS containing 0.5% milk powder (w/v). The membranes were incubated in the human serum overnight with gentle shaking, followed by three washes with TBS.

Afterwards, the membranes were incubated with polyclonal goat anti-human IgG Fcy conjugated with HRP. The conjugated antibodies were diluted 1:2000 in TBS-1% BSA. After incubation for one hour at room temperature, the membranes were washed three times with TBS. The positive clones were visualized using 30% solution of hydrogen peroxidase. Positive clones were further subcloned to monoclonality by repeated rounds of transfection and testing.

At the end of this screening procedure, ten cDNA clones (MEL 1-10) were obtained from the MEL-N1 library; three cDNA clones (Thy 1-3) were obtained from the Thy-N1 library; seven cDNA clones (Thy 5-6, 9, 11-12 and 14-15) were obtained from the Thy-N2 library.

## Example 2

### Sequencing the isolated cDNA clones.

5 The insert size of the isolated cDNA clones was determined using restriction enzymes and listed in Table I. The inserts of the cDNA clones were sequenced from the 3' end using standard techniques. See Sambrook et al. (1989), for example. SEQ ID NOS: 1-20  
10 illustrate the sequences of the 3' portions of these isolated cDNA clones. Following nucleotide homology search of the databases, these sequences were resolved into known and unknown sequences. Table 1 summarizes the results. In Table 1, the "+" signs are used to indicate the relative strength of reactivity of each  
15 clone toward the corresponding patient serum.

SEQ ID NO: 1 (MEL 1) corresponds to a portion of the partial mRNA sequence for the repressor protein (SEQ ID NO: 21). SEQ ID NO: 2 (MEL 2) corresponds to a portion of the KIAA0201 gene (SEQ ID NO: 22, homologue  
20 to heat shock protein HSP). SEQ ID NOS: 4 and 8-10 (MEL 4 and MEL 8-10) correspond to portions of the Ki-67 nuclear antigen gene (SEQ ID NO: 23 and 24). SEQ ID NOS: 5-6 (MEL 5-6) correspond to portions of the CENP-B gene (SEQ ID NO: 25). SEQ ID NO: 3 (MEL 3) is matched  
25 by several EST sequences in Genbank. SEQ ID NO: 7 (MEL 7) does not find any sequence match in the databases.

SEQ ID NO: 11 (Thy 1) corresponds to a portion of the TAFII68 (TBP associated factor) gene (SEQ ID NO: 26). SEQ ID NO: 12 (Thy 2) corresponds to  
30 a portion of the lipocortin II gene (SEQ ID NO: 27). SEQ ID NO: 13 (Thy 3) corresponds to a portion of the thyroglobulin gene (SEQ ID NO: 28). SEQ ID NO: 16 (Thy 9) corresponds to a portion of the thymosin beta-4 gene



(SEQ ID NO: 29). SEQ ID NO: 17 (Thy 12) corresponds to a portion of the Acid ceramidase gene (SEQ ID NO: 30). SEQ ID NOS: 14,17 and 19-20 (Thy 5, Thy 11, Thy 14 and Thy 15) are only matched by EST sequences in the databases.

5

Table II

SEQ ID NO	Clone	Serum react	Insert size (kb)	Access. No.	Identity
1	Mel 1	++	0.4	D30612	mRNA (partial) for repressor protein
2	Mel 2	+++++	0.7	D86956	KIAA0201, homolog to HSP
3	Mel 3	+	1.65	Novel	EST matches
4	Mel 4	++++	0.9	X65551/50	Ki-67 nuclear antigen, LONY-BR-8 (Breast SEREX)
8	Mel 8	+++	0.8		
9	Mel 9	++++	0.9		
10	Mel 10	++++	1.0		
5	Mel 5	++	1.25	X55039	CENP-B centromere autoantigen
6	Mel 6	+++	1.2		
7	Mel 7	+++	0.9	Novel	No EST match
11	Thy 1	+	0.8	X98893	TAF 1168
12	Thy 2	+	1.2	D000617	lipocortin II
13	Thy 3	+	1.7	X05615	thyroglobulin
14	Thy 5	+	2.7	Novel	Novel-EST matches
15	Thy 6	++	3.4	Novel	Novel-ESTs
16	Thy 9	+	0.6	M17733	thymosin beta-4
17	Thy 11	+	4.2	Novel	Novel-EST matches
18	Thy 12	++	0.8	U70063	Acid ceramidase
19	Thy 14	++	2.9	Novel	Novel-EST matches
20	Thy 15	++	2.5	Novel	Novel-EST matches

Table III

SEQ ID NO.	Accession NO.	Identity
21	D30612	Homo sapiens mRNA for repressor protein, partial cds
22	D86956	Human mRNA for KIAA0201 gene, complete cds
23	X65550	H.sapiens mki67a mRNA (long type) for antigen of monoclonal antibody Ki-67
24	X65551	H.sapiens mki67a mRNA (short type) for antigen of monoclonal antibody Ki-67
25	X55039	Human hCENP-B gene for centromere autoantigen B (CENP-B)
26	X98893	H.sapiens mRNA for TBP associated factor (TAFII68)
27	D00017	Homo sapiens mRNA for lipocortin II, complete cds
28	X05615	Human mRNA for thyroglobulin
29	M17733	Human thymosin beta-4 mRNA, complete cds
30	U70063	Human acid ceramidase mRNA, complete cds

### Example 3

#### Clone Reactivity with Sera from Allogeneic Cancer Patients

5           The SEREX clones were tested for reactivity  
with 52 allogeneic sera from cancer patients (7 rectal,  
13 lung, 21 breast, 11 colon) and 10 allogeneic sera  
from normal individuals. The procedure was essentially  
10 as the SEREX method described in Example 1, except that  
'defined' cDNA molecules, i.e., the isolated clones  
were being expressed, blotted and screened with  
allogeneic sera rather than autologous sera. The  
allogeneic sera were treated in the same way the  
autologous sera were treated which as described in  
15 Example 1. Briefly, XL-1 E Coli cells were grown to OD  
1.0, spun down and suspended in 10 ml MgSO<sub>4</sub>. 20 ml of  
primary phage stock in SM-buffer were added to 100 ml  
of bacterial solution. Phage was sorbed for 15 min at  
28°C, then 0.5 ml of 2 YT medium and IPTG were added  
20 and samples were incubated at 42°C until lysis (6-7  
hrs). Afterwards, cell debris was spun down and 2 ml  
solution were transferred to Hybond-C filters,  
incubated with allogeneic sera samples overnight (sera  
1:100) and developed by standard method with anti-human  
25 anti-IgG horse radish peroxidase conjugate, stained  
with DAB. The level of immunoreactivity was estimated  
in arbitrary units, where 4=high signal level, 3=medium  
signal level, 2=weak signal, 1= absence of signal. An  
average mean of signals for each clone and type of  
30 cancer have been calculated, and mean of average signal  
for normal sera have been subtracted. Table IV  
summarizes the results.

35

Table IV Dot Blot Analysis

		C L O N E S																			
ID NO		1	2	3	5	6	9	11	12	14	15	16	17	18	19	20	21	22	23	24	25
Rectal cancer																					
5	Rec1	1	2	1	4	3	1	1	2	1	2	2	3	3	3	2	2	2	2	2	2
	Rec8	1	3	3	3	3	3	3	3	2	2	3	2	2	3	3	2	2	3	3	3
	Rec3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	3	3	3
	Rec4	2	2	3	3	3	2	3	3	3	2	3	2	2	2	2	2	2	3	3	3
	Rec5	4	2	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	3
10	Rec6	4	2	3	3	3	3	3	3	3	2	2	3	2	2	2	2	2	2	2	3
	Rec2	3	2	3	3	3	2	3	3	3	3	3	4	3	3	3	2	2	2	3	3
		18	16	18	21	20	16	18	19	17	16	18	20	17	18	16	14	14	17	18	20
Lung cancer																					
15	Lu2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	2	3	3	3	3	3
	Lu3	1	3	3	4	3	3	3	3	3	1	2	2	2	2	2	2	2	3	3	3
	Lu46	1	2	3	3	3	2	1	1	1	3	2	3	3	3	3	3	3	2	2	4
	Lu18	3	2	3	4	3	3	3	3	2	2	2	2	2	2	2	2	2	3	3	3
	Lu24	1	1	1	3	3	3	3	2	2	3	2	2	2	3	3	3	2	3	3	4
20	Lu26	3	2	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	Lu40	1	3	3	3	3	2	3	3	3	1	2	2	2	3	3	2	2	3	3	4
	Lu44	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	4
	Lu17	1	3	3	3	3	2	2	3	2	3	3	2	2	3	3	3	1	3	3	4
	Lu49	3	2	2	3	3	2	3	3	3	2	2	3	2	3	3	3	3	2	2	3
25	Lu4	2	2	2	3	3	2	2	3	2	1	2	3	1	2	2	2	2	2	2	3
	Lu47	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	Lu50	2	1	1	3	3	1	1	2	2	1	2	2	3	3	3	3	1	2	2	2
		22	30	33	41	39	31	32	34	29	29	30	32	30	35	34	34	28	33	34	42
Breast cancer																					
30	Br2	3	2	1	3	2	3	2	2	3	3	2	2	3	2	2	2	2	2	2	3
	Br15	4	2	3	3	3	3	3	3	3	2	4	2	4	3	2	2	2	3	3	4
	Br8	4	1	1	2	2	1	2	2	3	1	1	3	3	2	2	2	2	1	1	3
	Br1	3	1	2	2	2	2	1	3	1	2	2	3	3	2	2	1	1	2	1	2
	Br9	2	2	2	2	3	3	3	3	1	3	2	3	2	2	2	2	2	1	2	1
35	Br3	2	1	3	2	3	3	3	2	2	2	1	3	2	2	2	2	2	2	3	3
	Br10	3	2	4	3	3	3	1	4	2	2	3	4	4	3	3	3	2	2	2	2
	Br17	3	3	3	3	3	2	3	3	3	2	3	3	3	3	3	1	1	3	3	3
	Br16	1	1	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	2	1
	Br4	2	2	2	1	2	2	2	2	1	1	1	2	2	2	2	1	1	1	1	2
40	Br6	3	2	2	1	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	3
	Br14	2	2	1	1	4	3	3	3	2	2	1	3	3	3	3	3	2	2	3	3
	Br5	3	3	3	2	4	3	3	3	2	2	2	3	3	3	3	3	1	1	2	3
	Br20	1	2	2	2	2	2	2	2	1	2	2	1	2	2	1	2	1	1	1	2
	Br12	3	1	3	2	3	3	2	3	3	3	3	3	3	2	2	2	3	2	2	3
45	Br19	3	3	3	2	3	3	2	3	2	2	2	3	3	1	3	3	1	1	1	2
	Br18	3	3	3	2	3	3	2	2	1	1	2	2	2	2	2	2	3	1	1	3
	Br11	2	1	2	1	3	2	2	2	1	1	2	2	2	2	2	2	2	1	1	2
	Br248	1	1	2	2	2	2	3	2	4	2	3	3	2	3	3	1	1	3	3	4
	Br257	1	2	3	3	3	3	3	3	4	1	3	2	3	4	4	3	3	3	4	4
50	Br263	1	2	2	3	3	2	4	3	4	2	2	1	2	2	2	1	1	2	3	3
		50	39	48	43	57	51	49	54	45	40	44	51	54	48	48	42	34	37	43	56
Colon cancer																					
55	Co5	4	3	3	3	3	3	3	3	3	2	2	3	3	3	3	3	1	3	3	3
	Co30	3	2	3	3	3	3	3	3	3	2	2	3	3	3	3	3	2	3	3	3
	Co17(?)	4	2	3	3	3	3	3	3	3	2	3	3	3	3	3	2	2	3	3	3
	Co37	3	1	2	2	2	2	2	2	2	2	2	3	3	2	2	2	1	1	2	2
	Co33	3	3	3	3	3	3	3	3	3	2	2	3	3	2	2	2	2	2	2	3

WO 00/50595

PCT/US00/04929

=

5

Co4	4	2	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	3	3
Co34	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	3	3
Co36	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	3	3
Co2	2	2	2	2	3	3	2	2	2	2	3	3	3	3	3	1	1	2	2	3
Co3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	2	3	3
Co32	3	3	3	3	3	3	3	3	1	2	2	3	2	2	2	1	1	3	3	3
	35	26	31	31	32	32	31	31	29	26	28	33	32	29	29	22	18	29	30	32

C L O N E S

10

ID	1	2	3	5	6	9	11	12	14	15	16	17	18	19	20	21	22	23	24	25
Normal																				
sera																				
No10	3	1	1	2	1	2	2	1	2	2	3	3	2	3	2	2	2	2	2	2
No8	1	1	3	2	2	2	2	2	2											
No5	1	2	2	3	1	1	3	2	2	1	1	2	2	1	2	2	3	1	2	2
No22	2	2	2	1	2	2	3	3	1	3	2	2	2	1	4	1	3	1	2	2
No13	1	1	2	2	1	2	3	2	1	1	1	1	1	1	1	2	1	2	1	1
No3	1	2	3	2	1	2	2	1	1	1	1	2	3	2	3	2	3	1	2	2
No21	1	2	3	3	2	2	2	2	2	1	1	2	2	1	3	2	2	1	2	2
No1	2	2	2	1	1	2	2	2	2	1	1	1	3	1	2	1	2	1	1	1
No2	1	1	2	1	1	1	1	1	1	1	1	2	3	1	1	2	2	1	2	2
No15	2	2	1	1	1	1	1	1	1	1	1	2	3	1	2	1	2	1	1	1
	15	16	21	18	13	17	21	17	15	12	12	17	21	12	21	14	21	10	15	15

All sera scoring 4 or 3 were classed as positive and the results of the dot blotting were summarized in Table V.

**Table V Clone Reactivity with Allogenic Sera**

ID	Clone	SEQ ID NO	Allogenic cancer sera				
			Rectal (n=7)	Lung (n=13)	Breast (n=21)	Colon (n=11)	Normal (n=10)
10	1 Thy1	11	4	3	11	10	1
	2 Thy2	12	2	6	4	5	0
	3 Thy3	13	5	9	9	9	9
	5 Thy5	14	6	13	6	9	2
	6 Thy6	15	6	13	13	10	0
	9 Thy9	16	3	6	11	10	0
15	11 Thy11	17	5	8	9	9	3
	12 Thy12	18	5	9	11	9	1
	14 Thy14	19	4	5	8	8	0
	15 Thy15	20	2	6	3	4	1
20	16 Mel1	1	4	4	6	6	1
	17 Mel2	2	5	6	11	11	1
	18 Mel3	3	3	5	11	10	4
	19 Mel4	4	4	9	7	7	1
	20 Mel5	5	2	8	7	7	3
25	21 Mel6	6	0	8	6	2	0
	22 Mel7	7	0	4	2	0	3
	23 Mel8	8	3	7	4	8	0
	24 Mel9	9	4	8	7	8	0
	25 Mel10	10	6	11	13	10	0

Based on the data in Table V, the mean of the intensity values for each cancer sera type was calculated for each clone. The mean of the intensity values for each normal sera type was calculated For each clone. The difference between the cancer sera and normal sera is presented in Table VI. A value over 1.0 indicates a specific recognition of the clone by the type of cancer sera.

So for instance, SEQ ID No's 4, 8, 9, 10, which represent sequences of Ki-67, are specifically recognized by serum antibodies from rectal, lung, breast and colon cancer patients. Ki-67 is a marker of proliferation used in immunohistochemistry. The present invention has shown for the first time the association of this antigen with cancer.



**Table VI Specific Clone reactivity with allogenic cancer sera**

	ID	Clone	SEQ ID NO	Allogenic cancer sera			
				Rectal (n=7)	Lung (n=13)	Breast (n=21)	Colon (n=11)
5	1	Thy1	11	1.07	0.19	0.88	1.68
	2	Thy2	12	0.69	0.71	0.26	0.76
	3	Thy3	13	0.47	0.44	0.19	0.72
	5	Thy5	14	1.2	1.35	0.24	1.02
10	6	Thy6	15	1.55	1.7	1.41	1.61
	9	Thy9	16	0.59	0.68	0.73	1.21
	11	Thy11	17	0.47	0.36	0.23	0.72
	12	Thy12	18	1.01	0.92	0.87	1.12
15	14	Thy14	19	0.92	0.73	0.64	1.14
	15	Thy15	20	1.09	1.03	0.7	1.16
20	16	Mel1	1	1.37	1.11	0.9	1.35
	17	Mel2	2	1.16	0.76	0.73	1.3
	18	Mel3	3	0.32	0.21	0.47	0.81
	19	Mel4	4	1.37	1.49	1.09	1.44
	20	Mel5	5	0.91	0.52	0.19	0.54
	21	Mel6	6	0.6	1.22	0.6	0.6
	22	Mel7	7	0	0.05	0	0
25	23	Mel8	8	1.42	1.54	0.76	1.64
	24	Mel9	9	1.07	1.12	0.54	1.23
	25	Mel10	10	1.36	1.73	1.17	1.41

**Example 3**

Reactivity of a Fragment of Ki67  
Recombinantly Expressed in Bacteria  
With Allogenic Sera from Cancer Patients

5

A 0.5 kB sequence of Mel-9 clone was amplified by PCR, using Vent polymerase and a pair of specific primers. The primers used are:

10

Oligo N1, Ki67 sense, Nhe, 6His, 5610  
ATTGCTAGCCACCACCACCACCACAACTGGACCCAGCAGCAAGTGTAAC  
(SEQ ID NO:31); and  
Oligo N2, Ki67 antisense, EcoRI, 6420  
CGGGAATTCCTATAGAGCCTCAGCCTTTTCCTTAGG (SEQ ID NO: 32)

15

Amplified cDNA fragment of Ki67 was subcloned into pET23d in a correct reading frame with the His-tag epitope. Expression of recombinant His-tag/Ki67 was carried out in DE3 pLysS cells in the presence of 1 mM IPTG. Recombinant protein had a predicted molecular weight (about 21 kDa) and was purified nearly to homogeneity by affinity chromatography on Talon Sepharose. Purified His-tag/Ki67 was used for heterologous screening of sera from healthy individuals and cancer patients.

25

30

35

Highly purified recombinant Ki67 was coupled to 96-well immunoassay plates (0.1-1 mkg per well). Non-specific binding of sera's IgG to plates was blocked by BSA. Binding of recombinant Ki-67 by specific antibodies present in normal and cancer sera was measured by ELISA using standard techniques. Four experiments were done. In each experiment, each sample of normal or cancer sera was tested against recombinant Ki-67. The mean values for corresponding sera types were calculated in each experiment and averages for normal and cancer sera were compared to determine differences. The difference in the measured intensity reflects the

difference in the amount of specific antibodies between cancer and normal sera.

Table VII presents the results. The results of this study indicate that sera from lung and breast cancer patients show increased immunoreactivity towards recombinant Ki67. The differences between the cancer sera and normal sera in immunoreactivity towards recombinant Ki67 were considered valid if p-value was less than 0.05. Statistical analysis indicated that significant differences were seen with lung and breast cancer sera, indicating that these cancer seras contained greater amounts of Ki-67 specific antibodies compared to normal sera.

Table VII

ELIZA: Recombinant Ki-67 screened with allogenic cancer and normal sera

	Exp	Sera Compared	Difference	Statistically Significant
20	exp 1	N1 vs. LU1	+	Yes
	exp 1	N1 vs. BR1	+	Yes
	exp 1	N1 vs. THY1	+	No
	exp 2	N2 vs. LU2	+	Yes
25	exp 2	N2 vs. CO2	+	No
	exp 3	N3 vs. LU3	+	Yes
	exp 3	N3 vs. BR3	+	Yes
	exp 3	N3 vs. THY3	+	No
30	exp 4	N4 vs. LU4	+	Yes
	exp 4	N4 vs. BR4	+	Yes

## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule or a part thereof, wherein said nucleic acid molecule has a sequence as set forth in any one of SEQ ID NOS: 3, 7, 14, 17, 19 or 20.

2. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 3.

3. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 7.

4. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 14.

5. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 15.

6. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 17.

7. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 19.

8. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 20.

9. An isolated nucleic acid molecule comprising a nucleotide sequence, the complementary sequence of which hybridizes under stringent conditions to at least one nucleic acid molecule of SEQ ID NOS: 3, 7, 14-15, 17 or 19-20.

10. An isolated protein encoded by the isolated nucleic acid molecule or a part thereof of claim 1.

11. An isolated antibody specific for a protein encoded by the nucleic acid molecule or a part thereof of claim 1.

12. An expression vector comprising the nucleic acid molecule or a part thereof of claim 1, operably linked to a promoter to effect the expression of a protein encoded by said nucleic acid molecule or a part thereof.

13. A cell, transformed or tranfected with the isolated nucleic acid molecule or a part thereof of claim 1.

14. A cell, transformed or tranfected with the expression vector of claim 12.

15. The cell of claim 14, wherein said cell is an antigen presenting cell having on the surface, a complex of an MHC molecule and a peptide, said peptide being encoded by a fragment of said nucleic acid molecule.

16. An isolated peptide/HLA complex, wherein said peptide is encoded by a fragment of any one of SEQ ID NOS: 3, 7, 14-15, 17 or 19-20.

17. A method for diagnosing a pathological condition in a patient, wherein said condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising the steps of:

- (i) obtaining a sample from said patient;
- (ii) assessing the expression of said nucleic acid molecule in said sample; and
- (iii) determining the expression of said nucleic acid molecule as abnormal thereby diagnosing said pathological condition.

18. The method of claim 17, wherein said pathological condition is selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

19. The method of Claim 18, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NO: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

20. The method of Claim 18, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

21. The method of Claim 18, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS:

21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

22. The method of Claim 18, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

23. The method of Claim 18, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

24. The method of Claim 18, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

25. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of mRNA of said nucleic acid molecule.

26. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of a protein encoded by said nucleic acid molecule or parts thereof.

27. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of an antibody in the serum that is specific for a protein encoded by said nucleic acid molecule or parts thereof.

28. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying a cell expressing an MHC/peptide complex and wherein said peptide is encoded by a fragment of said nucleic acid molecule.

29. A composition comprising a carrier and an antisense DNA of a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

30. A composition comprising a carrier and a protein encoded by a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

31. A composition comprising a carrier and an antibody directed against a protein encoded by a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

32. A composition comprising an immunogenic cell and a carrier, wherein said cell expresses a peptide complexed with an MHC molecule, said peptide being encoded by a fragment of a nucleic acid molecule, and wherein said nucleic acid molecule is any one of SEQ ID NOS: 14-15, 17 or 19-20.

33. A method for treating a patient afflicted with a pathological condition, wherein said



condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20; said method comprising administering to said patient a therapeutically effective amount of at least one of: an antisense DNA of said nucleic acid molecule or part thereof, a protein encoded by said nucleic acid molecule or part thereof, an antibody specific for a protein encoded by said nucleic acid molecule or part thereof, or a cell expressing a MHC/peptide complex wherein said peptide is encoded by a fragment of said nucleic acid molecule.

34. The method of claim 33, wherein said pathological condition is selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

35. The method of claim 34, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

36. The method of claim 34, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleic acid sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

37. The method of Claim 34, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS:

21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

38. The method of Claim 34, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

39. The method of Claim 34, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

40. The method of Claim 34, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

41. A method for treating a subject afflicted with a pathological condition, wherein said condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising:

(i) removing an immuno-reactive cell containing sample from said subject,

(ii) contacting the immuno-reactive cell containing sample with immunogenic cells expressing a peptide encoded by a fragment of said nucleic acid molecule complexed with an MHC molecule;

(iii) selecting the cytolytic T cells that are specific for said peptide; and

(iv) introducing a therapeutic effective amount of the cytolytic T cells produced from step (iii) to said subject thereby alleviating said condition.

42. The method of claim 41, wherein said pathological condition is one selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

43. The method of claim 42, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

44. The method of claim 42, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleic acid sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

45. The method of Claim 42, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

46. The method of Claim 42, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

47. The method of Claim 42, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

48. The method of Claim 42, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

49. A method of identifying the association of a pathological condition with an abnormal expression of a nucleic acid molecule, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising:

obtaining the serum from a patient suffering said pathological condition; and

detecting the presence of an antibody in said serum specific for an antigen encoded by said nucleic acid molecule, as indicative of an association of said pathological condition with the abnormal expression of said nucleic acid molecule.

50. The method of claim 49, wherein said nucleic acid molecule is SEQ ID NO: 23 or 24.

51. The method of claim 49, wherein said pathological condition is a cancer.

52. The method of claim 49, wherein the detection is carried out using a SEREX screening assay.

SEQ ID NO: 1 (Me11)

5 TGTNCAANGGGGNTNAGTGGTNACNGNCATGGGTACNNGCCTNTTCCC  
NNNGCNCNGNATATTGNGTGCANGNCGCANTNTTTNGNANANGCAGCN  
ACNGTGGACTGGTCCCTCNACAGGCCAGTTTNNNGGCCCCCAGAGTCANG  
NCCTCNACCANTGANNGATTNTGTTCCNGTTCATCCNCAGNGNAGAAGGG  
GCGAGGGAGAGNCNTTNTGCTTTTGAGGGTNANCNGTNAGGNGTNTNTTC  
CCNGCAGCAGCCGGTCAAGTGGATANTAGNGTNTGNGCNTCNGGNTNTCG  
TGCNNTGGGCCTCCCAATTGGNGGTATNTGNACTGCCCCGTGNTCANGGAC  
10 NTGGCTACAGACCNTGNTGNGGCCANACCNTGCAGGCGCCTCGGGAAGCG  
CCCAAAGGATTCCCCCTNNANGTTGGTGCACNTGATCCATAGNTCCGGGCG  
CTGNGTCCCGNGGGGCCACAGTNNCCATNTCAGCGTCTTGCATGGCNTGG  
CACCGGGTGGGGTGGTATGCCCCAGGACCCNTGNTTGTGNCAAAAATGAC  
TTTCCNTGCCCTTGCCGTGGGGCCGGGGTTCCTCCCANCCGGGATCACAG  
15 TGGGCAGCCGGCACC CGCACCACTTTGGCGNGCGTCCTGCTTCCGCCCT  
CGCCCTCATNTACGNTGNNCCGCTTTCCTCNGACCCCTTTTNTCCGTGCA  
AAGGGAATTNTTGACATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAA  
AAA

20

SEQ ID NO: 2 (Me12)

CTCCGGGAAGCGGCTCCCATTTGTTGTTNGTACCCCGGGAATTTCGGCACG  
AGGAGTTCAGANGACAAGCTGTGTGGACCATATGAAAAATTTATATGTGA  
25 GCAGGATCNTCAAAATTTTTTGGGACTCCTCACCAGAACTGAAGACTGG  
CTGTATGAAGAAGGAGAGGACCCAAGCTAAACAAGCATATGTTGACAAGT  
TGGAAGAATTAATGAAAATTGGCACTCCAGTTAAAGTTCGGTTTCAGGAA  
GCTGAAGAACGGCCAAAATGTTTGAAGAACTAGGACAGAGGCTGCAGCA  
TTATGCCAAGATAGCAGCTGACTTCAGAAATAAGGATGAGAAATACANCC  
30 ATATTGATGAGTCTGAAATGAAAAAGTGGAGAAGTCTGTTAATGAAGTG  
ATGGAATGGATGAATAATGTCATGAATGCTCAGGCTAAAAAGAGTCTTGA  
TCAGGATCCAGTTGTACGTGCTCAGGAAATTAAACAAAAATCAAGGAAT  
TGAACAACACATGTGAACCCGTTGTAACACAACCGAAACCAAAAATTGAA  
TCACCCAAANTGGAAAGAACTCCAAATGGCCCAAATATTGNTAAAAAAA

AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 3 (Me13)

5 TGGGNTTTTCCCCCTTTTNGNAACCCNTTTCNTNCCCCCNNTTGC  
CCNTTNGGGTCTCGGGGGCCCCANTTTGGGNGNTTGGGGNGTTTNCCGGG  
NGGTTTCCCAACCGTGCCCCNCCGTGGGTNACCCCCCGNGGCNNCCAGG  
GGTNGGCCNTGGGGGTTTCCGGCCGGGGGTGCCTTTTCCCNNTNNCANN  
CNAGTNAGGNTTTTNTNGGGGGGCCCCAANCCCTTTTGGGAGGGGTC  
10 CCGNNGNAGGTCCNCNNTTGGCCCCCTNCAAGGGTNGGNGCCCCNCCCC  
CACCCCCCGGNCCCCCTTGGGAGNCCCGTTTAAATCNNTNGGGGGTCNT  
NGGCCTGGTTTTNCCTGGTTTNCNCTNCCCCGTNCCCTTTTTTGGCCCN  
TTCCCTTTGGNTTTTGCCCCTNGGTTTTTTTCCCGGTTGGGGNTTNCCA  
GGGGCCCCCCCCCTNGGAGTTNCCCAGGGGGTTCNNTTNGGNCNNTN  
15 CCGGNCCCCCTNCCTTTCCTCCCNNTTNGNNGGGNCCCCTTTTGGCCGG  
GGGGCCTTGGGGTGGCCCCGGGNCCCCCNCCCGNTNNNCNNTTNCCC  
NNTNGTTTNNATNAANTTTNCCCNCCCCCTTTTNGGGGNGACNTTT  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
20 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
A

SEQ ID NO: 4 (Me14)

25 TTGTGTTGGAATTNTTGAGCGGATTAACANTTTTNACACNGGNAACAGN  
TTTTGNCCNNTGATTACNCCAANGTTATTTTAGGGTTGACANTTTTGGA  
ATTACTCAAGGTAGGNTNTGGTTTAACATTGGCAAGGGTGTGCGCATAG  
CCGANGATATTCGGTAGAGTTATATTGAGCAGATCCCCCGGTGAAGGATT  
TAACCGTGTTATCTCGTTGGAATATTCATGGCGTATTTTGGATGATAAC  
30 GAGGCGCAAAAATGAAAAGTACTNTAGCAATTGTGAGCGGACAACAATT  
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCCGAGATCTGG  
ACGAGCTTTTTTTTTTTTCTCGGGAAGCGCGCCATTGTGTTGGTACCCG  
GGAATTCGGCACGAGGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAC  
TGGTAGCAAGAGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAG

AAGACTTGGCTGGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGAC  
AAGCCCACGACTCATGAGAAAACCTACCAAAATAGCCTGCAGATCTCCACA  
ACCAGACCCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAA  
GTCTCAGGAAAGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGA  
5 ACACCATCAGTAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGA  
TGAGAAAGACATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACC  
TGCCAGGAAATTTACCTGGCAGCAAAAGATGGCCACAAACTCCTAAGGAA  
AAGGCCCAGGC

10

SEQ ID NO: 5 (Me15)

ACCCCCAGGGGCAGGGGGAATTTTTTTGGGAAACCCGTTTNTGCATGGAG  
CCCAGNATTGNAGGGCCCCCANATCCCTTTNAGTAATTGNTTTCCCCCTG  
15 GTCTTGNAAACAGGCCCCGTTNACTTTGGCCGGGGCCCNNGGGGTGA  
GTTTCAGCCTTNANTTGCCTTGTTAATTGCNTCTTTTTTCAGAATCCTCTT  
TCTTCCCAATTTGNCCTTGGGTTTCAGGGGACCAGTTGGGGCGGNTGGGGA  
GTTGTCCGGTGTTACCACACNGTGCCNTCAGTGGANTAACCACAGCAGCA  
GCCAGGGATGGGCCTTGGAGGTTCCCGGCCGGAGAGTGCCTTTCCCCCTNT  
20 GCCATCCACGTCAGGTCTTTGGTGGGGGGACCCCAAAGCCATTTTGGGAA  
GGGCTCCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGNTGGCAGCCCC  
CACCCCCACCCCCCAGGCCGCCTTGAGAAGCACAGTTTAACTCANTGCGG  
GCTCNTGAGCCTGCTTCTGCCTGCTTTCCACNTCCCCAGTCCCTTTCTNT  
GGCCCTGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGT  
25 TTCCAAGAGGCCCCCACC GTGGAAGTAACCAAGGGCGNTTCCTTGTGGG  
CAGNTGCAGGCCCCATGCCTNTCCTCCCTCTNTGGCAGGGCCCCATCNTG  
GGCAGAGGGGCTGGGGNTGGGCCCAGAGTCCAGCCGTCCAGNTGCTCCT  
TTCCCAGTTTGATTTCAATAAATNTGTCCANTCCCCTTTTGTGGGGGTGA  
ACGTTTTTAACAGCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
30 AA

SEQ ID NO: 6 (Me16)

TTTGAACATAAAAGGTTGNGTCANTTGAACNTAGTTNTGCCCCCAAACCT  
TGGATTGGCAGCAACAACCCAGGGGCAGGAGAATTTTTTGGGCAACCNG  
TTGTGCATGGAGCCAGATTGCAGAGCCCCANATCCTTTTAGTAATGCTTT  
CCCTTGNTCTTGAACAGGCCCCGGTAACCTCGGCCGGGCCGGGGNTGAG  
5 GTCAGCCTCATTGCNTGCTTATTGCNTCTTTCTCAGAATCCTCTTTCNTC  
CCCATTTGGCCTTGGGCTCAGGGGACCAGGTGGGGCGGGTGGGAGCTTGT  
CCGGTGCTACCACACCGTGCCCTCAGTGGACTAACCACAGCAGCAGCCAG  
GGATGGGCCCTGGAGGTTCCCGGCCGGAGAGTGCTCTCCCCCTCTGCCAT  
CCACGTCAGGTCTTTGGTGGGGGGACCCCAAAGCCATTCTGGGAAGGGCT  
10 CCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGCTGGCAGCCCCACCC  
CCACCCCNAGGCCGCCTTGAGAAGCACAGTTTAACTCACTGCGGGCTCC  
TGAGCCTGCTTCTGCCTGCTTTCCACCTCCCCAGTCCCTTTCTCTGGCCC  
TGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGTTTCCA  
AGAGGCCCCCACCGTGGAAGTAACCAAGGGCGCTTCCTTGTGGGCAGCT  
15 GCAGGCCCCATGCCTCTCCTCCCTCTCTGGCAGGGCCCCATCCTGGGCAG  
AGGGGCCTGGGGCTGGGCCCAGAGTCCAGCCGTCCAGCTGCTCCTTTCCC  
AGTTTGATTTCAATAAATCTGTCCACTCCCCCTTTGTGGGGGTGAACGTT  
TTAACAGCCAAAAA

20

SEQ ID NO: 7 (Me17)

CCCCNNNTCCCTNGNACNTNGGNCNTTTTNTTGAAATTNGGGGGGNCNT  
CTTTTTTNNNTNGCCNTNNGGNNNNGNCCNTTTGNGGANTGGGGTTTTTT  
25 NTCGTTTTNNCNCTCNGTTTTTTTTTTGGGGGGGNTTCTNTTTGG  
GGNCCTGTNACCCCGGTTTTNGGGGGCCNTGGTNTTCTTNTTCCCT  
NGTTNNGGGGGACCCGTNCCCTTTTCNCCNNTTNGNACCGGGTNGCG  
GGGCCNCNTNNNCTCNNATTGGGACNNAANTTNGNTCNNTTGTNCCCC  
GGGNNCCCCNCCGGGCNGGGGGGGTTTNGGGTTTTTGNNTCNAAGN  
30 TNGGTNCCTTNGGCCNGGGTTTNNCCCCNNCCTTGNTTTGGGGNCCCCC  
CCCGGGGGGGGCTTTTTNGGNNCCCCNTTTNNTTNGNNCCCGGGTNNN  
GGGCCCCAATCCNTTTGGNATGGTTNCCCTNGTCCTTGAANCGGNCCNG  
TNNCCTNGGCCGGGCCNGGGNTTGGGTTTGGGGTTTCCNGGGGCCCCC  
CCCCNTNGGNGTTNCCCAGGGGGGTTCNTTTNGGCCGNTTCNGGCCCCC



TNCCTTTTCCCTCCCCNTTTGGNCGGGCCCCCTTNTNGGCCGGGGGGCCTTG  
GGGTNGCCCCGGGNCCCNCCNCCCGNTNGNCCNTTNCCCCGNTTNGTTT  
NCNTNAANTTNTCCCCNCCCCCTTTTGGGGGNNNANGTTTTTNCCCCC  
NAAA  
5 AA  
AAA  
AAAAA

10 SEQ ID NO: 8 (Me18)

TGAAAAGGGGCNTTNAANGGCNTTTAAGGAATTTTGCAAAGCCAGATTG  
TTTGGACCCAGCAAANTNTTGAANTTGGGATGGAGANGTTGNCCAAGG  
AACACCTTAGGGANGAGGGCCCAATTCACTNGAAGACCTTGCCCGGNTTC  
15 AAAGGAGTTNTTCCAGACACCGGACCCACATTGAGGAATCAACAACCTGAT  
GACAAAACCTACCAAAACAGCNTGCAATCTTCCACCACCCAGAATCAATG  
GACACTCCAACAAGCACAAGAGGCGGCCCAAAACACCTTTGGGGAAAAGG  
GATATAGTGGAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCACACA  
CACAGACAAAGTACCAGGAGATGAGGATAAGGCATCAACGTGTTTCAGGGA  
20 AACTGCAAACAGAACTGGACCCAGCAGCAAGTGTAACCTGGTAGCAAGA  
GGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTTGGCT  
GGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCCACGAC  
TCATGAGAAAACCTACCAAAATAGCCTGCAGATCTCCACAACCAGACCCAG  
TGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAAA  
25 GCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAGT  
AGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGACA  
TGAAAGCATTTATGGGAACCTCCAGTGCAGAAATTGGACCTGCCAGGAAAT  
TTACCTGGCAGCAAAGATGGCCACAAACTCCTAAGGAAAAGGCCCAGGC

30

SEQ ID NO:9 (Me19)

TTTTGGGCACCCCCAGGGTTTTAANANNTTATTGNTTNCCGGGNTTNGT  
AATTNTTTGTNNTGAAATTTTTTGAGCCGNATAACAANTTNCANCACAG

GGAAACAGGTNTTGNCCNATTGATTACNCCCAAGGTATTTTNGGTTGAC  
AATTATTGANTACTTCAAGTTNNCTNTTAGCTTTACATTGCAAAGGGTGT  
CGGCNTAAGCCGAAGATATCGGGTNGAGTTATATTGAGCAGAATCCCCC  
GTTGAAGGATTTAACCGTGTATCTNGNTGGAATATTCATGGCGTATTTT  
5 TGGATGATAACGAGGCGCAAAAANTGAAAAGTACTTCTTGCAATTGTGAG  
CGGACAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGC  
TCCGAGATCTGGACGAGCTTTTTTTTTTTTTCTCGGGAAGCGCGCCATTG  
TGTGGTACCCGGGAATTCGGCACGAGGAAAGACATCAACACATTTGTGG  
GGACTCCAGTGGAGAACTGGACCCAGCAGCAAGTGAAGTGGTAGCAAG  
10 AGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTTGGC  
TGGCTTGAAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCACGA  
CTCATGAGAAAACCTACCAAAATAGCCTGCAGATCTCCACAACCAGACCCA  
GTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAA  
AGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAG  
15 TAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGAC  
ATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGGAAA  
TTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCCCAGG

20 SEQ ID NO: 10 (Mel110)

CCGGAAGTTCAGGGGAAGGGCCANNACCGGACAACCACCGGGGGGACC  
GCCAGGNGATTGGAAAGGGGCNTTCAAAGGCGTTTTAAAGGAATCTTGCAA  
AGCCGGATGTTGGACCCCAGCAAANTATTGGAANTGGGATTGAGAGGTTG  
25 GCCCAAGAACACNTAAGGAAGAGGCCCCAATCANTAGANGACCTTGCCGG  
CTTCAAAGAGCTNTTCCAGACACCAGGACCACATTGAGGAATCAACAACT  
TGATGACAAAACCTACCAAAACAGCNTGCAAATCTCCACCACCAGAATCAA  
TGGACACTCCAACAAGCACAAGGAGGCGGCCCAAAACACCTTTGGGGAAA  
AGGGATATAGTGAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCAC  
30 ACACACAGACAAAGTACCAGGAGATGAGGATAAAGGCATCAACGTGTTCA  
GGGAAACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGC  
AAGAGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTT  
GGCTGGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCCA  
CGACTCATGAGAAAACCTACCAAAATAGCCTGCAGATCTCCACAACCAGAC

5 CCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAG  
GAAAGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCAT  
CAGTAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAA  
GACATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGG  
AAATTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCC  
AGGC

SEQ ID NO: 11 (Thy1)

10 TGTGTGGAATTTTTGACCGGATACAATTTTACCCCGGGAACCAGNTNTA  
CCCTTGATTACCCCAAGCTATTTAGGTGACACTNTTGGATTACTCAAGC  
TGCTNTAGCTTTACATCGCAAGGGTGTCTGGCATAAGCCGAAGNATATCCG  
GAGAGTTATATTGAGCANATCCCCCGGTGAAGGATTTAACCGTGTTATC  
15 TCGTTGGAATATTCATGGCGTATTTTGGATGATAACGAGGCGCAAAAAAT  
GAAAAGTACTCTAGCAATTGTGAGCGGACAACAATTTACACAGGAAACA  
GCTATGACCATGATTACGCCAAGCTCCGAGATCTGGACGAGCTTTTTTTT  
TTTTTCTCGGGAAGCGCGCCATTGTGTTGGTACCCGGGAATTCGGCACGA  
GGGAGATCGAGGAGCTATGGAGGAGACAGAAGCCGGGGGGGCTATGGAGG  
20 AGACCGTGGTGGTGGCAGTGGCTACGGTGGAGACCGAAGTGGAGNNTATG  
GAGGAGACAGGAGTGGTGGCGGCTATGGAGGAGACCGAGGTGGGGGCTAC  
GGAGGAGACCGAGGTGGCTATGGAGGCAAAATGGGAGGAAGAAACGACTA  
CAGAAATGATCAGCGCAACCGACCATACTGATGACTGTTTTGAATGTTCC  
TTTGTCTCTGACATGATCCATAGTGAAATTGCCAGAGTTTGCCTGCTGC  
25 TTTCCCTCGTGGCCTCTTCTTGGGTGTGAAATTAAGTGACATTTGGATTTT  
TATTTGGGTGGGAGGGCTGGGACAGTTTTTCT

30 SEQ ID NO: 12 (Thy2)

TTCCCTTTNGCCTNCCCGGGGAAGGGCCCAAAAAGGAANTTGCATTNG  
CAATTGAAGTTCACCCNTTATTTTGCCCCACTTGGAACGGTGATTTTTG  
GCCNTATTGAGAACACCTTGNTCAGTATGAGGCTTTTGAGCTAAANGCTT  
NCCATGAAGGGGCTGGGAACCGACGAGGATTCTCTCATTGAGATCATCTG

CTCCAGAACCAACCAGGAGTGCAGGAAATTAACAGAGTCTACAAGGAAAT  
GTACAGACTGATCTGGAGAAGGACATTATTTCCGACACATCTGGTGACTT  
CCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCT  
CTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGATCTCTATGACG  
5 CTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATG  
ACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAG  
TTACAGCCCTTATGACATGTTGGAAAGCATCAGGAAAGAGGTTAAAGGAG  
ACCTGGAAAATGCTTTCTGAACCTGGTTCAGTGCATTTCAGAACAAAGCCC  
CTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCG  
10 AGATAAGGTCCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGT  
TGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTAT  
TATATCCAGCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCT  
GTGTGGTGGAGATGACTGAAGCCCGACACGGCCTGAGCGTCCAGAAATGG  
TGCTCACCATGCTTCCAGCTAACAGG

15

SEQ ID NO: 13 (Thy3)

AGGGNTTNTAAACGGGGCNAAGGTTTTAAAGCAATTTTGGGNAAATGGAG  
20 CCCGGNCCCGTTGGAAAAACANCCTTTTACAGGCATTCAGAATTTNTCTG  
GTTGGGGAGGATTACAGATGCCCCGCTTGGAGGCTGTTGNTACATGGTATTA  
TTCTTTGNGCACTCCACGGATGATTATGCCTCCTTNTTCCCGGGCTNTGG  
AGAATGCCACCCGGGATTACTTTATCATTTGCCCTATAATCGACATGNCC  
AGTGCTTGGCAAAGAGGGCCCCGAGGAAACGTCTTCATGTACCATGCTCNT  
25 GAAAACTACGGCCATGGCAGCCTGGAGCTGCTGGCGGATGTTCAGTTTGC  
CTTGGGGCTTCCCTTCTACCCAGCCTACGAGGGGCAGTTTCTCTGGAGG  
AGAAGAGCCTGTCGCTGAAAATCATGCAGTACTTTTCCCACTTCATCAGA  
TCAGGAAATCCCAATTACCCTTATGAGTTCTCACGGAAAGTACCCACATT  
TGCAACCCCTGGCCTGACTTTGTACCCCGTGCTGGTGGAGAGAACTACA  
30 AGGAGTTCAGTGAGCTGCTCCCCAATCGACAGGGCCTGAAGAAAGCCGAC  
TGCTCCTTCTGGTCCAAGTACATCTCGTCTCTGAAGACATCTGCAGATGG  
AGCCAAGGGCGGGCAGTCAGCAGAGAGTGAAGAGGAGGAGTTGACGGCTG  
GATCTGGGCTAAGAGAAGATCTCCTAAGCCTCCAGGAACCAGGCTCTAAG  
ACTACAGCAAGTGACCAGCCCTTGAGCTCCCCAAAAACCTCACCCGAGGC

TGCCCCACTATGGTCATCTTTTTCTCTAAAAATAGCCACTTACCTTCAATAA  
AGTATCTACATGCGGGAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 14 (Thy5)

5  
CGCCTGACTATCTTATATGATCTGCNGAACTGNATGTATCCAAGTAAGT  
AGTTAGCTAAGGAAGGTTNNTTCATGCTTTNCTGTTACAGNTGTGNNCTG  
TTTTTTAAGAATGTAACCTGTTTTAGNGTANAATGCATCTGGGNNTTNNT  
NCCNGCCACGGTGACANNAAACCGGGTNTNGGTCNGGGNANGTTGGNTCN  
10 TTCNCTTNCGNAGAATCCCTTNTTCATTCCTCTTCTCTGTGTTCAATCC  
TCTTCTGTGCTGTTCTGAAGCTTCTACCAATACTCTTCCATATTGTCTT  
TTTCAGTGAAGAGAAATGCATTCAAGATTAGGTCCCTCCTGTCTATCCAG  
TTTCAGGATTTTATGTTGTTTTATACACAGTTATTTTCAGTATAGAACTG  
GCTTTATTGCCAAGTGTTTTTTTTAAACATGTTTTAACTCTCATATGAGCA  
15 AACTGTCCAACCTTCAGTTTTTTCATAAGATTAAACTTCTTACGATCAAATT  
TGTCTCTTGCAATGATGTGATGAGTTGCCAAATAATTGAGATTATTTTAA  
AATGTTTTGTTTCATATTCTTGTTTTATAATTAAAATTTACATTCAGTGTG  
AAAAAAAAAAAAAAAAAAAAAAAAAAAA

20  
SEQ ID NO: 15 (Thy6)

CANCTAAGCCGNTTNGGAAGGGATACACTCGGAAGTTTGCCAATTTTAAC  
GATCTTGCAGAACTTCGGCAACCATTTCCCTCTTTGAAGAGNGGACANCCA  
25 GCNGCAGNTTTNNTCNGAAAGGCGGCTCCAGGATNTTTGGCAAAAGTTTG  
NAGNTNGGAAGAANCNACTTGTTTGGGGTTATNGCCCAGGCATTCAGGGT  
TTTNCAGGNTGAATTGGAAANCCGTTCTAATCAGGTGCGATGTGCAGAGA  
AAAATTACAACACAAGGAATTGGAGTCACAGGAACAGATAACTTACATAC  
GACAAGAATATGAAACAAAATTGAAAGGATTGATGCCAGCATCCCTAAGA  
30 CAAGAACTTGAAGACACCATTTCCCTCCCTAAAATCACAGGTTAATTTTCT  
GCAAAAGAGAGCTTCCATCCTTCAGGAAGAACTGACTACATATCAAGGCA  
GAAGGTAAC TGACGAGAGAATGCAACGGATGCAATTTCCAGGCTGTGCT  
GTGGACTTCTTCCAGCAGGTTTGAAGATTTGGATATTGTAACTGTGAGA  
TCAGTGGCATTTTTTTAAATCCTTAAATGTAATTAAGATCATAAAAACATG

CATCATTCATAAAAAAAAAAAAAAAAAA

SEQ ID NO: 16 (Thy9)

5 CGGGAATNTCGNTANGTCGAACTGAGGAGACAGAGACGCAAGAGAAAAAT  
CCACTGCCTTCCAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATC  
GTAATGAGGCGTGCGCCGCCAATATGCACTGTACATTCCACAAGCATTGC  
CTTCTTATTTTACTTCTTTTAGCTGTTTAACTTTGTAAGATGCAAAGAGG  
TTGGATCAAGTTTAAATGACTGTGCTGCCCCCTTTCACATCAAAGAACTAC  
10 TGACAACGAAGGCCGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTG  
GCAGGGAAGGAAAGAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGGAA  
GAAGTGGGGTGGGACGACAGTGAAA

15 SEQ ID NO: 17 (Thy11)

TCGGAACAGCNAACAAAGACCATGTCAAGGTCCCAAAGCCCACGGGGGTG  
AAGAAGGGATGGCAGNGNGNATATGCAGTCGTCTGTGACTGCAAGCTCTT  
CNTGTATGATCTGCNTGAAGGAAAATCCACCCAGCCTGGTGTCAATTGCGA  
20 GCCAAGTCTTGGATCTCAGAGATGACGAGTTTCCGTGAGNTCAGTCCTG  
GCCTCAGATGCATTCATGNTACACGCCGAGATATTCCATGTATATTCAGG  
GTGACGGCCTCTCTCTTAGGTGCACCTTNTAAGACCAGCTCTNTGCTCAT  
TNTGACNGAAAATGAGAATGAAAAGAGGAAGTGGG

25

SEQ ID NO: 18 (Thy12)

GCTCCGGAAATTTTGGACGGGNCTTTTTTTTTTTTTTCTCGGGGAAGCG  
30 GCNCCCATTTGTGTTTGTACCCCGGGAATTTCCGCNACGGGGACCAAAA  
TTGAAGTTGGACAAACGGTTCTTTGCACAAATTGACGTACCATTTTCACA  
GTTTAATTCGTGAAGGTTTGGAAAGGTTAACCANGTTCTTATTAGTACTT  
TTCATAAGCAGTTGGATTTTCTGAAAAATACAGTAACATAATTTTATAGTA  
ACTTACTTAAAATTTCTTTAAACTCCCTATCAATCTGAAGAACAACATA

5 AAAACCTGTTTATTACATGAATGCTACTTATGAGAATTTAAAATATGGGT  
TCACTTCCTATTTTCCACAAGTCTTTGACTTGTTTATTTACTAAATTAAC  
AGAACGTGGGATGCAGTTTTTTAAGTTAGCAACTTCCTTAGGGTTACTGG  
GAAGTAGAGTAATTATGAAAAAGGGAACACTTCAATTATTGTATAAAAGA  
10 TTGCTTTGCATACTGATTACTTCTTGAACCCCAAAAAGTGCTATTTAGAG  
GCAAGGGCCCATTTTGTGCCCATTAAAAGAAATATACAGGTGAATGTCTG  
TCTCATCCCTCTAATCATATGTAATAAAATTATATCGCTGTCAATAACAG  
CAAAGATAATGATATATTAATTTTAACAGCAGTTAGAACCAGAAGGAAAA  
GGCTGTTATACAGAAAAACATACAAATATGTAGGTAGAAGTGAAAACTG  
15 AAGAATGTGGAGTGTTTACTGTCCCGTTACTCACACAGACGTGCTGGATT  
CAACACCCACGCTGAATCTCCATTTATTCCACGGAGGTGGAGTTCACCAT  
GGTTCGACTGCCCACCAGATCCCCAAATGTCAAAGTGAAACAAAACCTCAG  
TGAAT

15

SEQ ID NO: 19 (Thy14)

CACTTGAAATTTTNGTTAGGNCCCTTTGGGNTTCCCTTNTTCTTGTTNNT  
TAANNTGGTTNTTGCAGCTTGTCCCTTTTTGCCCAACATAGGNCCTAATT  
20 TCAATGGAACCTGTTAGTTTTNCTCTGGGGATTCTTTAACTTTAGAGCCAT  
TTNCTTTTTCTTCAAAANTGATGAACTTTTTGGTTTGAAAGGCTTANGGA  
GTGAAAAGCTCCTTGAAAATCCAGGCGGTATGGAAGGTGCTGCTACCCA  
TATCTTTTTGACTTTCTTTGTTTTCATGACTTTAACTTCATGGCATCTCC  
TTTGTAGTAAAAGGAGACAGACCATTAATTTAGCATTTCTTTGTGATTT  
25 ATAAGTACTGAGCATGAAGTACTTGTCTGCCCCCATTTCAGGCCAGAG  
TTATTTTCTATTTATGTATTAGTCTAGGCTGATCTTTTAGGGCACAATAG  
AAACCATGGGGCGTGGAGCATGAGTTGTGAATGGCAGGGATCATCTCTGGG  
TAAAAAAAACCTAGAATCATTTCTGATGTGCAACATTGTCAAGTGAAGAA  
GCTAACAGTTCAACTACCGAGATTATTTGATAACCTGGGTTTTCTCATTC  
30 ATCCATCAAGCACCATCAACCAGTCAGCCATTATTATTTATATATGTATT  
ACCAAAAGCAGTCTATCTGCCTGTGACCTCCAATGTACACTGCCAAACAC  
AAGAGTAGGACACATCTGTTCTGGGTTCTTGACCTATCTGTCTCCAATTC  
ATCTCCCCTTTTCAGCCATTTCAACAACTACTCTTTGGAGCTCTGAGAT  
GACATCTTGTGTTTTATATAGATGTATCTTTTAAAAATAGTTCACGTTT

GGAGAATTCTTTTGTACTCATTTGCTTTTGTCTGAGAACCATGTCTATT  
TTTATAACTGGAGTGTGAGTTCTGTATCTTCTCACATTCTGTATACTGTA  
TCCATTT

5

SEQ ID NO: 20 (Thy15)

GGCGGCTTTGTNGCAGNNAAGGCNGGNTNNCNAGGGATNGTTNGGACAN  
AAAGGTTTGAAGGATTGCGGAAGGAAGCAGNTTGATTNGGNGGNTANTG  
10 ACCCAAGCCAATCCAAGGTTTTNANCACGGNTGAAATTTGGAAACCNGTT  
NCTAAATNCAGGTGCGGATGTGCAGGAGAAAAATTACCAACCNCAAGGA  
NTTTGGAGTCACAGGAACNGGTTAACTTACATANGACAAGACTNNTGAAA  
CCAAAATTGAAAGGATTGATGCCAGCATCCCTAAGACAAGAAGCTTGAGAC  
ACCATTTCCCTCCCCTAAAGTCACAGNTTAATTTTCTGCAAAAGAGAGCTT  
15 CCATCNTTCAGGAAGAACTTGANTACATATCAAGGCAGAAGGTAAGTCA  
CGAGAGANTGCAACGGATGCAATTTCCAGGCTGTGCTGTGGACTTCTTCC  
AGCAGGTTTGAAGATTGGATATTGTAACTGTGAGATCAGTGGCATTTT  
TTAAATCCTTAAATGTANTTAAGATCATAAAAACATGCATCATTTCATACA  
CTAGTGGGGTGGATTATTTGTGTCNTGCCTAAGTTATTTTTTTAACATTC  
20 CTTTATTTCCGATTTTCATGTTTGTGTGCATTTGAGTATGTGCTGAGAAC  
TGCTTATATTGGGCAAAGTGATTTCCCTATGATATGCCTTGTTAATCCTTT  
TGCATAGAATTTTACCAGTTGCGTACGATCAAAATCACGTTTGTAGTATC  
ATATCAAAAATTCTAACCTGTTTACATTGTTTTCATGTTTCATGTTTCCTAT  
GTTATTAAAATATTATTTTGTAAAAA

25

SEQ ID NO: 21

gi|2723456|dbj|D30612|D30612 Homo sapiens mRNA for repressor protein  
, partial cds  
30 ACCCACGCGTCCGGCCGCCGAAGGGGACTGTTTGCTCCTACGGGCTGTAGATGGAGCTGTCCGGCCCCGG  
AGAGGGGAAGGCGCCTGGAAAACGTTCTTCTCTCCCTGGCCGACCCGAGCGGGGAACAGCACTCCCAG  
GATGCAGTTTGTGTCAACACGGCCGAGCCTCAGCAGCTGGGCATCCAGGGCCTGGGGCTGGACAGCGGG  
AGCTGGAGCTGGGCCCAGGCTCTGCCCCGAGCAGGTCTGCCACCAGGAGCCGGCGCTGCGCGGGGAAA  
TGGCCGAGGGAATGCCGCCCATGCAGGCTCAAGAATGGGACATGGACGCCCGGCGGCAATGCC'TTTCA  
GTTCCCACCCTTTCCAGATAGGGCACCTGTCTTCCCCGACCGCATGATGCGAGAGCCCCAGTTGCCCA  
35 GCAGAGATCTCACTCTGGACTGTGGTGGCTGCCATTACAGGCTGTGGAGAGGAAGGTGGATGCCAGGCCA  
GCCAGCTGCTGAACCTGGAGGGGCGACGGGGACAGCCGAGAAGAAGCTGGCCGACTGTGAAAAGACGGC



13

CATGGCCTGGCACCGGGTGGGGTGGTATGCCCCCTTGTTTGTGTCAAAAATGACTTTCCCTGCCCTTGCC  
GTGGGTCCGGCGTTCTCCAGCCGGGATCACAGTGGGCAGCCGGCACCCGGCACCCTTTGGCGAGCGT  
CCTGCTTCCGCCCTCGCCCTCATCTACGCTGCTCCGCTTTCCTCAGACCCCTTTTGGCCGTGCAAAGGAA  
TTCTTGACATTAAATAAAAGGTATCCAGATTGCAGACTGCATGTTACAGAGCTGGGGGTCTCCAGCTT  
5 GCCTACAGTAAAGCCTCAATGAACTGG

SEQ ID NO: 22

>gi|1503985|dbj|D86956|D86956 Human mRNA for KIAA0201 gene, complete cds

5 CTGAGGAAGTGGGACCTCCCCTTTTGGGTGGTAGTTCAGCGCCGGCGCCGGTGTGCGAGCCGCGGCAGA  
GTGAGGCAGGCAACCCGAGGTGCGGAGCGACCTGCGGAGGCTGAGCCCCGCTTTCTCCCAGGGTTTCTTA  
TCAGCCAGCCGCCGCTGTCCCCGGGGAGTAGGAGGCTCCTGACAGGCCGCGGCTGTCTGTGTCTCCTTC  
TGAGTGTGAGAGGAACGGCCAGACCCCGGGGCCGAGCAGAACGCGCCAGGGCAGAAAGCGGCGGCAG  
GAGAAGCAGGCAGGGGGCCGGAGGACGCAGACCCGAGACCCGAGGCGGAGGCGGACCGCGAGCCGGCCATG  
10 TCGGTGGTGGGGTTGGACGTGGGCTCGCAGAGCTGCTACATCGCGGTAGCCCCGGCCGGGGGCATCGAGA  
CCATCGCCAATGAGTTCAGCGACCGGTGCACCCCGTCAGTCATATCATTTGGATCAAAAAATAGAACAAT  
CGGAGTTGCAGCCAAAAATCAGCAAATCACTCATGCAAACAATACGGTGTCTAACTTCAAAGATTTTCAT  
GGCCGAGCATTCAATGACCCCTTCATTCAAAGGAGAAGGAAAACCTTGAGTTACGATTTGGTTCCATTGA  
AAAATGGTGGAGTTGGAATAAAGGTAATGTACATGGGTGAAGAACATCTATTTAGTGTGGAGCAGATAAC  
15 AGCCATGTTGTTGACTAAGCTGAAGGAACTGCTGAAAACAGCCTCAAGAAACCAGTAACAGATTGTGTT  
ATTTTCAGTCCCCTCCTTCTTTACAGATGCTGAGAGGCGATCTGTGTTAGATGCTGCACAGATTGTTGGCC  
TAACTGTTTAAAGACTTATGAATGACATGACAGCTGTTGCTTTGAATTACGGAATTTATAAGCAGGATCT  
CCCAAGCCTGGATGAGAAACCTCGGATAGTGGTTTTTGTGATATGGGACATTCAGCTTTTCAAGTGTCT  
GCTTGTGCTTTTAAACAAGGGAATAAAGGTAAGGTAAGGTAAGGTAAGGTAAGGTAAGGTAAGGTAAGG  
20 ACTTCGATGAAAAGTTAGTGAACATTTTTGTGCAGAAATTTAAACTAAGTACAAGTTGGATGCAAAATC  
CAAAATACGAGCCTCCTACGTCTGTATCAGGAATGTGAAAACTGAAAAAGCTAATGAGCTCTAACAGC  
ACAGACCTTCCACTGAATATCGAATGCTTTATGAATGATAAAGATGTTTCCGGAAGATGAACAGGTCAC  
AATTTGAAGAACTCTGTGCTGAACCTTCGCAAAAGATAGAAGTACCCCTTTATTCACTGTTGGAACAAAC  
TCATCTCAAAGTAGAAGATGTGAGTGCAGTTGAGATTGTTGGAGGCGCTACACGAATTCAGCTGTGAAG  
25 GAAAGAATTGCCAAATCTTTGAAAAGATATTAGCACAACTCAATGCAGATGAAGCAGTAGCCAGAG  
GATGTGCATTACAGTGTGCAATACTTTCCCCGGCATTAAAGTTAGAGAATTTTCCGTCACAGATGCAGT  
TCCTTTTCCAATATCTCTGATCTGGAACCATGATTCAGAAGATACTGAAGGTGTTTCATGAAGCTTTAGT  
CGAAACCATGCTGCTCCTTTCTCAAAGTTCTCACCTTTCTGAGAAGGGGGCCTTTTGAGCTAGAAGCTT  
TCTATTCTGATCCCCAAGGAGTTCCATATCCAGAAGCAAAAATAGGCCGCTTTGTAGTTCAGAATGTTTC  
30 TGCACAGAAAAGATGGAGAAAAATCTAGAGTAAAAGTCAAAGTGCGAGTCAACACCCATGGCATTTCACC  
ATCTCTACGGCATCTATGGTGGAGAAAGTCCCAACTGAGGAGAATGAAATGTCTTCTGAAGCTGACATGG  
AGTGTCTGAATCAGAGACCACAGAAAACCCAGACACTGATAAAAATGTCCAGCAAGACAACAGTGAAGC  
TGGAACACAGCCCCAGGTACAACTGATGCTCAACAAACCTCACAGTCTCCCCCTTACCTGAACCTTACC  
TCAGAAGAAAACAAAATCCAGATGCTGACAAAGCAAATGAAAAAAAAGTTGACCAGCCTCCAGAAGCTA  
35 AAAAGCCCCAAAATAAAGGTGGTGAATGTTGAGCTGCCTATTGAAGCCAACCTGGTCTGGCAGTTAGGGAA  
AGACCTTCTTAACATGTATATTGAGACAGAGGGTAAGATGATAATGCAAGATAAATTGGAAAAAGAAAGG  
AATGATGCTAAAAATGCAGTTGAGGAATATGTGTATGAGTTCAGAGACAAGCTGTGTGGACCATATGAAA  
AATTTATATGTGAGCAGGATCATCAAAATTTTTTGGAGACTCCTCACAGAACTGAAGACTGGCTGTATGA  
AGAAGGAGAGGACCAAGCTAAACAAGCATATGTTGACAAGTTGGAAGAATTAATGAAAATTGGCACTCCA  
40 GTTAAAGTTCGGTTTTAGGAAGCTGAAGAACGGCCAAAAATGTTTGAAGAACTAGGACAGAGGCTGCAGC  
ATTATGCCAAGATAGCAGCTGACTTCAGAAATAAGGATGAGAAATACAACCATATTGATGAGTCTGAAAT

GAAAAAAGTGGAGAAGTCTGTTAATGAAGTGATGGAATGGATGAATAATGTCATGAATGCTCAGGCTAAA  
AAGAGTCTTGATCAGGATCCAGTTGTACGTGCTCAGGAAATTAAAACAAAAATCAAGGAATTGAACAACA  
CATGTGAACCCGTTGTAACACAACCGAAACCAAAAATTGAATCACCCAAACTGGAAAGAACTCCAAATGG  
CCCAAAATATTGATAAAAAGGAAGAAGATTTAGAAGACAAAAACAATTTTGGTGCTGAACCTCCACATCAG  
5 AATGGTGAATGTTACCCTAATGAGAAAAATTCTGTTAATATGGACTTGGACTAGATAACCTTAAATTGGC  
CTATTCCTTCAATTAATAAAATATTTTGGCCATAGTATGTGACTCTACATAACATACTGAAACTATTTAT  
ATTTTCTTTTTTAAGGATATTTAGAAATTTTGTGTATTATATGGAAAAAGAAAAAGCTTAAGTCTGTA  
GTCTTTATGATCCTAAAAGGGAAAATTGCCTTGGTAACTTTCAGATTCCTGTGGAATTGTGAATTCATAC  
TAAGCTTTCTGTGCAGTCTCACCATTTGCATCACTGAGGATGAAACTGACTTTTGTCTTTTGGAGAAAAA  
10 AAAGTGTACTGCTTGTTCAGAGGGCTGTGATTAAATCTTTAAGCATTGTTCCTGCCAAGGTAGTTTT  
CTTGCATTTTGCTCTCCATTCAGCATGTGTGTGGGTGTGGATGTTTATAAACAAGACTAAGTCTGACTTC  
ATAAGGGCTTTCTAAAACCATTTCTGTCCAAGAGAAAATGACTTTTTGCTTTGATATTAAAAATTCATG  
AGTAAACAAAAGCTAGTCAAATGTGTTAGCAGCATGCAGAACAAAACTTTAAACTTTCTCTCTCACTA  
TACAGTATATTGTCATGTGAAAGTGTGGAATGGAAGAAATGTCGATCCTGTTGTAAGTGAATTGTGAACAC  
15 TTTTATGAGCTTTAAAATAAAGTTCATCTTATGGTGTCAATTTCT

SEQ ID NO: 23

>gi|415818|emb|X65550|HSMKI67 H.sapiens mki67a mRNA (long type) for antigen of monoclonal antibody Ki-67

5 CTACCGGGCGGAGGTGAGCGCGCGCCGGCTCCTCCTGCGGCGGACTTTGGGTGCGACTTGACGAGCGGT  
GGTTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGGAAGAGTTGTAAATTTGCTTCTGGCCTTCCC  
CTACGGATTATACCTGGCCTTCCCCCTACGGATTATACTCAACTTACTGTTTAGAAAATGTGGCCACGAG  
ACGCCTGGTTACTATCAAAAAGGAGCGGGTGCAGCGTCCCCACTTTCCTGAGCCTCAGCACCTGCTTG  
TTTGAAGGGGTATTGAATGTGACATCCGTATCCAGCTTCCTGTTGTGTCAAAACAACATTGCAAAATTG  
10 AATCCATGAGCAGGAGGCAATATTACATAATTTCACTTCCACAAATCCAACACAAGTAAATGGGTCTGT  
TATTGATGAGCCTGTACGGCTAAAACATGGAGATGTAATAACTATTATTGATCGTTTCCTTCAGGTATGAA  
AATGAAAGTCTTCAGAATGGAAGGAAGTCAACTGAATTTCCAAGAAAAATACGTGAACAGGAGCCAGCAC  
GTCGTGTCTCAAGATCTAGCTTCTCTTCTGACCCTGATGAGAAAGCTCAAGATTCCAAGGCCTATTCAAA  
AATCACTGAAGGAAAAGTTTCAGGAAATCCTCAGGTACATATCAAGAATGTCAAAGAAGACAGTACCGCA  
15 GATGACTCAAAAGACAGTGTGCTCAGGGAACAACTAATGTTTATTCCTCAGAACATGCTGGACGTAATG  
GCAGAAATGCAGCTGATCCCATTCTTCTGGGGATTTTAAAGAAATTTCCAGCGTTAAATTAGTGAGCCGTTA  
TGGAGAATTGAAGTCTGTTCCCACTACACAATGTCTTGACAATAGCAAAAAAATGAATCTCCCTTTTGG  
AAGCTTTATGAGTCAGTGAAGAAAGAGTTGGATGTAAATCACAAGAAAGAAATGTCCTACAGTATTGTA  
GAAAATCTGGATTACAACTGATTACGCAACAGAGAAAGAAAGTGCTGATGGTTTACAGGGGAGACCCA  
20 ACTGTTGGTCTCGCGTAAGTCAAGACCAAAATCTGGTGGGAGCGGCCACGCTGTGGCAGAGCCTGCTTCA  
CCTGAACAAGAGCTTGACCAGAACAAGGGGAAGGAAGAGACGTGGAGTCTGTTTACAGACTCCCAGCAAGG  
CTGTGGGCGCCAGCTTTCCTCTCTATGAGCCGGCTAAAATGAAGACCCCTGTACAATATTACAGCAACA  
AAATCTCCACAAAACATAAGAACAAGACCTGTATACTACTGGTAGAAGAGAATCTGTGAATCTGGGT  
AAAAGTGAAGGCTTCAAGGCTGGTGATAAACTCTTACTCCAGGAAGCTTCAACTAGAAATCGAACAC  
25 CAGCTAAAGTTGAAGATGCAGCTGACTCTGCCACTAAGCCAGAAAATCTCTCTTCCAAAACCAGAGGAAG  
TATTCCTACAGATGTGGAAGTTCTGCCTACGGAACTGAAATTCACAATGAGCCATTTTAACTCTGTGG  
CTCACTCAAGTTGAGAGGAAGATCCAAAAGGATTCCCTCAGCAAGCCTGAGAAATTGGGCACTACAGCTG  
GACAGATGTGCTCTGGGTTACCTGGTCTTAGTTTCACTGATATCAACAACCTTTGGTGATTCCATTAATGA  
GAGTGAGGGAATACCTTTGAAAAGAAGGCGTGTGTCTTTGGTGGGCACCTAAGACCTGAACTATTTGAT  
30 GAAAACCTTGCCCTCTAATACGCCTCTCAAAAGGGGAGAAGCCCCAACCAAAAGAAAGTCTCTGGTAATGC  
ACACTCCACCTGTCTGAAGAAAATCATCAAGGAACAGCCTCAACCATCAGGAAAACAAGAGTCAGGTTT  
AGAAATCCATGTGGAAGTGAAGGCACAAAGCTTGGTTATAAGCCCTCCAGCTCCTAGTCCTAGGAAAAT  
CCAGTTGCCAGTGATCAACGCCGTAGGTCTGCAAAACAGCCCCTGCTTCCAGCAGCAAAATCTCAGACAG  
AGGTTCCCTAAGAGAGGAGGAGAAAGAGTGGCAACCTGCCCTTCAAAGAGAGTGTCTATCAGCCGAAGTCA  
35 ACATGATATTTTACAGATGATATGTTCCAAAAGAAGAAGTGGTGCTTCGGAAGCAAATCTGATTGTTGCA  
AAATCATGGGCAGATGTAGTAAACTTGGTGCAAAACAAACAACTAAAGTCATAAAACATGGTCTCTC  
AAAGGTCAATGAACAAAAGGCAAAGAAGACCTGCTACTCCAAAGAAGCCTGTGGGCGAAGTTCACAGTCA  
ATTTAGTACAGGCCACGCAAACTCTCCTTGTACCATAATAATAGGGAAGCTCATACTGAAAAGTACAT  
GTGCCTGCTCGACCCTACAGAGTGCTCAACAACCTTCATTTCCAACCAAAAAATGGACTTTAAGGAAGATC  
40 TTTCAGGAATAGCTGAAATGTTCAAGACCCAGTGAAGGAGCAACCGCAGTTGACAAGCACATGTCACAT  
CGCTATTTCAAATTCAGAGAATTTGCTTGGAAAACAGTTTCAAGGAAGTTCAGGAGAAGAACCTCTG

CTCCCCACCTCAGAGAGTTTTGGAGGAAATGTGTTCTTCAGTGCACAGAATGCAGCAAAACAGCCATCTG  
ATAAATGCTCTGCAAGCCCTCCCTTAAGACGGCAGTGTATTAGAGAAAATGGAAACGTAGCAAAAACGCC  
CAGGAACACCTACAAAATGACTTCTCTGGAGACAAAACTTCAGATACTGAGACAGAGCCTTCAAAAACA  
GTATCCACTGTAAACAGGTCAGGAAGGTCTACAGAGTTCAGGAATATACAGAAGCTACCTGTGGAAAGTA  
5 AGAGTGAAGAAACAAATACAGAAATTGTTGAGTGCATCCTAAAAAGAGGTCAGAAGGCAACACTACTACA  
ACAAAGGAGAGAAGGAGAGATGAAGGAAATAGAAAGACCTTTTGAGACATATAAGGAAAATATTGAATTA  
AAAGAAAACGATGAAAAGATGAAAGCAATGAAGAGATCAAGAAGCTTGGGGGCAGAAATGTGCACCAATGT  
CTGACCTGACAGACCTCAAGAGCTTGCCTGATACAGAACTCATGAAAGACACGGCACGTGGCCAGAATCT  
10 CCTCCAAACCCAAGATCATGCCAAGGCACCAAGAGTGAGAAAGGCAAAATCACTAAAATGCCCTGCCAG  
TCATTACAACCAGAACCAATAAACACCCCAACACACACAAAACAACAGTTGAAGGCATCCCTGGGGAAAG  
TAGGTGTGAAAGAAGAGCTCCTAGCAGTCGGCAAGTTTACACGGACGTCAGGGGAGACCACGCACACGCA  
CAGAGAGCCAGCAGGAGATGGCAAGAGCATCAGAACGTTTAAGGAGTCTCCAAAGCAGATCCTGGACCCA  
GCAGCCCGTGTAAGTGAATGAAGAAGTGGCCAAGAAGCGCTAAGGAAGAGGCCAGTCACTAGAAGACC  
TGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGTCCCTCTGAGGAATCAATGACTGATGAGAAAACCTAC  
15 CAAAATAGCCTGCAATCTCCACCACCAGAATCAGTGGACACTCCAACAAGCACAAAGCAATGGCCTAAG  
AGAAGTCTCAGGAAAGCAGATGTAGAGGAAGAATTCTTAGCACTCAGGAAACTAACACCATCAGCAGGGA  
AAGCCATGCTTACGCCCAAACAGCAGGAGGTGATGAGAAAGACATTAAAGCATTTATGGGAACTCCAGT  
GCAGAAACTGGACCTGGCAGGAACCTTACCTGGCAGCAAAAGACAGCTACAGACTCCTAAGGAAAAGGCC  
CAGGCTCTAGAAGACCTGGCTGGCTTTAAAGAGCTCTTCCAGACTCCTGGTCACACCGAGGAATTAGTGG  
20 CTGCTGGTAAAACCACTAAAATACCTTGCGACTCTCCACAGTCAGACCCAGTGGACACCCCAACAAGCAC  
AAAGCAACGACCCAAGAGAAGTATCAGGAAAGCAGATGTAGAGGGAGAACTCTTAGCGTGCAGGAATCTA  
ATGCCATCAGCAGGCAAAGCCATGCACACGCCTAAACCATCAGTAGGTGAAGAGAAAGACATCATCATAT  
TTGTGGGAACTCCAGTGCAGAACTGGACCTGACAGAGAACTTAACCGGCAGCAAGAGACGGCCACAAAC  
TCCTAAGGAAGAGGCCCAGGCTCTGGAAGACCTGACTGGCTTTAAAGAGCTCTTCCAGACCCCTGGTCAT  
25 ACTGAAGAAGCAGTGGCTGCTGGCAAACTACTAAAATGCCCTGCCAATCTTCTCCACCAGAATCAGCAG  
ACACCCCAACAAGCACAAAGAAGGCAGCCCAAGACACCTTTGGAGAAAAGGGACGTACAGAAGGAGCTCTC  
AGCCCTGAAGAAGCTCACACAGACATCAGGGGAAACCACACACAGATAAAGTACCAGGAGGTGAGGAT  
AAAAGCATCAACGCGTTTAGGGAACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGCA  
AGAGGCACCCAAAACTAAGGAAAAGGCCAACCCTAGAAGACCTGGCTGGCTGGAAAGAGCTCTTCCA  
30 GACACCAGTATGCACTGACAAGCCACGACTCACGAGAAAACTACCAAAATAGCCTGCAGATCACAACCA  
GACCCAGTGGACACACCAACAAGCTCCAAGCCACAGTCCAAGAGAAGTCTCAGGAAAGTGGACGTAGAAG  
AAGAATTCTTCGCACTCAGGAAACGAACACCATCAGCAGGCAAAGCCATGCACACACCCAAACCAGCAGT  
AAGTGGTGAGAAAAACATCTACGCATTTATGGGAACCTCAGTGCAGAACTGGACCTGACAGAGAACTTA  
ACTGGCAGCAAGAGACGGCTACAACTCCTAAGGAAAAGGCCCAGGCTCTAGAAGACCTGGCTGGCTTTA  
35 AAGAGCTCTTCCAGACACGAGGTACACTGAGGAATCAATGACTAACGATAAACTGCCAAAGTAGCCTG  
CAAATCTTCACAACCAGACCTAGACAAAAACCCAGCAAGCTCCAAGCGACGGCTCAAGACATCCCTGGGG  
AAAGTGGGCGTGAAAGAAGAGCTCCTAGCAGTTGGCAAGCTCACACAGACATCAGGAGAGACTACACACA  
CACACACAGAGCCAACAGGAGATGGTAAGAGCATGAAAGCATTATGGAGTCTCCAAAGCAGATCTTAGA  
CTCAGCAGCAAGTCTAACTGGCAGCAAGAGGCAGCTGAGAACTCCTAAGGGAAAGTCTGAAGTCCCTGAA  
40 GACCTGGCCGGCTTTCATCGAGCTCTTCCAGACACCAAGTCACACTAAGGAATCAATGACTAATGAAAAA  
CTACCAAAAGTATCCTACAGAGCTTCACAGCCAGACCTAGTGGACACCCCAACAAGCTCCAAGCCACAGCC

CAAGAGAAGTCTCAGGAAAGCAGACACTGAAGAAGAATTTTATAGCATTTAGGAAACAAACGCCATCAGCA  
GGCAAAGCCATGCACACACCCAAACCAGCAGTAGGTGAAGAGAAAGACATCAACACGTTTTTGGGAACTC  
CAGTGCAGAAACTGGACCAGCCAGGAAATTTACCTGGCAGCAATAGACGGCTACAAACTCGTAAGGAAAA  
GGCCCAGGCTCTAGAAGAACTGACTGGCTTCAGAGAGCTTTTCCAGACACCATGCACTGATAACCCACACA  
5 GCTGATGAGAAAAC TACCAAAAAAATACTCTGCAAATCTCCGCAATCAGACCCAGCGGACACCCCAACAA  
ACACAAAGCAACGGCCCAAGAGAAGCCTCAAGAAAGCAGACCTAGAGGAAGAATTTTTAGCATTCAGGAA  
ACTAACACCATCAGCAGGCAAAGCCATGCACACGCCTAAAGCAGCAGTAGGTGAAGAGAAAGACATCAAC  
ACATTTGTGGGGACTCCAGTGGAGAACTGGACCTGCTAGGAAATTTACCTGGCAGCAAGAGACGGCCAC  
AAACTCCTAAAGAAAAGGCCAAGGCTCTAGAAGATCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGG  
10 TCACACTGAGGAATCAATGACCGATGACAAAATCACAGAAGTATCCTGCAAATCTCCACAACCAGACCCA  
GTCAAAACCCCAACAAGCTCCAAGCAACGACTCAAGATATCCTTGGGGAAAGTAGGTGTGAAAGAAGAGG  
TCCTACCAGTCGGCAAGCTCACACAGACGTCAGGGAAGACCACACAGACACACAGAGAGACAGCAGGAGA  
TGGAAAGAGCATCAAAGCGTTTAAGGAATCTGCAAAGCAGATGCTGGACCCAGCAAAC TATGGAAC TGGG  
ATGGAGAGGTGGCCAAGAACACCTAAGGAAGAGGCCCAATCACTAGAAGACCTGGCCGGCTTCAAAGAGC  
15 TCTTCCAGACACCAGACCACACTGAGGAATCAACAAC TATGACAAAAC TACCAAAATAGCCTGCAAATC  
TCCACCACCAGAATCAATGGACACTCCAACAAGCACAAGGAGGCGGCCCAAAACACCTTTGGGGAAAAGG  
GATATAGTGAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCACACACAGACAAAGTACCAGGAG  
ATGAGGATAAAGGCATCAACGTGTT CAGGGAAC TGC AAAACAGAACTGGACCCAGCAGCAAGTGTAAAC  
TGGTAGCAAGAGGCAGCCAAGAAC TCTAAGGGAAGAGCCCAACCCCTAGAAGACTTGGCTGGCTTGAAA  
20 GAGCTCTTCCAGACACCAGTATGCACTGACAAGCCACGACTCACGAGAAAAC TACCAAAATAGCCTGCA  
GATCTCCACAACCAGACCCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAA  
AGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAGTAGGGAAGCTATGGACACA  
CCCAAACCAGCAGGAGGTGATGAGAAAGACATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACC  
TGCCAGGAAATTTACCTGGCAGCAAAAGATGGCCACAAAC TCTAAGGAAAAGGCCCAGGCTCTAGAAGA  
25 CCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGCACTGACAAGCCACGACTGATGAGAAAAC TACC  
AAAATAGCCTGCAAATCTCCACAACCAGACCCAGTGGACACCCCAAGCACAAGCAACGGCCCAAGA  
GAAACCTCAGGAAAGCAGACGTAGAGGAAGAATTTTATAGCACTCAGGAAACGAACACCATCAGCAGGCAA  
AGCCATGGACACCCCAAAACCAGCAGTAAGTGTGAGAAAAATATCAACACATTTGTGGAAACTCCAGTG  
CAGAAACTGGACCTGCTAGGAAATTTACCTGGCAGCAAGAGACAGCCACAGACTCCTAAGGAAAAGGCTG  
30 AGGCTCTAGAGGACCTGGTTGGCTTCAAAGAACTCTTCCAGACACCAGGTCACTAGGGAATCAATGAC  
TGATGACAAAATCACAGAAGTATCCTGTAAATCTCCACAGCCAGAGTCATTCAAAACCTCAAGAAGCTCC  
AAGCAAAGGCTCAAGATACCCCTGGTGAAAGTGGACATGAAAGAAGAGCCCTAGCAGTCAGCAAGCTCA  
CACGGACATCAGGGGAGACTACGCAAAACACACACAGGCCAACAGGAGATAGTAAGAGCATCAAAGCGTT  
TAAGGAGTCTCCAAAGCAGATCCTGGACCCAGCAGCAAGTGTAACTGGTAGCAGGAGGCAGCTGAGAACT  
35 CGTAAGGAAAAGGCCCGTGCTCTAGAAGACCTGGTTGACTTCAAAGAGCTCTTCTCAGCACCAGGT CACA  
CTGAAGAGTCAATGACTATTGACAAAAACAAAAATTCCTGCAAATCTCCCCACCAGAACTAACAGA  
CACTGCCACGAGCACAAGAGATGCCCCAAGACACGTCCCAGGAAAGAAGTAAAAGAGGAGCTCTCAGCA  
GTTGAGAGGCTCACGCAACATCAGGGCAAAGCACACACACAAAAAGAACAGCAAGCGGTGATGAGG  
GCATCAAAGTATTGAAGCAACGTGCAAAGAAGAAACCAACCCAGTAGAAGAGGAACCCAGCAGGAGAAG  
40 GCCAAGAGCACCTAAGGAAAAGGCCCAACCCCTGGAAGACCTGGCCGGCTTCACAGAGCTCTCTGAAACA  
TCAGGTCACACTCAGGAATCACTGACTGCTGGCAAAGCCACTAAAATACCCCTGCGAATCTCCCCACTAG

AAGTGGTAGACACCACAGCAAGCACAAAGAGGCATCTCAGGACACGTGTGCAGAAGGTACAAGTAAAAGA  
AGAGCCTTCAGCAGTCAAGTTCACACAAACATCAGGGGAAACCACGGATGCAGACAAAGAACCAGCAGGT  
GAAGATAAAGGCATCAAAGCATTTGAAGGAATCTGCAAAACAGACACCGGCTCCAGCAGCAAGTGTAAGT  
GCAGCAGGAGACGGCCAAGAGCACCCAGGGAAAGTGCCCAAGCCATAGAAGACCTAGCTGGCTTCAAAGA  
5 CCCAGCAGCAGGTACACTGAAGAATCAATGACTGATGACAAAACCACTAAAATACCCTGCAAATCATCA  
CCAGAACTAGAAGACACCGCAACAAGCTCAAAGAGACGGCCAGGACACGTGCCCAGAAAGTAGAAGTGA  
AGGAGGAGCTGTTAGCAGTTGGCAAGCTCACACAAACCTCAGGGGAGACCACGCACACCGACAAAGAGCC  
GGTAGGTGAGGGCAAAGGCACGAAAGCATTTAAGCAACCTGCAAAGCGGAACGTGGACGCAGAAGATGTA  
ATTGGCAGCAGGAGACAGCCAAGAGCACCTAAGGAAAAGGCCCAACCCCTGGAAGACCTGGCCAGCTTCC  
10 AAGAGCTCTCTCAAACACCAGGCCACACTGAGGAACTGGCAAATGGTGCTGCTGATAGCTTTACAAGCGC  
TCCAAAGCAAAACCTGACAGTGGAAGAACCTCTAAAAATATCCAGAAGAGTTCTTCGGGGCCCTAAAGTA  
GAACCCGTGGGAGACGTGGTAAGCACCAGAGACCCCTGTAAAATCACAAAGCAAAAGCAACACTTCCCTGC  
CCCCACTGCCCTTCAAGAGGGGAGGTGGCAAAGATGGAAGCGTCACGGGAACCAAGAGGCTGCGCTGCAT  
GCCAGCACCAGAGGAAATTGTGGAGGAGCTGCCAGCCAGCAAGAAGCAGAGGGTTGCTCCCAGGGCAAGA  
15 GGCAAATCATCCGAACCCGTGGTCATCATGAAGAGAAGTTTGAGGACTTCTGCAAAAAGAATTGAACCTG  
CGGAAGAGCTGAACAGCAACGACATGAAAACCAACAAAGAGGAACACAAATTACAAGACTCGGTCCCTGA  
AAATAAGGGAATATCCCTGCGCTCCAGACGCCAAGATAAGACTGAGGCAGAACAGCAAATAACTGAGGTC  
TTTGTATTAGCAGAAAGAATAGAAATAAACAGAAATGAAAAGAAGCCCATGAAGACCTCCCCAGAGATGG  
ACATTGAGAAATCCAGATGATGGAGCCCGAAACCCATACCTAGAGACAAAGTCACTGAGAACAAAAGGTG  
20 CTTGAGGTCTGCTAGACAGAATGAGAGCTCCAGCCTAAGGTGGCAGAGGAGAGCGGAGGGCAGAAGAGT  
GCGAAGGTTCTCATGCAGAATCAGAAAGGGAAGGAGAAGCAGGAAATTCAGACTCCATGTGCCTGAGAT  
CAAGAAAGACAAAAAGCCAGCCTGCAGCAAGCACTTTGGAGAGCAAATCTGTGCAGAGAGTAACGCGGAG  
TGTCAGAGGTGTGCAGAAAATCCAAAGAAGGTGAGGACAATGTGTGTGTCAAGAAAATAACAACCAGA  
AGTCATAGGGACAGTGAAGATATTTGACAGAAAAATCGAACTGGGAAAAATATAATAAAGTTAGTTTGT  
25 GATAAGTTCTAGTGCAGTTTTTGTCTATAAATTACAAGTGAATTTCTGTAAGTAAGGCTGTCAGTCTGCTTA  
AGGGAAGAAAACCTTTGGATTGCTGGGTCTGAATCGGCTTCATAAACTCCACTGGGAGCACTGCTGGGCT  
CCTGGACTGAGAATAGTTGAACACCGGGGGCTTTGTGAAGGAGTCTGGGCCAAGGTTTGCCCTCAGCTTT  
GCAGAATGAAGCCTTGAGGTCTGTCACCAACCCACAGCCACCTTACAGCAGCCTTAACTGTGACACTTGCC  
ACACTGTGTGCTCGTTTGTTCCTATGTTCTCCAGGGCACGGTGGCAGGAACAACATATCCTCGTCTGTC  
30 CCAACACTGAGCAGGCACTCGGTAAACACGAATGAATGGATAAGCGCACGGATGAATGGAGCTTACAAGA  
TCTGTCTTTCCAATGGCCGGGGGCATTTGGTCCCCAAATTAAGGCTATTGGACATCTGCACAGGACAGTC  
CTATTTTTGATGTCTTTCTTTCTGAAAATAAAGTTTTGTGCTTTGGAGAATGACTCGTGAGCACATCT  
TTAGGGACCAAGAGTGACTTTCTGTAAGGAGTGACTCGTGGCTTGCCCTTGGTCTCTTGGGAATACTTTTC  
TAACTAGGGTTGCTCTCACCTGAGACATTCTCCACCCGCGGAATCTCAGGGTCCCAGGCTGTGGGCCATC  
35 ACGACCTCAAACCTGGCTCCTAATCTCCAGCTTTCTGTGATTGAAAGCTTCGGAAGTTTACTGGCTCTGC  
TCCCGCCTGTTTTCTTTCTGACTCTATCTGGCAGCCCGATGCCACCCAGTACAGGAAGTGACACCAGTAC  
TCTGTAAAGCATCATCATCCTTGAGAGACTGAGCACTCAGCACCTTCAGCCACGATTTTCAGGATCGCTT  
CCTTGTGAGCCGCTGCCTCCGAAATCTCCTTTGAAGCCAGACATCTTCTCCAGCTTCAGACTTGTAGA  
TATAACTCGTTTCATCTTCACTTTTCCACTTTGCCCCCTGTCTCTCTGTGTTCCCCAAATCAGAGAA  
40 TAGCCCGCCATCCCCAGATCACCTGTCTGGATTCTTCCCATTCACCCACCTTGCCAGGTGCAGGTGAG  
GATGGTGCACCAGACAGGGTAGCTGTCCCCAAAATGTGCCCTGTGCGGGCAGTGCCCTGTCTCCACGTT



5 TGT'TTCCCCAGTGTCTGGCGGGGAGCCAGGTGACATCATAAATACTTGCTGAATGAATGCAGAAATCAGC  
GGTACTGACTTGTACTATATTGGCTGCCATGATAGGGTCTCACAGCGTCATCCATGATCGTAAGGGAGA  
ATGACATTCTGCTTGAGGGAGGGAATAGAAAGGGGCAGGGAGGGGACATCTGAGGGCTTCACAGGGCTGC  
AAAGGGTACAGGGATTGCACCAGGGCAGAACAGGGGAGGGTGTTCAGGAAGAGTGGCTCTTAGCAGAGG  
10 CACTTTGGAAGGTGTGAGGCATAAATGCTTCCTTCTACGTAGGCCAACCTCAAAACTTTTCAGTAGGAATG  
TTGCTATGATCAAGTTGTTCTAACACTTTAGACTTAGTAGTAATTATGAACCTCACATAGAAAAATTTCA  
TCCAGCCATATGCCTGTGGAGTGAATATTTCTGTTTAGTAGAAAAATCCTTTAGAGTTCAGCTCTAACCA  
GAAATCTTGCTGAAGTATGTCAGCACCTTTTCTCACCCCTGGTAAGTACAGTATTTCAAGAGCACGCTAAG  
GGTGGT'TTTCATTTTACAGGGCTGTTGATGATGGGTAAATAATGTTCAATTAAGGGCTACCCCCGTGTTT  
15 AATAGATGAACACCACCTTCTACACAACCCCTCCTTGGTACTGGGGGAGGGAGAGATCTGACAAATACTGCC  
CATTCCCCTAGGCTGACTGGATTTGAGAACAATAACCCACCCATTTCCACCATGGTATGGTAACCTTCTCT  
GAGCTTCAGTTTCCAAGTGAATTTCCATGTAATAGGACATTTCCATTAAATACAAGCTGTTTTTACTTTT  
TCGCCTCCCAGGGCCTGTGCGATCTGGTCCCCCAGCCTCTCTTGGGCTTCTTACACTAACTCTGTACCT  
ACCATCTCCTGCCTCCCTTAGGCAGGCACCTCCAACCACCACACACTCCCTGCTGTTTTCCCTGCCTGGA  
20 ACTTTCCCACCAGCCCCACCAAGATCATTTTCATCCAGTCTGAGCTCAGCTTAAGGGAGGCTTCTTGCTT  
GTGGGT'TCCCTCACCCCATGCCTGTCTCCAGGCTGGGGCAGGTTCTTAGTTTGCTGGAATTTGTTCTG  
TACCTCTTTGTAGCACGTAGTGTGTGAACTAAGCCACTAATTGAGTTTCTGGCTCCCCTCCTGGGGTT  
GTAAGTTTGTTCATTATGAGGGCCGACTGTATTTCTTGGTTACTGTATCCCAGTGACCAGCCACAGGA  
GATGTCCAATAAAGTATGTGATGAAATGGTCTTAAAAA

SEQ ID NO: 24

25 >gi|415820|emb|X65551|HSMKI67A H.sapiens mki67a mRNA (short type) for  
antigen of monoclonal antibody Ki-67  
CTACCGGGCGGAGGTGAGCGCGGCGCCGGCTCCTCCTGCGGCGGACTTTGGGTGCGACTTGACGAGCGGT  
GGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGGAAGAGTTGTAAATTGCTTCTGGCCTTCCC  
CTACGGATTATACCTGGCCTTCCCCTACGGATTATACTCAACTTACTGTTTAGAAAAATGTGGCCCACGAG  
30 ACGCCTGGTTACTATCAAAAGGAGCGGGGTCGACGGTCCCACCTTTCCCCTGAGCCTCAGCACCTGCTTG  
TTTGGAAGGGGTATTGAATGTGACATCCGTATCCAGCTTCCTGTTGTGTCAAAACAACATTGCAAAATTG  
AAATCCATGAGCAGGAGGCAATATTACATAATTTCAGTTCCACAAATCCAACACAAGTAAATGGGTCTGT  
TATTGATGAGCCTGTACGGCTAAAACATGGAGATGTAATAACTATTATTGATCGTTCCTTCAGGTATGAA  
AATGAAAGTCTTCAGAATGGAAGGAAGTCAACTGAATTTCCAAGAAAAATACGTGAACAGGAGCCAGCAC  
GTCGTGTCTCAAGATCTAGCTTCTCTTCTGACCCTGATGAGAGTGAGGGAATACCTTTGAAAAGAAGCGG  
35 TGTGTCTTTGGTGGGCACCTAAGACCTGAACATTTGATGAAAACCTGCCTCCTAATACGCCTCTCAAA  
AGGGGAGAAGCCCCAACCAAAAGAAAGTCTCTGGTAATGCACACTCCACCTGTCCTGAAGAAAATCATCA  
AGGAACAGCCTCAACCATCAGGAAAACAAGAGTCAGGTTTCAAGAAATCCATGTGGAAGTGAAGGCACAAAG  
CTTGGTTATAAGCCCTCCAGCTCCTAGTCTTAGGAAAACCTCCAGTTGCCAGTGATCAACGCCGTAGGTCC  
TGCAAAACAGCCCCTGCTTCCAGCAGCAAATCTCAGACAGAGGTTCCCTAAGAGAGGAGGAGAAAGAGTGG  
40 CAACCTGCCTTCAAAAGAGAGTGTCTATCAGCCGAAGTCAACATGATATTTTACAGATGATATGTTCCAA  
AAGAAGAAGTGGTGTCTCGGAAGCAAATCTGATTGTTGCAAAATCATGGGCAGATGTAGTAAACTTGGT

GCAAAACAAACACAACTAAAGTCATAAAACATGGTCCTCAAAGGTCAATGAACAAAAGGCAAAAGAAGAC  
CTGCTACTCCAAAGAAGCCTGTGGGCGAAGTTCACAGTCAATTTAGTACAGGCCACGCAAACTCTCCTTG  
TACCATAATAATAGGGAAAGCTCATACTGAAAAAGTACATGTGCCTGCTCGACCCTACAGAGTGCTCAAC  
AACTTCATTTCCAACCAAAAAATGGACTTTAAGGAAGATCTTTCAGGAATAGCTGAAATGTTCAAGACCC  
5 CAGTGAAGGAGCAACCGCAGTTGACAAGCACATGTCACATCGCTATTTCAAATTCAGAGAATTTGCTTGG  
AAAACAGTTTCAAGGAACTGATTTCAGGAGAAGAACCCTGCTCCCCACCTCAGAGAGTTTGGAGGAAAT  
GTGTTCTTCAGTGCACAGAATGCAGCAAAACAGCCATCTGATAAATGCTCTGCAAGCCCTCCCTTAAGAC  
GGCAGTGTATTAGAGAAAATGGAAACGTAGCAAAAACGCCAGGAACACCTACAAAATGACTTCTCTGGA  
GACAAAACTTCAGATACTGAGACAGAGCCTTCAAAAACAGTATCCACTGTAAACAGGTCAGGAAGGTCT  
10 ACAGAGTTTCAGGAATATACAGAAGCTACCTGTGGAAAGTAAGAGTGAAGAAACAAATACAGAAATTTGTTG  
AGTGCATCCTAAAAAGAGGTCAGAAGGCAACACTACTACAACAAAGGAGAGAAGGAGAGATGAAGGAAAT  
AGAAAGACCTTTTGAGACATATAAGGAAAATATTGAATTAAAAGAAAACGATGAAAAGATGAAAGCAATG  
AAGAGATCAAGAACTTGGGGGCAGAAATGTGCACCAATGTCTGACCTGACAGACCTCAAGAGCTTGCCTG  
ATACAGAACTCATGAAAGACACGGCACGTGGCCAGAATCTCCTCCAACCCAAGATCATGCCAAGGCACC  
15 AAAGAGTGAGAAAGGCAAAATCACTAAAAATGCCCTGCCAGTCATTACAACCAGAACCAATAAACACCCCA  
ACACACACAAAAACAACAGTTGAAGGCATCCCTGGGGAAAGTAGGTGTGAAAGAAGAGCTCCTAGCAGTCG  
GCAAGTTACACGGACGTGAGGGGAGACCACGCACACGCACAGAGAGCCAGCAGGAGATGGCAAGAGCAT  
CAGAACGTTTAAGGAGTCTCCAAGCAGATCCTGGACCCAGCAGCCCGTGAAGTGAATGAAGAAGTGG  
CCAAGAACGCCTAAGGAAGAGGCCAGTCACTAGAAGACCTGGCTGGCTTCAAAGAGCTCTTCCAGACAC  
20 CAGGTCCCTCTGAGGAATCAATGACTGATGAGAAAATACCAAAATAGCCTGCAAAATCTCCACCACCAGA  
ATCAGTGGACACTCCAACAAGCACAAGCAATGGCCTAAGAGAAGTCTCAGGAAAGCAGATGTAGAGGAA  
GAATTTCTAGCACTCAGGAACTAACACCATCAGCAGGGAAAGCCATGCTTACGCCCAAACCAGCAGGAG  
GTGATGAGAAAAGACATTAAAGCATTTATGGGAACTCCAGTGCAGAACTGGACCTGGCAGGAACTTTACC  
TGGCAGCAAAAGACAGCTACAGACTCCTAAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTTAAA  
25 GAGCTCTTCCAGACTCCTGGTCACACCGAGGAATTAGTGGCTGCTGGTAAAACCACTAAAATACCCTGCG  
ACTCTCCACAGTCAGACCCAGTGGACACCCCAACAAGCACAAGCAACGACCCAAGAGAAGTATCAGGAA  
AGCAGATGTAGAGGGAGAACTCTTAGCGTGCAGGAATCTAATGCCATCAGCAGGCAAAGCCATGCACACG  
CCTAAACCATCAGTAGGTGAAGAGAAAGACATCATATTTGTGGGAACTCCAGTGCAGAACTGGACC  
TGACAGAGAACTTAACCGGCAGCAAGAGACGGCCACAACTCCTAAGGAAGAGGCCAGGCTCTGGAAGA  
30 CCTGACTGGCTTTAAAGAGCTCTTCCAGACCCCTGGTCATACTGAAGAAGCAGTGGCTGCTGGCAAACT  
ACTAAAATGCCCTGCGAATCTTCTCCACCAGAATCAGCAGACACCCCAACAAGCACAAGAAGGCAGCCCA  
AGACACCTTTGGAGAAAAGGGACGTACAGAAGGAGCTCTCAGCCCTGAAGAAGCTCACACAGACATCAGG  
GGAAACCACACACACAGATAAAGTACCAGGAGGTGAGGATAAAAGCATCAACGCGTTTAGGGAACTGCA  
AAACAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGCAAGAGGCACCCAAAACTAAGGAAAAGGCC  
35 AACCCTAGAAAGACCTGGCTGGCTGGAAAGAGCTCTTCCAGACACCAGTATGCACTGACAAGCCCACGAC  
TCACGAGAAAATACCAAAATAGCCTGCAGATCACAACCAGACCCAGTGGACACACCAACAAGCTCCAAG  
CCACAGTCCAAGAGAAGTCTCAGGAAAGTGGACGTAGAAGAAGAATTCTTCGCACTCAGGAAACGAACAC  
CATCAGCAGGCAAAGCCATGCACACCCAAACCAGCAGTAAGTGGTGAGAAAAACATCTACGCATTTAT  
GGGAACTCCAGTGCAGAACTGGACCTGACAGAGAACTTAAGTGGCAGCAAGAGACGGCTACAACTCCT  
40 AAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTTAAAGAGCTCTTCCAGACACGAGGTCACTG  
AGGAATCAATGACTAACGATAAACTGCCAAAGTAGCCTGCAAACTTTCACAACCAGACCTAGACAAAAA

CCCAGCAAGCTCCAAGCGACGGCTCAAGACATCCCTGGGGAAAGTGGGCGTGAAAGAAGAGCTCCTAGCA  
GTTGGCAAGCTCACACAGACATCAGGAGAGACTACACACACACACAGAGCCAACAGGAGATGGTAAGA  
GCATGAAAGCATTTATGGAGTCTCCAAAGCAGATCTTAGACTCAGCAGCAAGTCTAACTGGCAGCAAGAG  
5 GCAGCTGAGAACTCCTAAGGGAAAGTCTGAAGTCCCTGAAGACCTGGCCGGCTTCATCGAGCTCTTCCAG  
ACACCAAGTCACACTAAGGAATCAATGACTAATGAAAAAACTACCAAAGTATCCTACAGAGCTTCACAGC  
CAGACCTAGTGGACACCCCAACAAGCTCCAAGCCACAGCCCAAGAGAAGTCTCAGGAAAGCAGACACTGA  
AGAAGAATTTTTAGCATTTAGGAAACAAACGCCATCAGCAGGCAAAGCCATGCACACACCCAAACCAGCA  
GTAGGTGAAGAGAAAGACATCAACACGTTTTTGGGAACTCCAGTGCAGAACTGGACCAGCCAGGAAATT  
TACCTGGCAGCAATAGACGGCTACAAACTCGTAAGGAAAAGGCCAGGCTCTAGAAGAACTGACTGGCTT  
10 CAGAGAGCTTTTCCAGACACCATGCACTGATAACCCACAGCTGATGAGAAAATACCAAAAAATACTC  
TGCAAATCTCCGCAATCAGACCCAGCGGACACCCCAACAAACACAAAGCAACGGCCCAAGAGAAGCCTCA  
AGAAAGCAGACGTAGAGGAAGAATTTTAGCATTTCAGGAACTAACACCATCAGCAGGCAAAGCCATGCA  
CACGCCTAAAGCAGCAGTAGGTGAAGAGAAAGACATCAACACATTTGTGGGGACTCCAGTGGAGAAACTG  
GACCTGCTAGGAAATTTACCTGGCAGCAAGAGACGGCCACAACTCCTAAAGAAAAGGCCAAGGCTCTAG  
15 AAGATCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGTCACACTGAGGAATCAATGACCGATGACAA  
AATCACAGAAGTATCCTGCAAATCTCCACAACCAGACCCAGTCAAAACCCCAACAAGCTCCAAGCAACGA  
CTCAAGATATCCTTGGGGAAAGTAGGTGTGAAAGAAGAGGTCCTACCAGTCGGCAAGCTCACACAGACGT  
CAGGGAAGACCACACAGACACACAGAGAGACAGCAGGAGATGGAAAGAGCATCAAAGCGTTTAAGGAATC  
TGCAAAGCAGATGCTGGACCCAGCAAACTATGGAAC TGGGATGGAGAGGTGGCCAAGAACACCTAAGGAA  
20 GAGGCCCAATCACTAGAAGACCTGGCCGGCTTCAAAGAGCTCTTCCAGACACCAGACCACACTGAGGAAT  
CAACAACTGATGACAAAATACCAAAATAGCCTGCAAATCTCCACCACCAGAATCAATGGACACTCCAAC  
AAGCACAAGGAGGCGGCCAAAACACCTTTGGGGAAAAGGGATATAGTGAAGAGCTCTCAGCCCTGAAG  
CAGCTCACACAGACCACACACAGACAAAGTACCAGGAGATGAGGATAAAGGCATCAACGTGTTTACGGG  
AAACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAC TGGTAGCAAGAGGCAGCCAAGAACTCCTAA  
25 GGGAAAAGCCCAACCCCTAGAAGACTTGGCTGGCTTGAAAGAGCTCTTCCAGACACCAGTATGCACTGAC  
AAGCCCACGACTCACGAGAAAATACCAAAATAGCCTGCAGATCTCCACAACCAGACCCAGTGGGTACCC  
CAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAAAGCAGACGTAGAGGAAGAATCCTTAGCACT  
CAGGAAACGAACACCATCAGTAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGAC  
ATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGGAAATTTACCTGGCAGCAAAAGAT  
30 GGCCACAAACTCCTAAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTCAAAGAGCTCTTCCAGAC  
ACCAGGCACTGACAAGCCACGACTGATGAGAAAATACCAAAATAGCCTGCAAATCTCCACAACCAGAC  
CCAGTGGACACCCACAGCAAGCACAAGCAACGGCCCAAGAGAAACCTCAGGAAAGCAGACGTAGAGGAAG  
AATTTT TAGCACTCAGGAAACGAACACCATCAGCAGGCAAAGCCATGGACACCCCAAAACCAGCAGTAAG  
TGATGAGAAAAATATCAACACATTTGTGGAAACTCCAGTGCAGAACTGGACCTGCTAGGAAATTTACCT  
35 GGCAGCAAGAGACAGCCACAGACTCCTAAGGAAAAGGCTGAGGCTCTAGAGGACCTGGTTGGCTTCAAAG  
AACTCTTCCAGACACCAGGTCACACTGAGGAATCAATGACTGATGACAAAATCACAGAAGTATCCTGTAA  
ATCTCCACAGCCAGAGTCATTTCAAACCTCAAGAAGCTCCAAGCAAAGGCTCAAGATACCCCTGGTGAAA  
GTGGACATGAAAGAAGAGCCCTAGCAGTCAGCAAGCTCACACGGACATCAGGGGAGACTACGCAAAACAC  
ACACAGAGCCAACAGGAGATAGTAAGAGCATCAAAGCGTTTAAGGAGTCTCCAAAGCAGATCCTGGACCC  
40 AGCAGCAAGTGTAAGTGGTAGCAGGAGGCAGCTGAGAATCGTAAGGAAAAGGCCCGTGCTCTAGAAGAC  
CTGGTTGACTTCAAAGAGCTCTTCTCAGCACCCAGGTCACACTGAAGAGTCAATGACTATTGACAAAAACA

CAAAAATTCCCTGCAAAATCTCCCCACCAGAACTAACAGACACTGCCACGAGCACAAAGAGATGCCCCAA  
GACACGTCCCAGGAAAGAAGTAAAAGAGGAGCTCTCAGCAGTTGAGAGGCTCACGCAAACATCAGGGCAA  
AGCACACACACACAAAAGAACCAGCAAGCGGTGATGAGGGCATCAAAGTATTGAAGCAACGTGCAAAGA  
AGAAACCAAACCCAGTAGAAGAGGAACCCAGCAGGAGAAGGCCAAGAGCACCTAAGGAAAAGGCCCAACC  
5 CCTGGAAGACCTGGCCGGCTTCACAGAGCTCTCTGAAACATCAGGTCACTCAGGAATCACTGACTGCT  
GGCAAAGCCACTAAAAATACCCTGCGAATCTCCCCACTAGAAAGTGGTAGACACCACAGCAAGCACAAAGA  
GGCATCTCAGGACACGTGTGCAGAAGGTACAAGTAAAAGAAGAGCCTTCAGCAGTCAAGTTCACACAAAC  
ATCAGGGGAAACCACGGATGCAGACAAAGAACCAGCAGGTGAAGATAAAGGCATCAAAGCATTGAAGGAA  
TCTGCAAAACAGACACCGGCTCCAGCAGCAAGTGTAAGTGGCAGCAGGAGACGGCCAAGAGCACCCAGGG  
10 AAAGTGCCCCAAGCCATAGAAGACCTAGCTGGCTTCAAAGACCCAGCAGCAGGTCACTGAAGAATCAAT  
GACTGATGACAAAACCACTAAAAATACCCTGCAAAATCATACCAGAACTAGAAGACACCGCAACAAGCTCA  
AAGAGACGGCCAGGACACGTGCCCAGAAAGTAGAAGTGAAGGAGGAGCTGTTAGCAGTTGGCAAGCTCA  
CACAAACCTCAGGGGAGACCACGCACACCGACAAAGAGCCGGTAGGTGAGGGCAAAGGCACGAAAGCATT  
TAAGCAACCTGCAAAGCGAACGTGGACGCAGAAGATGTAATTGGCAGCAGGAGACAGCCAAGAGCACCT  
15 AAGGAAAAGGCCAACCCCTGGAAGACCTGGCCAGCTTCCAAGAGCTCTCTCAAACACCAGGCCACACTG  
AGGAACTGGCAAATGGTGTCTGTGATAGCTTTACAAGCGCTCCAAAGCAAACACCTGACAGTGGAAAACC  
TCTAAAAATATCCAGAAGAGTTCTTCGGGCCCTAAAGTAGAACCCGTGGGAGACGTGGTAAGCACCAGA  
GACCTGTAAAATCACAAAGCAAAAGCAACACTTCCCTGCCCCACTGCCCTTCAAGAGGGGAGGTGGCA  
AAGATGGAAGCGTCACGGGAACCAAGAGGCTGCGCTGCATGCCAGCACCAGAGGAAATTGTGGAGGAGCT  
20 GCCAGCCAGCAAGAAGCAGAGGGTTGCTCCCAGGGCAAGAGGCAAATCATCCGAACCCGTGGTCATCATG  
AAGAGAAGTTTGAGGACTTCTGCAAAAAGAATTGAACCTGCGGAAGAGTGTAACAGCAACGACATGAAAA  
CCAACAAAGAGGAACACAAATTACAAGACTCGGTCCCTGAAAATAAGGGAATATCCCTGCGCTCCAGACG  
CCAAGATAAGACTGAGGCAGAACAGCAAATAACTGAGGTCTTTGTATTAGCAGAAAGAATAGAAATAAAC  
AGAAATGAAAAGAAGCCCATGAAGACCTCCCCAGAGATGGACATTGAGATCCAGATGATGGAGCCCGGA  
25 AACCCTACCTAGAGACAAAGTCACTGAGAACAAAAGGTGCTTGAGGTCTGCTAGACAGAATGAGAGCTC  
CCAGCCTAAGGTGGCAGAGGAGAGCGGAGGGCAGAAGAGTGCGAAGGTCTCATGCAGAATCAGAAAGGG  
AAAGGAGAAGCAGGAAATTCAGACTCCATGTGCCTGAGATCAAGAAAGACAAAAGCCAGCCTGCAGCAA  
GCACTTTGGAGAGCAAATCTGTGCAGAGAGTAACGCGGAGTGTCAAGAGGTGTGCAGAAAATCCAAAGAA  
GGCTGAGGACAATGTGTGTGTCAAGAAAATAACAACCAGAAGTCATAGGGACAGTGAAGATATTGACAG  
30 AAAAAATCGAACTGGGAAAAATATAATAAAGTTAGTTTTGTGATAAGTTCTAGTGACAGTTTTTGTCAATAA  
TTACAAGTGAATTCTGTAAGTAAGGCTGTCAGTCTGCTTAAGGGAAGAAAACCTTTGGATTTGCTGGGTCT  
GAATCGGCTTCATAAACTCCACTGGGAGCACTGCTGGGCTCCTGGACTGAGAATAGTTGAACACCGGGGG  
CTTTGTGAAGGAGTCTGGGCAAGGTTTGCCTCAGCTTTGCAGAATGAAGCCTTGAGGTCTGTACCAC  
CCACAGCCACCCTACAGCAGCCTTAACGTGTGACACTTGCCCACTGTGTGTCGTTTGTTCCTATGTT  
35 CTCCAGGGCACGGTGGCAGGAACAACATCCTCGTCTGTCCCAACACTGAGCAGGCACTCGGTAACACAG  
AATGAATGGATAAGCGCACGGATGAATGGAGCTTACAAGATCTGTCTTTCCAATGGCCGGGGGCATTTGG  
TCCCCAAATTAAGGCTATTGGACATCTGCACAGGACAGTCCATTTTTGATGTCTTTCTTTCTGAAAA  
TAAAGTTTTGTGCTTTGGAGAATGACTCGTGAGCACATCTTTAGGGACCAAGAGTGACTTTCTGTAAGGA  
GTGACTCGTGGCTTGCTTGGTCTCTTGGGAATACTTTTCTAACTAGGGTTGCTCTCACCTGAGACATTC  
40 TCCACCCGCGGAATCTCAGGCTCCAGGCTGTGGGCCATCACGACCTCAAACCTGGCTCCTAATCTCCAGC  
TTTCCTGTCTATGAAAGCTTCGGAAGTTTACTGGCTCTGCTCCCGCTGTTTTCTTTCTGACTCTATCTG

GCAGCCCGATGCCACCCAGTACAGGAAGTGACACCAGTACTCTGTAAAGCATCATCATCCTTGGAGAGAC  
TGAGCACTCAGCACCTTCAGCCACGATTTTCAGGATCGCTTCCTTGTGAGCCGCTGCCTCCGAAATCTCCT  
TTGAAGCCCAGACATCTTTCTCCAGCTTCAGACTTGTAGATATAACTCGTTCATCTTCATTTACTTTCCA  
CTTTGCCCCCTGTCTCTCTGTGTTCCCCAAATCAGAGAATAGCCCGCCATCCCCCAGATCACCTGTCTG  
5 GATTCTCTCCCATTCACCCACCTTGCCAGGTGCAGGTGAGGATGGTGCACCAGACAGGGTAGCTGTCCCC  
CAAAATGTGCCCTGTGCGGGCAGTGCCTGTCTCCACGTTTGTTCCTCCAGTGTCTGGCGGGGAGCCAGG  
TGACATCATAAACTACTTGCTGAATGAATGCAGAAATCAGCGGTACTGACTTGTACTATATTGGCTGCCAT  
GATAGGGTTCTCACAGCGTCATCCATGATCGTAAGGGAGAATGACATTCTGCTTGAGGGAGGGAATAGAA  
AGGGGCAGGGAGGGGACATCTGAGGGCTTCACAGGGGTGCAAAGGGTACAGGGATTGCACCAGGGCAGAA  
10 CAGGGGAGGGTGTTCAGGAAGAGTGGCTCTTAGCAGAGGCACCTTTGGAAGGTGTGAGGCATAAATGCTT  
CCTTCTACGTAGGCCAACCTCAAACTTTTCAGTAGGAATGTTGCTATGATCAAGTTGTTCTAACACTTTA  
GACTTAGTAGTAATTATGAACCTCACATAGAAAAATTTTCATCCAGCCATATGCCTGTGGAGTGGAATATT  
CTGTTTAGTAGAAAAATCCTTTAGAGTTTCAGCTCTAACCAGAAATCTTGCTGAAGTATGTCAGCACCTTT  
TCTCACCTCGGTAAGTACAGTATTTCAAGAGCACGCTAAGGGTGGTTTTTCATTTTACAGGGCTGTTGATG  
15 ATGGGTAAATAATGTTTCATTTAAGGGCTACCCCGTGTTTAATAGATGAACACCACTTCTACACAACCT  
CCTTGGTACTGGGGGAGGGAGAGATCTGACAAATCTGCCCATTCCTTAGGCTGACTGGATTGAGAAC  
AAATACCCACCCATTTCCACCATGGTATGGTAACCTTCTCTGAGCTTCAGTTCCAAGTGAATTTCCATGT  
AATAGGACATTCCTTAAATACAAGCTGTTTTTACTTTTTTCGCCTCCCAGGGCCTGTGCGATCTGGTCC  
CCCAGCTCTCTTGGGCTTTCTTACACTAACTCTGTACCTACCATCTCCTGCCTCCCTTAGGCAGGCACC  
20 TCCAACCACCACACACTCCCTGCTGTTTTCCCTGCCTGGAACCTTCCCACCAGCCCCACCAAGATCATTT  
CATCCAGTCCTGAGCTCAGCTTAAGGGAGGCTTCTTGCCCTGTGGGTCCCTCACCCCCATGCCTGTCCCTC  
CAGGCTGGGGCAGGTTCTTAGTTTGCTGGAATTGTTCTGTACCTCTTTGTAGCACGTAGTGTGTGAAA  
CTAAGCCACTAATTGAGTTTCTGGCTCCCTCCTGGGGTTGTAAGTTTTGTTTCATTCATGAGGGCCGACT  
GTATTTCTGGTTACTGTATCCCAGTGACCAGCCACAGGAGATGTCCAATAAAGTATGTGATGAAATGGT  
25 CTTAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 25

>gi|29860|emb|X55039|HSCENPB Human hCENP-B gene for centromere  
autoantigen B (CENP-B)

5 TAGATTTACAACCTGTAATGCTGATTTTAAAAATAACTTAAGTGTGTAACAATAGGTTACATACGCTAGTG  
TTCATTTCATAGCTGGAATGCTACACAATCATTTAAAAAGCGTGTGGCAATGATACTTACCGATATGGCAA  
AATTCTCACTACTTGTATGCCAGGTAAAACAGCAGGAGATGCCAGATATACAGTCTATACAGTCTGATGCC  
AGTTTTATATAATAAATTTTAAAAAGAAAACGACATGCATCTAGAGAAAAGACTGGAAGGAAATGTATC  
10 AAAATGTTACCTGTGCATCTCTCCAGGTGACGTGAAAAGCGTTTTCAACTTCCTGAATTTTTCAGGTTT  
CGCAAAAAAAAAAGTGCCTTATTTTACCTTAATTAAAAAAAAAAAAAAAAAACAAACAAAAACCTGGTTCTT  
ATTCTTTTTTGAGCAGCAAGTCGCTGTCCGCCGGGCGCAGTAGCGATGCACCGCGTCCCCGCCCGCGTCGC  
TGCCGGGTGCGCGGAGGCCGCGCAGCAGGGCAGGTCCAGCAGGCCGCGCGCCCCCGCGCGGTATGTGCC  
CGGCGGCGGGAAGGGGGTGGGCGCGGAGGGCGGGGAGGAGCGCGGGCGTCCCCGCGCTTCCGCGGAGA  
TCCCGCTCCGCCCCGCTCGCCGCGCGTCCCAGTCCCCGCGCGGCCACTTCTGCCTTCCGCGCCCCGCG  
15 CCGCCCCGCTCGCTGCGCCCGTGCCTGCGCCCCGCGCGCGCGCGGACGCGGCGCGCGCGGTCCCCGGA  
GGTGCCCGGCCCGCGCGGTGCTGCCCCCGCGCGCGCGCGCGGAGCCGCTTGTCTCGGGCGGGGCGCGC  
GGGAGAGGCCGCCAGGTGCCCCCGCCACGGGCGCGGGCCCCCGCCCCGGGGCGGCGGCGGCGGCGCGG  
GCCCCGGGGCGGGGGCGCGCGGGATGGGCCCAAGAGGCGACAGCTGACGTTCCGGGAGAAGTCACGG  
ATCATCCAGGAGGTGGAGGAGAATCCGGACCTGCGCAAGGGCGAGATCGCGCGGCGCTTCAACATCCCGC  
20 CGTCCACGCTGAGCACGATCCTGAAGAACAAGCGCCCATCCTGGCGTCGGAGCGCAAGTACGGGGTGGC  
CTCCACCTGCCGAAGACCAACAAGCTGTCTCCCTACGACAAGCTCGAGGGCTTGCTCATCGCCTGGTTC  
CAGCAGATCCGCGCGCGCGGCTGCGCGTCAAGGGCATCATCCTCAAGGAGAAGGCGCTGCGCATAGCCG  
AGGAGCTGGGCATGGACGACTTCACCGCCTCCAACGGCTGGCTGGACCGCTTCCGCCGGCGCCACGGCGT  
GGTGTCTGACAGCGCGTGGCCCCGCGCGCGCGGAAACGCTGCCCCCGCACCCCGCGCGCGCTGCC  
25 AGTCCGGCGCGCGTGCCCTCGGAGGGCAGTGGCGGGAGCACTACTGGTTGGCGCGCTCGGGAGGAGCAGC  
CGCCGTCGGTGGCCGAGGGCTACGCCTCGCAGGACGTGTTTACGCGCCACCGAGACCAGTCTATGTTACGA  
CTTCTGCCCCGACAGGCCGCGGGGCTGTGCGGAGGCGACGACGGCGCGTCAAGCCACCCAGCGCCTG  
AGCGTCTGCTATGCGCCAATGCCGACGGCAGCGAGAAGCTGCCCCCGCTGGTGGCCGGCAAGTCGGCCA  
AGCCCCGCGCAGGCCAAGCCGGCTGCCCTGCGACTACACGCCAACTCCAAGGGTGGTGTACCAACCCA  
30 GGCCCTGGCCAAGTACTTGAAGGCCCTTGACACCCGAATGGCTGCAGAGTCTCGCCGGGTCTGCTGTTG  
GCCGGCCGCTTGGCTGCCCAGTCTTGGACACCTCGGGCCTGCGGCATGTGCAGCTGGCCTTCTTCCCTC  
CCGACACCGTGCATCCGCTGGAGAGGGAGTGGTCCAGCAGGTGAAGGGCCACTACCGCCAGGCCATGCT  
GCTCAAGGCCATGGCCGCGCTAGAGGGCCAGGATCCCTCAGGCCTGCAGCTGGGTCTCACGGAGGCCCTG  
CACTTTGTGGCTGCCGCTGGCAGGCAGTGGAGCCTTCGGACATAGCCGCTGCTTTCTGTAGGCTGGCT  
35 TTGGGGGTGGCCCTAATGCCACCATCACCCTTCCCTCAAGAGTGAGGGAGAGGAAGAGGAGGAGGAGGA  
GGAAGAAGAGGAGGAGGAAGAGGGTGAAGGAGAGGAAGAGGAGGAGGAAGGGAGGAGGAGGAGGAGGA  
GGGGGGAAGGAGAGGAATTGGGGAGGAAGAGGAGGTGGAGGAGGAGGTGATGTTGATAGTGATGAAG  
AAGAGGAGGAAGATGAGGAGAGCTCCTCGGAGGGCTTGAAGCTGAGGACTGGGCCAGGGAGTAGTGGA  
GGCCGCTGGCAGCTTCGGGGCTTATGGTGGCCAGGAGGAAGCCAGTGCCTACTCTGCATTTCTTGAA  
40 GGTGGGAGGACTCTGATTGACAGTGAGGAAGAGGACGATGAGGAAGAGGATGATGAAGATGAAGACG  
ACGATGATGATGAGGAGGATGGTGTAGGTGCCTGTACCCAGCTTTGGGGAGGCCATGGCTTACTTTGC

CATGGTCAAGAGGTACCTGACCTCCTTCCCCATTGATGACCGCGTGCAGAGCCACATCCTCCACTTGGAA  
CACGATCTGGTTCATGTGACCAGGAAGAACCACGCCAGGCAGGCGGGAGTTCGAGGTCTTGGACATCAAA  
GCTGAGTCACTGGACCTAGCTGTGCCCCAACCTAGATTGGCAGCACCACCCAGGGCAGAGGACTCTCT  
GGGCACCCGCTGTGCATGGAGCCAGAGTGCAGAGCCCCAGATCCTTTAGTAATGCTTCCCCTGGTCCTGC  
5 AACAGGCCCGGTCACCTCGGCCGGGCGGGGCTGAGGTACAGCTCACTGCCTGCTTATTGCCTCTTTCT  
CAGAATCCTCTTTCTCCTCCCCATTGGCCCTGGGCTCAGGGGACCAGGTGGGGCGGGTGGGGAGCTGTCCG  
GTGCTACCACACCGTGCCCTCAGTGGACTAACCACAGCAGCAGCCAGGGATGGGCCCTGGAGGTTCCCCG  
CCGGAGAGTGCCTCTCCCCCTGCCATCCACGTCAGGTCTTTGGTGGGGGACCCCAAAGCCATTCTGGG  
AAGGGCTCCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGCTGGCAGCCCCACCCCCACCCCCAGGC  
10 CGCCTTGAGAAGCACAGTTTAACTCACTGCGGGCTCCTGAGCCTGCTTCTGCCTGCTTTCCACCTCCCCA  
GTCCCTTTCTCTGGCCCTGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGTTTCCAAGA  
GGCCCCCACCCTGGAAGTAACCAAGGGCGCTTCCTTGTGGCAGCTGCAGGCCCATGCCTCTCCTCCC  
TCTCTCTGGCAGGGCCCATCTGGGCAGAGGGGCTGGGGCTGGGCCAGAGTCCAGCCGTCCAGCTGCT  
CCTTTCCAGTTTGATTTCAATAAATCTGTCCACTCCCCTTTTGTGGGGGTGAACGTTTAAACAGCCAAG  
15 GGTGCATCCTTCATGGTCTGGGCTTGCCTGTCTTGGGGGACTTATTCGTCTGGCTCTCTTTGGTCCT  
TGCTCTGGTGGGACATGGAGGCAAGTGTGAGAGGGTTGCCCTGACCGGAAGAGGGGCAGGAGGAGACCT  
CAAGCTT

SEQ ID NO: 26

>gi|1628402|emb|X98893|HSTAFII68 H.sapiens mRNA for TBP associated factor, TAFII68

5 GTTGTTCCTCGGCGGGCTGTGGGGCCTCCGCGCCGCGGCCGTTAGTCATGTCGGATTCTGGAAGTTACGGT  
CAGTCTGGGGGTGAGCAGCAAAGTTATTCTACCTATGGAAATCCAGGCAGCCAAGGCTATGGACAAGCAT  
CACAAAGCTATTCTGGCTATGGGCAAACGACTGATTCTCTTATGGACAGAACTACAGCGGTTACTCCAG  
TTATGGACAAAGTTATTCACAGTCCTATGGTGGTTATGAGAATCAAAGCAGAGCTCATATAGCCAGCAA  
CCATATAATAACCAGGGACAGCAGCAAAACATGGAATCATCAGGAAGCCAAGGTGGAAGAGCACCTTCCT  
10 ATGACCAGCCAGACTATGGTCAACAAGATTTCATATGACCAGCAGTCAGGCTATGATCAACATCAAGGCTC  
ATATGATGAGCAGTCAAATTATGATCAGCAGCATGATTCCCTATAGTCAAAACCAGCAGTCCTATCATTTCA  
CAAAGGGAAAACCTACAGCCACCACACACAAGATGACCGTCGTGATGTGAGTAGGTATGGAGAAGATAATA  
GAGGATATGGCGGGTCACAGGGAGGAGGTAGAGGGCGTGGGGGATATGACAAGGATGGAAGAGGTCCTAT  
GACAGGATCAAGTGGTGGTGACCGCGGTGGCTTCAAAAATTTTGGTGGTCACAGGGATTATGGACCCAGA  
15 ACAGATGCTGATTCAGAATCTGATAATTCAGATAACAACACAATCTTTGTGCAAGGACTTGGGGAGGGTG  
TGTCTACAGATCAAGTTGGGGAGTTCTTTAAACAAATAGGAATTATCAAGACAAATAAGAAGACCCGAAA  
ACCAATGATAAATCTTTATACAGACAAGGACACAGGAAAGCCAAAGGGGGAGGCAACAGTGTCAATTTGAT  
GACCTCTCTTCAGCTAAGGCAGCCATTGACTGGTTTGATGGAAAAGAATTCCATGGCAACATCATTAAG  
TGTCTTTTGCCACTAGAAGACCTGAATTCATGAGAGGAGGTGGAAGTGGAGGTGGCGGGCAGGCCGTGG  
20 AGGATATAGAGGTCGTGGAGGCTTTCAAGGGAGAGGTGGAGACCCCAAAAGTGGGGATTGGGTTTGCCCT  
AATCCGTCATGCGGAAATATGAACTTTGCTCGAAGGAATTCCTGCAATCAGTGAATGAGCCTAGACCAG  
AGGACTCTCGTCCCTCAGGAGGAGATTTCCGGGGAGAGGCTACGGTGGAGAGAGGGGCTACAGAGGTCCG  
CGGGGGCAGAGGTGGAGACCGAGGCGGCTATGGTGGAGACAGAACTGGGGGTGGCTATGGTGGAGACAGA  
AGCAGCGGTGGTGGCTACAGCGGAGATAGAAGTGGGGCGGCTATGGTGGAGACAGAAAGTGGGGGTGGCT  
25 ATGGTGGGGACAGAGGCGGCGGCTATGGTGGGGACAGAGGAGGCGGCTATGGAGGAGACCGAGGAGGTGG  
CTATGGAGGAGATCGAGGTGGCTATGGAGGAGACCGAGGTGGAGGCTATGGTGGAGACCGAGGAGGCTAT  
GGAGGAGATCGAGGAGGTTACGGAGGAGATCGAGGAGGTTATGGAGGAGATCGAGGAGGCTATGGAGGAG  
ACAGAAGCCGGGGGGGCTATGGAGGAGACCGTGGTGGTGGCAGTGGCTACGGTGGAGACCGAAGTGGAGG  
CTATGGAGGAGACAGGAGTGGTGGCGGCTATGGAGGAGACCGAGGTGGGGGCTACGGAGGAGACCGAGGT  
30 GGCTATGGAGGCAAAATGGGAGGAAGAAACGACTACAGAAATGATCAGCGCAACCGACCATACTGATGAC  
TGTTTTGAATGTTCCCTTTGTCTCTGACATGATCCATAGTGAAATTGCCAGAGTTTGCCTGGTGTCTCC  
TCGTGGCCTCTTCTTGGGTAGTGAAATTAAGTGACATTTGGATTTTATTTGGGTGGGAGGGCTGGGACA  
GTTTTTCTTCTAGAAATGTCTGTTGAGATTTCCCCCTTTAGTTTCCAACCTTCTCCCCAACCTTGGAGC  
TAAATGCGTTGTAAATATTGCCAAAATGAAAAGTGTGTTGTAATACTGCAATAAAGGCTGCTTGTGTTTT  
35 GTGGAAAAAAAAAAAAAAAAAAAAA



SEQ ID NO: 27

>gi|219909|dbj|D00017|HUMLIC Homo sapiens mRNA for lipocortin II,  
complete cds

5 CATTGGGGACGCTCTCAGCTCTCGGCGCACGGCCCAGCTTCCTTCAAATGTCTACTGTTCACGAAATC  
CTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCAAGTGCATATGGGTCTGTCAAAGCCTATA  
CTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGT  
CACCATTGTCAACATTTTGACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCCTACCAGAGA  
AGGACCAAAAAGGAACCTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGG  
10 GCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGGCTGGGAACCGA  
CGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTGCAGGAAATTAACAGAGTCTAC  
AAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATTCGGACACATCTGGTGACTTCCGCAAGCTGA  
TGTTTGGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGA  
TGCTCGGGATCTCTATGACGCTGGAGTGAAGAGGAAAGGAACGATGTTCCCAAGTGATCAGCATCATG  
15 ACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATGT  
TGGAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCA  
GAACAAGCCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCGAGATAAGGTC  
CTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTAGGTCTGAATTCAAGAGAAAAGT  
ACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCT  
20 GTGTGGTGGAGATGACTGAAGCCCGACACGGCCTGAGCGTCCAGAAATGGTGCTCACCATGCTTCCAGCT  
AACAGGTCTAGAAAACCAGCTTGCGAATAACAGTCCCCGTGGCCATCCCTGTGAGGGTGACGTTAGCATT  
ACCCCCAACCTCATTTTAGTTGCCTAAGCATGCCTGGCCTTCCTGTCTAGTCTCTCCTGTAAGCCAAAG  
AAATGAACATTCCAAGGAGTTGGAAGTGAAGTCTATGATGTGAAACACTTTCCTCTGTGACTGTGTC  
ATAAACAGATGAATAAACTGAATTTGTACTTT

25

SEQ ID NO: 28

>gi|37173|emb|X05615|HSTHYRR Human mRNA for thyroglobulin

5 GCAGTGGTTTCTCCTCCTTCCTCCCAGGAAGGGCCAGGAAATGGCCCTGGTCCTGGAGATCTTCACCCCT  
GCTGGCCTCCATCTGCTGGGTGTCGGCCAATATCTTCGAGTACCAGGTTGATGCCCAGCCCCCTTCGTCCC  
TGTGAGCTGCAGAGGGAAACGGCCTTTCTGAAGCAAGCAGACTACGTGCCCCAGTGTGCAGAGGATGGCA  
GCTTCCAGACTGTCCAGTGCCAGAACGACGGCCGCTCCTGCTGGTGTGTGGGTGCCAACGGCAGTGAAGT  
GCTGGGCAGCAGGCAGCCAGGACGGCCTGTGGCTTGTCTGTCAATTTTGTGAGCTACAGAAACAGCAGATC  
TTACTGAGTGGCTACATTAACAGCACAGACACCTCCTACCTCCCTCAGTGTGAGGATTGAGGGGACTACG  
10 CGCCTGTTTCAGTGTGATGTGCAGCATGTCCAGTGTGGTGTGTGGACGCAGAGGGGATGGAGGTGTATGG  
GACCCGCCAGCTGGGGAGGCCAAAGCGATGTCCAAGGAGCTGTGAAATAAGAAATCGTCGTCTTCTCCAC  
GGGGTGGGAGATAAGTCACCACCCAGTGTCTGCGGAGGGAGAGTTTATGCCTGTCCAGTGCAAATTTG  
TCAACACCACAGACATGATGATTTTGTATCTGGTCCACAGCTACAACAGGTTTCCAGATGCATTTGTGAC  
CTTCAGTTCCTTCCAGAGGAGGTTCCCTGAGGTATCTGGGTATTGCCACTGTGCTGACAGCCAAGGGCGG  
15 GAACTGGCTGAGACAGGTTTGGAGTTGTTACTGGATGAAATTTATGACACCATTTTGTCTGGCCTGGACC  
TTCTTCCACCTTCACTGAAACCACCTGTACCGGATACTGCAGAGACGGTTCCCTCGCAGTTCAATCAGT  
CATCTCTGGCAGATTCCGATGCCCCACAAAATGTGAAGTGGAGCGGTTTACAGCAACCAGCTTTGGTCAC  
CCCTATGTTCCAAGCTGCCGCCGAAATGGCGACTATCAGGCGGTGCAGTGCCAGACGGAAGGGCCCTGCT  
GGTGTGTGGACGCCCAGGGGAAGGAAATGCATGGAACCCGGCAGCAAGGGGAGCCGCCATCTTGTGCTGA  
20 AGGCCAATCTTGTGCCTCCGAAAGGCAGCAGGCCTTGTCCAGACTCTACTTTGGGACCTCAGGCTACTTC  
AGCCAGCACGACCTGTTCTCTTCCCCAGAGAAAAGATGGGCCTCTCCAAGAGTAGCCAGATTTGCCACAT  
CCTGCCACCCACGATCAAGGAGCTCTTTGTGGACTCTGGGCTTCTCCGCCCAATGGTGGAGGGACAGAG  
CCAACAGTTTTTCTGTCTCAGAAAATCTTCTCAAAGAAGCCATCCGAGCAATTTTCCCTCCCGAGGGCTG  
GCTCGTCTTGCCCTTCAGTTTACCACCAACCCAAAGAGACTCAGCAAAACCTTTTGGAGGGAAATTTT  
25 TGGTGAATGTTGGCCAGTTTAACTTGTCTGGAGCCCTTGGCACAAGAGGCACATTTAACTTCAGTCAATT  
TTTCCAGCAACTTGGTCTTGCAAGCTTCTTGAATGGAGGGAGACAAGAAGATTTGGCCAAGCCACTCTCT  
GTGGGATTAGATTCAAATCTTCCACAGGAACCCCTGAAGCTGCTAAGAAGGATGGTACTATGAATAAGC  
CAACTGTGGGCAGCTTTGGCTTTGAAATTAACCTACAAGAGAACCAAAATGCCCTCAAATTCCTTGCTTC  
TCTCCTGGAGCTTCCAGAATTCCTTCTCTTCTTGCAACATGCTATCTCTGTGCCAGAAGATGTGGCAAGA  
30 GATTTAGGTGATGTGATGGAACGGTACTCGACTCCAGACCTGTGAGCAGACACCTGAAAGGCTATTTG  
TCCCATCATGCACGACAGAAGGAAGCTATGAGGATGTCCAATGCTTTTCCGAGAGTGCTGGTGTGTGAA  
TTCTTGGGGCAAAGAGCTTCCAGGCTCAAGAGTCAGAGATGGACAGCCAAGGTGCCCCACAGACTGTGAA  
AAGCAAAGGGCTCGCATGCAAAGCCTCATGGGCAGCCAGCCTGCTGGCTCCACCTTGTTTGTCCCTGCTT  
GTACTAGTGAGGGACATTTCTTGCCTGTCCAGTGCTTCAACTCAGAGTGCTACTGTGTTGATGCTGAGGG  
35 TCAGGCCATTCTTGGAACTCGAAGTGCAATAGGGAAGCCCAAGAAATGCCCCACGCCCTGTCAATTACAG  
TCTGAGCAAGCTTTCTCAGGACGGTGCAGGCCCTGCTCTCTAACTCCAGCATGCTACCCACCTTTCCG  
ACACCTACATCCCACAGTGCAGCACCGATGGGCAGTGGAGACAAGTGCAATGCAATGGGCCTCCTGAGCA  
GGTCTTCGAGTTGTACCAACGATGGGAGGCTCAGAACAAAGGGCCAGGATCTGACGCCTGCCAAGCTGCTA  
GTGAAGATCATGAGCTACAGAGAAGCAGCTTCCGGAACCTTCAGTCTCTTTATTCAAAGTCTGTATGAGG  
40 CTGGCCAGCAAGATGTCTTCCGGTGCTGTGACAATACCCTTCTCTGCAAGATGTCCCACTAGCAGCACT  
GGAAGGGAAACGGCCCCAGCCCAGGAGAATATCCTCCTGGAGCCCTACCTCTTCTGGCAGATCTTAAAT

GGCCAACTCAGCCAATACCCGGGGTCTACTCAGACTTCAGCACTCCTTTGGCACATTTTGATCTTCGGA  
ACTGCTGGTGTGTGGATGAGGCTGGCCAAGAACTGGAAGGAATGCGGTCTGAGCCAAGCAAGCTCCCAAC  
GTGTCCTGGCTCCTGTGAGGAAGCAAAGCTCCGTGTACTGCAGTTCAATTAGGGAAACGGAAGAGATTGTT  
TCAGCTTCCAACAGTTCTCGGTTCCCTCTGGGGGAGAGTTTCTGGTGGCCAAGGGAATCCGGCTGAGGA  
5 ATGAGGACCTCGGCCCTTCTCCGCTCTTCCCGCCCCGGGAGGCTTTCGCGGAGTTTCTGCGTGGGAGTGA  
TTACGCCATTTCGCTGGCGGCTCAGTCTACCTTAAGCTTCTATCAGAGACGCCGCTTTTCCCGGACGAC  
TCGGCTGGAGCATCCGCCCTTCTGCGGTGGGGCCCCCTACATGCCACAGTGTGATGCGTTTGGAAAGTTGGG  
AGCCTGTGCAGTGCCACGCTGGGACTGGGCACTGCTGGTGTGTAGATGAGAAAGGAGGGTTTCATCCCTGG  
CTCACTGACTGCCCCGCTCTGTGAGATTCCACAGTGCCCCGACAACCTGCGAGAAATCTCGAACCAGTGGG  
10 CTGCTTTCCAGTTGGAAACAGGCTAGATCCCAAGAAAACCCATCTCCAAAAGACCTGTTCTGCTCCAGCCT  
GCCTAGAAAACAGGAGAATATGCCAGGCTGCAGGCATCGGGGGCTGGCACCTGGTGTGTGGACCCTGCATC  
AGGAGAAGAGTTGCGGCCCTGGCTCGAGCAGCAGTGCCAGTGCCCAAGCCTCTGCAATGTGCTCAAGAGT  
GGAGTCTCTCTAGGAGAGTCAGCCCAGGCTATGTCCCAGCTGCAGGGCAGAGGATGGGGGCTTTTCCC  
CAGTGCAATGTGACCAGGCCAGGGCAGCTGCTGGTGTGTATGGACAGCGGAGAAGAGGTGCCTGGGAC  
15 GCGCGTGACCGGGGGCCAGCCCGCTGTGAGAGCCCGCGGTGTCCGCTGCCATTCAACGCGTCGGAGGTG  
GTTGGTGGAAACATCCTGTGTGAGACAATCTCGGGCCCCACAGGCTCTGCCATGCAGCAGTGCCAATTGC  
TGTGCCGCCAAGGCTCCTGGAGCGTGTTCACACAGGGCCATTGATATGTAGCCTGGAGAGCGGACCGCTG  
GGAGTCACAGCTGCCTCAGCCCCGGGCTGCCAACGGCCCCAGCTGTGGCAGACCATCCAGACCCAAGGG  
CACTTTTCAGCTCCAGCTCCCGCCGGGCAAGATGTGCAGTGTGACTACGCGGGTTTGCTGCAGACTTTCC  
20 AGGTTTTTCATATTGGATGAGCTGACAGCCCGCGGCTTCTGCCAGATCCAGGTGAAGACTTTTGGCACCCCT  
GGTTTCCATTCTGTCTGCAACAACCTCCTCTGTGCAGGTGGGTGTCTGACCAGGGAGCGTTTAGGAGTG  
AATGTTACATGGAAATCACGGCTTGAGGACATCCCAGTGGCTTCTCTTCTGACTTACATGACATTGAGA  
GAGCCTTGGTGGGCAAGGATCTCCTTGGGCGCTTCACAGATCTGATCCAGAGTGGCTCATTCACAGCTTCA  
TCTGGACTCCAAGACGTTCCAGCGGAAACCATCCGCTTCTCTCAAGGGGACCCTTTGGCACCTCTCCT  
25 AGGACACGGTTTGGGTGCTCGGAAGGATTCTACCAAGTCTTGACAAGTGAGGCCAGTCAGGACGGACTGG  
GATGCGTTAAGTGCCATGAAGGAAGCTATTCCTCAAGATGAGGAATGCATTCTTGTCTGTTGGATTCTA  
CCAAGAACAGGCAGGGAGCTTGGCCTGTGTCCCATGTCTGTGGGCAGAACGACCATTCTGCGCGAGCT  
TTCAGCCAGACTCACTGTGTACTGACTGTGAGGAACGAAGCAGGCTGCAATGTGACCAGAATGGCC  
AGTATCGAGCCAGCCAGAAGGACAGGGGCAGTGGGAAGGCCTTCTGTCTGGACGGCGAGGGGCGGAGGCT  
30 GCCATGGTGGGAAACAGAGGCCCTCTTGAGGACTCACAGTGTGATGATGCAGAAGTTTGAGAAGGTT  
CCAGAATCAAAGGTGATCTTCGACGCCAATGCTCCTGTGGCTGTGAGATCCAAAGTTCTTGATTCTGAGT  
TCCCCGTGATGCAGTGCTTGACAGATTGCACAGAGGACGAGGCCTGCAGCTTCTTACCCTGTCCACGAC  
GGAGCCAGAGATTCTCTGTGATTTCTATGCTTGGACAAGTGACAATGTTGCCTGCATGACTTCTGACCAG  
AAACGAGATGCAGTGGGGAACCTCAAAGGCCACCAGCTTTGGAAGTCTTCGCTGCCAGGTGAAAGTGAGGA  
35 GCCATGGTCAAGATTCTCCAGCTGTGTATTTGAAAAAGGGCCAAGGATCCACCACAACACTTCAGAAACG  
CTTTGAACCCACTGGTTTCCAAAACATGCTTTCTGGATTGTACAACCCCATTTGTGTTCTCAGCCTCAGGA  
GCCAATCTAACCGATGCTCACCTCTTCTGTCTTCTTGCAATGCGACCGTGATCTGTGTTGCGATGGCTTCG  
TCCTCACACAGGTTCAAGGAGGTGCCATCATCTGTGGGTGCTGAGCTCACCCAGTGTCTGCTTTGTAA  
TGTCAAAGACTGGATGGATCCCTCTGAAGCCTGGGCTAATGCTACATGTCCTGGTGTGACATATGACCAG  
40 GAGAGCCACCAGGTGATATTGCGTCTTGAGACCAGGAGTTCATCAAGAGTCTGACACCCTTAGAAGGAA  
CTCAAGACACCTTTACCAATTTTCAGCAGGTTTATCTCTGGAAAGATTCTGACATGGGGTCTCGGCCTGA

GTCTATGGGATGTAGAAAAACACAGTGCCAAGGCCAGCATCTCCAACAGAAGCAGGTTTGACAACAGAA  
CTTTTCTCCCCTGTGGACCTCAACCAGGTCAATTGTCAATGGAAATCAATCACTATCCAGCCAGAAGCACT  
GGCTTTTCAAGCACCTGTTTTCAGCCCAGCAGGCAAACCTATGGTGCCTTTCTCGTTGTGTGCAGGAGCA  
CTCTTTCTGTCTAGCTCGCAGAGATAACAGAGAGTGCATCCTTGTACTTCACCTGCACCCCTACCCAGAG  
5 GCACAGGTGTGTGATGACATCATGGAGTCCAATACCCAGGGCTGCAGACTGATCCTGCCCTCAGATGCCAA  
AGGCCCTGTTCCGGAAGAAAGTTATACTGGAAGATAAAGTGAAGAAGTTTACACTCGCCTGCCGTTC  
AAAAGTATGGGGATATCCATTAGAAATAAAGTGCCCATGTCTGAAAAATCTATTTCTAATGGGTTCTTT  
GAATGTGAACGACGGTGCAGTCCGACCCATGCTGCACTGGCTTTGGATTCTAAATGTTTCCAGTTAA  
AAGGAGGAGAGGTGACATGTCTCACTCTGAACAGCTTGGGAATTCAGATGTGCAGTGAGGAGAATGGAGG  
10 AGCCTGGCGCATTTTGGACTGTGGCTCTCCTGACATTGAAGTCCACACCTATCCCTTCGGATGGTACCAG  
AAGCCCATGTCTCAAAATAATGCTCCAGTTTTCGCCCTTTGGTTGTTCTGCCCTTCCTCACAGAGAAAG  
TGTCTCTGGAATCGTGGCAGTCCCTGGCCCTCTCTTCAGTGGTTGTTGATCCATCCATTAGGCACTTTGA  
TGTGCCCCATGTCTCAGCACTGCTGCCACCAGCAATTTCTCTGCTGTCCGAGACCTCTGTTGTCTGGAATGT  
TCCCCAATGAGGCCCTGTCTCATCACCCTCTGCAACCCCACTCGGGGCTGTGAGATGTATGTTCTATG  
15 CTGATACTCAAAGCTGCACACATAGTCTGCAGGGTCGGAAGTCCGACTTCTGCTTCGTGAAGAGGCCAC  
CCACATCTACCGGAAGCCAGGAATCTCTCTGCTCAGCTATGAGGCATCTGTACCTTCTGTGCCCATTTCC  
ACCCATGCCCCGCTGTGGGCAGGTCCCAGGCCATCCAGGTGGGTACCTCATGGAAGCAAGTGGACCACT  
TCCTTGGAGTTCCATATGCTGCCCGCCCTGGCAGAGAGGCACTTCCAGGCACCAGAGCCCTTGAAGT  
GACAGGCTCCTGGGATGCCAGCAAGCCAAAGGCCAGCTGCTGGCAGCCAGGCACCAGAACATCCAGTCT  
20 CCTGGAGTCAGTGAAGATTGTTTGTATCTCAATGTGTTTATCCCTCAGAATGTGGCCCTAACGCGTCTG  
TGCTGGTGTCTTCCACAACACCATGGACAGGGAGGAGAGTGAAGGATGGCCGGCTATCGACGGCTCCTT  
CTTGGCTGCTGTTGGCAACCTCATCGTGGTCACTGCCAGCTACCGAGTGGGTGTCTTCGGCTTCCTGAGT  
TCTGGATCCGAGAGGTGAGTGGCAACTGGGGGCTGCTGGACAGGTGGCGGCTCTGACCTGGGTGCAGA  
CCCCATCCGAGGATTGGCGGGGACCCCGGCGCTGTCCCTGGCAGCAGACCGTGGCGGGGCTGATGT  
25 GGCCAGCATCCACCTTCTCACGGCCAGGGCCACCAACTCCCAACTTTTCCGAGAGCTGTGCTGATGGGA  
GGCTCCGCACTCTCCCCGGCCGCCGTCATCAGCCATGAGAGGGCTCAGCAGCAGGCAATTGCTTTGGCAA  
AGGAGGTCAAGTTGCCCCATGTCTATCCAGCCAAGAGTGGTGTCTGCTCCGCCAGAAGCCTGCCAATGT  
CCTCAATGATGCCAGACCAAGCTCCTGGCCGTGAGTGGCCCTTCCACTACTGGGTCTGTGATCGAT  
GGCCACTTCTCCGTGAGCCTCCAGCCAGAGCACTGAAGAGGTCTTTATGGGTAGAGGTGATCTGCTCA  
30 TTGGGAGTTCTCAGGACGACGGGCTCATCAACAGAGCAAAGGCTGTGAAGCAATTTGAGGAAAGTCGAGG  
CCGGACCAGTAGCAAAACAGCCTTTTACCAGGCACTGCAGAATTCTCTGGGTGGCGAGGACTCAGATGCC  
CGCGTCGAGGCTGCTGCTACATGGTATTACTCTCTGGAGCACTCCACGGATGACTATGCCTCCTTCTCCC  
GGGCTCTGGAGAATGCCACCCGGGACTACTTTATCATCTGCCCTATAATCGACATGGCCAGTGCCTGGGC  
AAAGAGGGCCCGAGGAAACGTCTTCATGTACCATGCTCCTGAAAACACGGCCATGGCAGCCTGGAGCTG  
35 CTGGCGGATGTTTCAAGTTTGCCTTGGGGCTTCCCTTCTACCCAGCCTACGAGGGGAGTTTCTCTGGAGG  
AGAAGAGCCTGTGCTGAAAATCATGCAGTACTTTTCCCACTTCATCAGATCAGGAAATCCCAACTACCC  
TTATGAGTTCTCACGGAAGTACCCACATTTGCAACCCCTGGCTGACTTTGTACCCCGTGTGGTGGGA  
GAGAACTACAAGGAGTTCAAGTGTGCTCCCCAATCGACAGGGCCTGAAGAAAGCCGACTGCTCCTTCT  
GGTCCAAGTACATCTGCTCTGAAGACATCTGCAGATGGAGCCAAGGGCGGGCAGTCAGCAGAGAGTGA  
40 AGAGGAGGAGTTGACGGCTGGATCTGGGCTAAGAGAAGATCTCCTAAGCCTCCAGGAACAGGCTCTAAG  
ACCTACAGCAAGTGACCAGCCCTTGAGCTCCCCAAAACCTCACCCGAGGCTGCCCACTATGGTCATCTT

TTTCTCTAAAATAGTTACTTACCTTCAATAAAGTATCTACATGCGGTG

SEQ ID NO: 29

5

10

15

>gi|339688|gb|M17733|HUMTHYB4 Human thymosin beta-4 mRNA, complete cds  
ACAACTCGGTGGTGGCCACTGCGCAGACCAGACTTCGCTCGTACTCGTGCGCCTCGCTTCGCTTTTCCTC  
CGCAACCATGTCTGACAAACCCGATATGGCTGAGATCGAGAAATTCGATAAGTCGAAACTGAAGAAGACA  
GAGACGCAAGAGAAAAATCCACTGCCTTCCAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATCGT  
AATGAGGCGTGCGCCGCCAATATGCACTGTACATTCCACAAGCATTGCCTTCTTATTTTACTTCTTTTAG  
CTGTTTAACTTTGTAAGATGCAAAGAGGTTGGATCAAGTTTAAATGACTGTGCTGCCCTTTTACATCAA  
AGAACTACTGACAACGAAGGCCGCGCTGCCTTTCCCATCTGTCTATCTATCTGGCTGGCAGGGAAGGAAA  
GAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGGGAAGAAGTGGGGTGGGACGACAGTGAAATCTAGAGT  
AAAACCAAGCTGGCCCAAGTGTCTGCAGGCTGTAATGCAGTTTAATCAGAGTGCCATTTTTTTTTT

SEQ ID NO: 30

20

25

30

35

40

>gi|1743866|gb|U70063|HSU70063 Human acid ceramidase mRNA, complete  
cds  
GGCAGGAGGCTAGAGCGATGCCGGGCGGAGTTGCGTCGCCTTAGTCCTCCTGGCTGCCGCGCGTCAGCTG  
TGCCGTCGCGCAGCAGCGCGCGCCGTTGGACAGAGGACTGCAGAAAATCAACCTATCCTCCTTCAGGACCA  
ACGTACAGAGGTGCAGTTCATGGTACACCATAAATCTTGACTTACCACCCTACAAAAGATGGCATGAAT  
TGATGCTTGACAAGGCACCAATGCTAAAGGTTATAGTGAATTCTCTGAAGAATATGATAAATACATTCGT  
GCCAAGTGAAAAGTTATGCAGGTGGTGGATGAAAAATTGCCTGGCCTACTTGGCAACTTTCTCGGCCCT  
TTTGAAGAGGAAATGAAGGTTATTGCCGCTGTTACTGATATACCTTTAGGAGAGATTATTTTCATTCATA  
TTTTTTATGAATTATTTACCATTTGTACTTCAATAGTAGCAGAAGACAAAAAGGTCATCTAATACATGG  
GAGAAACATGGATTTTGGAGTATTTCTTGGGTGGAACATAAATAATGATACCTGGGTCATAACTGAGCAA  
CTAAAACCTTTAACAGTGAATTTGGATTTCCAAAGAAACAACAAAACCTGTCTTCAAGGCTTCAAGCTTTG  
CTGGCTATGTGGGCATGTTAACAGGATTCAAACCAGGACTGTTCAAGTCTTACACTGAATGAACGTTTCAG  
TATAAATGCTGGTTATCTGGGTATTCTAGAATGGATTCTGGGAAAGAAAGATGCCATGTGGATAGGGTTC  
CTCACTAGAACAGTTCTGGAAAATAGCACAAAGTTATGAAGAAGCCAAGAATTTATTGACCAAGACCAAGA  
TATTGGCCCCAGCCTACTTTATCCTGGGAGGCAACCAGTCTGGGGAAGGTTGTGTGATTACACGAGACAG  
AAAGGAATCATTGGATGTATATGAACCTCGATGCTAAGCAGGGTAGATGGTATGTGGTACAAACAAATTAT  
GACCGTTGGAAACATCCCTTCTTCTTCTGATGATCGCAGAACGCCTGCAAAGATGTGTCTGAACCGCACCA  
GCCAAGAGAATATCTCATTTGAAACCATGTATGATGTCTGTCAACAAAACCTGTCTCAACAAGCTGAC  
CGTATACACAACCTTGATAGATGTTACCAAAGGTCAATTTCGAAACTTACCTGCGGGACTGCCCTGACCCCT  
TGTATAGGTTGGTGAGCACACGTCTGGCCTACAGAATGCGGCCTCTGAGACATGAAGACACCATCTCCAT  
GTGACCGAACACTGCAGCTGTCTGACCTTCCAAAGACTAAGACTCGCGGCAGGTTCTCTTTGAGTCAATA  
GCTTGTCTTCGTCCATCTGTTGACAAATGACAGATCTTTTTTTTTTTTCCCCCTATCAGTTGATTTTTCTT  
ATTACAGATAACTTCTTTAGGGGAAGTAAAACAGTCATCTAGAATTCAGTGTGTTTCACTTTGA

5 CATTGTTGGGATCTGGTGGGCAGTCGAACCATGGTGAACCTCCACCTCCGTGGAATAAATGGAGATTCAGCG  
TGGGTGTTGAATCCAGCACGTCTGTGTGAGTAACGGGACAGTAAACACTCCACATTCTTCAGTTTTTCAC  
TTCTACCTACATATTTGTATGTTTTCTGTATAACAGCCTTTTCCTTCTGGTTCTAACTGCTGTAAAAT  
TAATATATCATTATCTTTGCTGTTATTGACAGCGATATTATTTTATTACATATCATTAGAGGGATGAGAC  
10 AGACATTACCTGTATATTTCTTTTAATGGGCACAAAATGGGCCCTTGCCCTCTAAATAGCACTTTTGGG  
GTTCAAGAAGTAATCAGTATGCAAAGCAATCTTTTATACAATAATTGAAGTGTCCCTTTTTCATAATTA  
CTCTACTTCCCAGTAACCCTAAGGAAGTTGCTAACTTAAAAAACTGCATCCCACGTTCTGTTAATTTAGT  
AAATAAACAAAGTCAAAGACTTGTGGAAAATAGGAAGTGAACCCATATTTTAAATTCTCATAAGTAGCATT  
15 GATGTAATAAACAGGTTTTTAGTTTGTCTTCAGATTGATAGGGAGTTTTTAAAGAAATTTTAGTAGTTAC  
TAAAATTATGTTACTGTATTTTTCAGAAATCAAACCTGCTTATGAAAAGTACTAATAGAACTTGTTAACCT  
TTCTAACCTTCACGATTAACCTGTGAAATGTACGTCATTTGTGCAAGACCGTTTGTCCACTTCATTTTGTA  
TAATCAGATTGTGTTCCCTGACACTCAATAAACAGTCACTGGAAAGAGTGCCAGTCAGCAGTCATGCACG  
CTGATAAAAAAAAAAAAAAAAAAAAA

15

SEQ ID NO:31 -- Oligo N1, Ki67 sense, Nhe, 6His, 5610:  
ATTGCTAGCCACCACCACCACCACCACAACTGGACCCAGCAGCAAGTGTAAC

20

SEQ ID NO: 32 -- Oligo N2, Ki67 antisense, EcoRI, 6420:  
CGGGAATTCCTATAGAGCCTCAGCCTTTTCCTTAGG

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**  
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

**THIS PAGE BLANK (USPTO)**